

## Chapter 2 Notes

- 1 Sally Fallon, Planet Thrive. planetthrive.com
- 2 Heinerman J. Fascinating Colostrum: An Ancient Food for Modern Times. (1999)
- 3 The Temple of Hathor at Serabit el-Khadim. Egyptianhealing.com.
- 4 Lotte Hughes, Historian of the Maasai, University of Oxford, 2002.
- 5 Isaiah 7:15.
- 6 Wickes IG. **A history of infant feeding. Part I. Primitive peoples: ancient works: renaissance writers.** *Archives of Disease in Childhood* 28:151-158 (1953).
- 7 Salmon M. **The Cultural Significance of Breastfeeding and Infant Care in Early Modern England and America.** *Journal of Social History* Winter, 1994.
- 8 Fox PF, McSweeney PLH. **Dairy Chemistry and Biochemistry.** Springer, 1998, p. 90.
- 9 Ehrlich P. **Über Immunität durch Verebung und Saugung.** *Zeitschrift für Hygiene und Infektionskrankheiten* 12:183 (1892)
- 10 Ehrlich P, Hubener W. **Über die Verebung der Immunität bei Tetanus.** *Zeitschrift für Hygiene und Infektionskrankheiten* 18:51 (1894)
- 11 Ehrlich P, Wasserman A. **Über die Gewinnung Diphtherie-Antitoxine aus Blutserum und Milch immunsirte Thiere.** *Zeitschrift für Hygiene und Infektionskrankheiten* 8:239 (1894)
- 12 Metchnikoff E. **The New Hygiene: Three Lectures on the Prevention of Infectious Diseases.** W.T. Keener, Chicago (1906)
- 13 Sabin AB. **Antipoliomyelitic substance in milk from human beings and certain cows.** *Journal of Diseases of Children*, 80:866 (1950)
- 14 Sabin AB, Fieldsteel AH. **Antipoliomyelitic activity of human and bovine colostrum and milk.** *Pediatrics* 29(1):105-115 (1962)

## Chapter 4 Notes

- 15 Prosser C, Stelwagen K, Cummins R, Guerin P, Gill N, Milne C. **Reduction in heat induced gastrointestinal hyperpermeability in rats by bovine colostrum and goat milk powders.** *Journal of Applied Physiology* 96:650-654 (2004).
- 16 Gastrointestinal Inflammation and Repair Group, Imperial College, London. Unpublished research. In an in vitro experimental study, colostrum stimulated intestinal cell growth and reestablished a healthy epithelial layer following injury. In an in vivo experimental study, colostrum powder was also shown to reduce gastric injury (2003).
- Peptide Immunotherapy: *Colostrum—A Physician's Reference Guide*
- 358 17 Carver JD, Barness LA. **Trophic factors for the gastrointestinal tract.** *Clinical Perinatology* 23(2):265-285 (1996).
- 18 Playford RJ, Woodman AC, Clark P, Watanapa P, Vesey D, Deprez PH, Williamson RC, Calam J. **Effect of luminal growth factor preservation on intestinal growth.** *Lancet* 341(8849):843-848 (1993).
- 19 Playford RJ, Floyd DN, Macdonald CE, et al. **Bovine colostrum is a health food supplement which prevents NSAID induced gut damage.** *Gut* 44:653-658 (1999).
- 20 Korhonen H, Suvaaja EL, Ahola-Luttila H, Sivela S, Kopola S, Husu J, Kosunen TU. **Bactericidal effect of bovine normal and immune serum, colostrum and milk against *Helicobacter pylori*.** *Journal of Applied Bacteriology* 78:655-662 (1995).
- 21 Bitzan MM, Gold BD, Philpott DJ, Huesca M, Sherman PM, Karch H, Lissner R, Lingwood CA, Karmali MA. **Inhibition of *Helicobacter pylori* and *Helicobacter mustelae* binding to lipid receptors by bovine colostrum.** *Journal of Infectious Diseases* 177:955-961 (1998).
- 22 Buhler C, Hammon H, Rossi GL, Blum JW. **Small intestinal morphology in eightday-old calves fed colostrum for different durations or only milk replacer and treated with long-R3-insulin-like growth factor I and growth hormone.** *Journal of Animal Science* 76:758-765 (1998).
- 23 Pluske JR, Morel PCH. **Increasing weaner pig productivity in New Zealand pig herds.** Unpublished research (1999). Piglets fed a liquid supplement with colostrum powder had a marked increase in villi height in the lumen of the small intestine, indicating greater digestion and absorption of nutrients. There were also an increased number of immune cells in the villi, indicating enhanced immune competency.
- 24 Blattler U, Hammon HM, Morel C, Philipona C, Rauprich A, Rome V, Huerou-Luron I, Guilloteau P, Blum JW. **Feeding colostrum, its composition and feeding duration variably modify proliferation and morphology of the intestine and digestive enzyme activities of neonatal calves.** *Journal of Nutrition* 131(4):1256-1263 (2001).
- 25 Deitch EA. **The Role of Intestinal Barrier Failure and Bacterial Translocation in the Development of Systemic Infection and Multiple Organ Failure.** *Archives of Surgery* 125:403-404 (1990).
- 26 Galland L. **Leaky Gut Syndrome: Breaking the Vicious Cycle.** *Townsend Letter for*

Doctors. 145(6):63-68 (1995).

27 Galland L, Barrie S. **Intestinal Dysbiosis and the Causes of Disease.** www.healthy.net/asp/templates/Article.asp?id=423

28 Rooney PL, Jenkins RT, Buchanan WW. **A Short Review of the Relationship Between Intestinal Permeability and Inflammatory Joint Disease.** *Clinical and Experimental Rheumatology* 8(1):75-83 (1990).

29 Jackson PG, Lessof MH, Baker RWR, Ferrett J, MacDonald DM. **Intestinal Permeability in Patients with Eczema and Food Allergy.** *Lancet* 1(8233):1285-6 (1981).

359

#### References

30 Altekruze SF, Bauer N, Chanlongbutra A, DeSagun R, Naugle A, Schlosser W, Umholtz R, White P. **Salmonella enteritidis in broiler chickens, United States, 2000-2005.** *Emerging Infectious Diseases* 12(12):1848-1852 (2006).

31 [http://www.wrongdiagnosis.com/fl/food\\_poisoning/death-types.htm](http://www.wrongdiagnosis.com/fl/food_poisoning/death-types.htm)

32 Ho PC, Lawton JW. **Human colostrum cells: phagocytosis and killing of *E. coli* and *C. albicans*.** *Journal of Pediatrics* 93(6):910-915 (1978).

33 Kim K, Pickering LK, DuPont HL, Sullivan N, Wilkins T. **In vitro and in vivo neutralizing activity of human colostrum and milk against purified toxins A and B of *Clostridium difficile*.** *Journal of Infectious Diseases* 150(1):57-62 (1984).

34 Tacket CO, Binion SB, Bostwick E, Losonsky G, Roy MJ, Edelman R. **Efficacy of bovine milk immunoglobulin concentrate in preventing illness after *Shigella flexneri* challenge.** *American Journal of Tropical Medicine and Hygiene* 47(3):276-283 (1992).

35 Watson C, Alp NJ. **Role of *Chlamydia pneumoniae* in atherosclerosis.** *Clinical Science* 114(8):509-531 (2008).

36 Tortora GJ, Funke BD, Case CL. **Microbiology: an Introduction.** 8th edition, pp 485-488. Pearson Education, 2004.

37 Baglioni T, Fioretti C. **[Serum immunoglobulins in colostrum and cow's milk studied by the immunoelectrophoretic method]** *Archivio Veterinario Italiano* 18(6):419-427 (1967). Both IgG and IgM identified in bovine colostrum using immunoelectrophoresis.

38 Mickelson KN, Moriarty KM. **Immunoglobulin levels in human colostrum and milk.** *Journal of Pediatric Gastroenterology and Nutrition* 1(3):381-384 (1982). Levels of sIgA, IgG and IgM were determined in human colostrum and milk. A mean concentration of 32 g/L was found for sIgA (1.5-83.7 g/L), 1.13 g/L for IgM and 0.53 g/L for IgG. While total amounts declined with time postpartum, relative proportions remained the same.

39 Korhonen H, Marnila P, Gill HS. **Bovine milk antibodies for health.** *British Journal of Nutrition* 84(Suppl.1):S135-S146 (2000). Bovine colostrum provides safe, effective protection against many pathogens.

40 Korhonen H, Syvaöja EL, Ahola-Luttilla H, Sivela S, Kopola S, Husu J, Kosunen TU. **Bactericidal effect of bovine normal and immune serum, colostrum and milk against *Helicobacter pylori*.** *Journal of Applied Bacteriology* 78(6):655-662 (1995). *Helicobacter pylori* is a major cause of gastritis and ulcers in humans. Serum and colostrum from non-immunized Friesian cows were found to be highly bactericidal against *H. pylori*. Post-colostral milk did not show any bactericidal effect against *H. pylori*.

41 Funatogawa K, Ide T, Kirikae F, Saruta K, Nakano M, Kirikae T. **Use of immunoglobulin enriched bovine colostrum against oral challenge with enterohemorrhagic *Escherichia coli* O157:H7 in mice.** *Microbiology and Immunology* 46(11):761-766 (2002). Colostrum can prevent infection against food-borne pathogens by preventing them

Peptide Immunotherapy: *Colostrum*—

*A Physician's Reference Guide*

360 from binding to the intestinal lining.

42 Widiastih DA, Matsuda I, Omoe K, Hu DL, Sugii S, Shinagawa K. **Passive transfer of antibodies to Shiga toxin-producing *Escherichia coli* O26, O111 and O157 antigens in neonatal calves by feeding colostrum.** *Journal of Veterinary Medicine* 66(2):213-215 (2004). Feeding colostrum to calves provided protection against Shiga toxin-producing *E. Coli*, a particularly deadly strain of *E. coli*.

43 Elahi S, Buchanan RM, Babiuk LA, Gerdtz V. **Maternal immunity provides protection against pertussis in newborn piglets.** *Infection and Immunity* 74(5):2619-2627 (2006).

44 Majumdar AS, Ghose AC. **Protective properties of anti-cholera antibodies in human colostrum.** *Infection and Immunity* 36:962-965 (1982). Colostrum was able to prevent infection with cholera. Colostrum samples from India, where cholera is common, had much higher levels of anti-cholera IgA than those from Sweden, where cholera is rare.

45 Stephan W, Dichtelmüller H, Lissner R. **Antibodies from colostrum in oral immunotherapy.** *Journal of Clinical Chemistry and Clinical Biochemistry* 28:19-23 (1990). An immunoglobulin preparation from pooled bovine colostrum was found to be very effective

in treating severe diarrhea, such as often found in AIDS patients.

46 Solomons, NW. **Modulation of the immune system and the response against pathogens with bovine colostrum concentrates.** *European Journal of Clinical Nutrition* 56(Suppl.3):524-528 (2002). The ability of colostrum to protect infants against pathogens, specifically those which cause gastroenteritis and severe diarrhea, makes it an ideal, cheap, safe and effective means of protecting children in those parts of the world where medical assistance is lacking or substandard and could save thousands of lives each year.

47 Rump JA, Arndt R, Arnold A, Bendick C, Dichtelmuller H, Franke M, Helm EB, Jager H, Kampmann B, Kolb P. **Treatment of diarrhea in human immunodeficiency virus-infected patients with immunoglobulins from bovine colostrum.** *Clinical Investigator* 70:588-594 (1992). Immunoglobulins from bovine colostrum were very effective in treating chronic diarrhea in AIDS patients from a variety of causes. Colostral immunoglobulins are highly resistant to digestion in the gastrointestinal tract.

48 Brussow H, Hilpert H, Walther I, Sidoti J, Mietens C, Bachmann P. **Bovine milk immunoglobulins for passive immunity to infantile rotavirus gastroenteritis.** *Journal of Clinical Microbiology* 25(6):982-986 (1987). Protection against rotavirus, a dangerous pathogen which can cause serious, even fatal diarrhea in infants, can be passed orally through milk or colostrum safely and effectively.

49 Acosta-Altamirano G, Rocha-Ramirez LM, Reyes-Montes R, Cote V, Santos, JI. **Antiamoebic properties of human colostrum.** *Advances in Experimental Medicine and Biology* 216B:1347-1352 (1987). In addition to its effectiveness against bacterial, viral and fungal infections, colostrum also provides protection against amoebic pathogens.

50 van Hooijdonk, AC, Kussendrager, KD, Steijns, JM. **In vivo antimicrobial and antiviral activity of components in bovine milk and colostrum involved in non-specific**

361

#### References

**defense.** *British Journal of Nutrition* 84(Suppl.1):S127-S134 (2000). Lactoferrin and lactoperoxidase, both present in colostrum in large amounts, provide non-specific defense against a broad spectrum of pathogens, including bacteria and viruses. This is significant both for the protection of commercially important animals as well as humans.

51 Andersson Y, Lindquist S, Lagerqvist C, Hernell O. **Lactoferrin is responsible for the fungistatic effect of human milk.** *Early Human Development* 59:95-105 (2000). Lactoferrin, through its iron-binding ability, is very effective against fungal infections with *Candida* and other fungi.

52 Qiu J, Hendrixson DR, Baker EN, Murphy TF, St Geme JW III, Plaut AG. **Human milk lactoferrin inactivates two putative colonization factors expressed by *Haemophilus influenzae*.** *Proceedings of the National Academy of Sciences USA* 95:12641-12646 (1998). Lactoferrin prevents colonization of *Haemophilus influenzae*, the primary cause of otitis media and other respiratory infections in children, by inactivating two colonization factors expressed by the bacteria.

53 Ellison RT III, Giehl TJ. **Killing of gram-negative bacteria by lactoferrin and lysozyme.** *Journal of Clinical Investigation* 88(4):1080-1091 (1991). Lactoferrin and lysozyme act together to kill gram-negative bacteria, such as *Vibrio cholerae* (cholera), *Salmonella typhimurium* (food poisoning) and *Escherichia coli*. The lactoferrin attaches to and destroys the cell wall of the bacteria, allowing the lysozyme to enter and lyse (burst) the organisms.

54 Samaranyake YH, Samaranyake LP, Pow EH, Beena VT, Yeung KW. **Antifungal effects of lysozyme and lactoferrin against genetically similar, sequential *Candida albicans* isolates from a human immunodeficiency virus-infected Southern Chinese cohort.** *Journal of Clinical Microbiology* 39(9):3296-3302 (2001). Lactoferrin plus lysozyme is very effective in killing nearly all oral strains of *Candida*, which is of particular importance to AIDS sufferers who are often unable to fight off *Candida* overgrowths, such as thrush.

55 Harmsen MC, Swart PJ, de Bethune MP, Pauwels R, De Clercq E, The TH, Meijer DK. **Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro.** *Journal of Infectious Diseases* 172(2):380-388 (1995). Lactoferrin can protect against infection by HIV and human cytomegalovirus by blocking entrance into the body.

56 Berkhout B, van Wamel JL, Beljaars L, Meijer DK, Visser S, Floris R. **Characterization of the anti-HIV effects of native lactoferrin and other milk proteins and peptide-derived peptides.** *Antiviral Research* 55(2):341-355 (2002). Bovine lactoferrin as well as peptides derived from lactoferrin block the entry process of HIV into cells.

57 Hara K, Ikeda M, Saito S, Matsumoto S, Numata K, Kato N, Tanaka K, Sekihara H. **Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes.** *Hepatology Research* 24(3):228 (2002). Bovine lactoferrin prevents infection of cultured human Peptide Immunotherapy: *Colostrum*—

### *A Physician's Reference Guide*

362 liver cells with hepatitis B virus, while transferrin, casein and lactalbumin had no effect.

58 Ikeda M, Sugiyama K, Tanaka T, Tanaka K, Sekihara H, Shimotohno K, Kato N.

**Lactoferrin markedly inhibits hepatitis C virus infection in cultured human**

**hepatocytes.** *Biochemistry and Biophysics Research Communications* 245(2):549-553 (1998).

Bovine lactoferrin inhibits the infection of cultured human liver cells by hepatitis C virus while transferrin does not.

59 Superti F, Ammendolia MG, Valenti P, Seganti L. **Anti-rotaviral activity of milk proteins: lactoferrin prevents rotavirus infection in the enterocyte-like cell line HT-29.**

*Medical Microbiology and Immunology (Berlin)* 186(2-3):83-91 (1997). Antiviral activity against rotavirus of alpha lactalbumin, beta lactoglobulin, apo-lactoferrin (iron-free) and iron saturated lactoferrin were compared to that of mucin, which has known antirotaviral activity. Beta lactoglobulin and both forms of lactoferrin showed anti-rotaviral activity with the strongest response elicited by apo-lactoferrin, which hinders viral attachment to cells by binding directly to the viruses. It also markedly inhibits viral antigen synthesis in the viral adhesion stage.

60 Brinkworth G, Buckley J. **Concentrated bovine colostrums protein supplementation reduces the incidence of self-reported symptoms of upper respiratory tract infections in adult males.** *European Journal of Nutrition* 42:228-232 (2003).

61 van der Strate BW, Beljaars L, Molema G, Harmsen MC, Meijer DK. **Antiviral activities of lactoferrin.** *Antiviral Research* 52(3):225-239 (2001). Lactoferrin is effective against both DNA and RNA viruses, including rotavirus, respiratory syncytial virus, herpes virus and HIV, both by blocking cellular receptors and by directly binding to the viruses.

62 Marchetti M, Pisani S, Antonini G, Valenti P, Seganti L, Orsi N. **Metal complexes of bovine lactoferrin inhibit in vitro replication of herpes simplex virus type 1 and 2.** *Biometals* 11(2):89-94 (1998). Bovine lactoferrin saturated with iron, manganese or zinc proved strongly inhibitory to viral replication of herpes simplex virus types 1 and 2 in cell cultures (Vero).

63 Gahr M, Speer CP, Damerau B, Sawatzki G. **Influence of lactoferrin on the function of human polymorphonuclear leukocytes and monocytes.** *Journal of Leukocyte Biology* 49(5):427-433 (1991). White blood cells (polymorphonuclear leucocytes) exposed to lactoferrin from bovine colostrum exhibit increased motility and produce more superoxide (a powerful antioxidant).

64 Shau H, Kim A, Golub SH. **Modulation of natural killer and lymphokine-activated killer cell cytotoxicity by lactoferrin.** *Journal of Leukocyte Biology* 51(4):343-349 (1992). Lactoferrin strongly augments the cytotoxic functions of natural killer (NK) cells and lymphokine-activated killer (LAK) cells. Newborn infants have low NK and LAK activity so lactoferrin may 'turn on' these cells in the infant.

65 Hashizume S, Kuroda K, Murakami H. **Identification of lactoferrin as an essential growth factor for human lymphocytic cell lines in serum-free medium.** *Biochimica* 363

### *References*

*et Biophysica Acta* 763(4):377-382 (1983). Lactoferrin is an essential growth factor for lymphocytes. It has higher growth stimulatory activity than transferrin. Bovine lactoferrin was found to be as effective as human.

66 Reiter B. **The lactoperoxidase-thiocyanate-hydrogen peroxide antibacterium system.** *Ciba Foundation Symposia* 65:285-294 (1978).

67 Kussendrager KD, van Hooijdonk AC. **Lactoperoxidase: physico-chemical properties, occurrence, mechanism of action and applications.** *British Journal of Nutrition* 84(Suppl 1):S19-S25 (2000). The lactoperoxidase system acts as an antimicrobial defense in bodily secretions such as tears, saliva and milk.

68 Stelwagen K, Carpenter E, Haigh B, Hodgkinson A, Wheeler TT. **Immune Components of Bovine Colostrum and Milk.** *Journal of Animal Science* epub ahead of print (2008). Human and bovine colostrum contain cytokines and antimicrobial proteins and peptides, including lactoferrin, defensins and cathelicidins.

69 Gopal PK, Gill HS. **Oligosaccharides and glycoconjugates in bovine milk and colostrum.** *British Journal of Nutrition* 84(Suppl.1):S69-S74 (2000). One way colostrum helps protect against infections is through the oligosaccharides and glycoconjugates it contains. These are complex sugars which compete for binding sites in the GI tract with pathogens.

70 Newburg DS. **Human milk glycoconjugates that inhibit pathogens.** *Current Medical Chemistry* 6(2):117-127 (1999). The protection offered by human milk may not be limited to just secretory IgA. However, milk and colostrum contain numerous complex carbohydrates, including glycoproteins, glycolipids, glycosaminoglycans, mucins and oligosaccharides. These complex carbohydrate glycoconjugates and oligosaccharides are synthesized by the many glycosyltransferases found in the mammary gland. Those

with homology to cell surface glycoconjugate pathogen may inhibit pathogen binding by competing for binding sites. One of the fucosyloligosaccharides inhibits *E. coli* toxin. Another inhibits infection by *Campylobacter jejuni*. Milk oligosaccharides inhibit the binding of *Streptococcus pneumoniae* and enteropathogenic *E. coli*. Lactadherin inhibits rotavirus. A mannosylated glycopeptide inhibits binding by enterohemorrhagic *E. coli*. A glycosaminoglycan prevents binding of gp120 (a form of HIV) to CD4, the first step in HIV infection. Milk mucin inhibits binding of S-fimbriated *E. coli*. Ganglioside GM1 reduces diarrhea due to cholera toxin and *E. coli* labile toxin. Glycosphingolipid Gb3 binds to shiga toxin.

71 Korhonen H, Marnila P, Gill HS. **Milk immunoglobulins and complement factors.** *British Journal of Nutrition* 84(Suppl.1):S75-S80 (2000). Bovine colostrum contains three main classes of immunoglobulin IgG (IgG1 75% and IgG2), IgM and IgA, plus hemolytic and bactericidal complement. Complement is a complex group of proteins which act in concert with antibodies to inactivate and/or kill pathogens.

72 Nakajima S, Baba AS, Tamura N. **Complement system in human colostrum:**

Peptide Immunotherapy: *Colostrum*—

*A Physician's Reference Guide*

364 **presence of nine complement components and factors of alternative pathway in human colostrum.** *International Archives of Allergy and Applied Immunology* 54(5):428-433 (1977). All nine components of the complement system (C1-C9) have been found in human colostrum.

73 Armogida SA, Yannaras NM, Melton AL, Srivastava MD. **Identification and quantification of innate immune system mediators in human breast milk.** *Allergy and Asthma Proceedings* 25(5):297-304 (2004). Mediators of the innate immune system were found in human colostrum and milk, including defensins, cathelicidins, and toll-like receptors.

74 LeBouder E, Rey-Nores JE, Rushmere NK, Grigorov M, Lawn SD, Affolter M, Griffin GE, Ferrara P, Schiffrin EJ, Morgan BP, Labeta MO. **Soluble forms of Toll-like receptor (TLR)-2 capable of modulating TLR2 signaling are present in human plasma and breast milk.** *Journal of Immunology* 171(12):6680-6689 (2003). Failure of the innate immune response to bacterial infection can lead to septic shock and death. Toll-like receptors play a crucial role in the innate immune response and is found in human colostrum and milk.

75 Pasare C, Medzhitov R. **Toll-like receptors: linking innate and adaptive immunity.** *Microbes and Infection* 6(15):1382-1387 (2004). Toll-like receptors (TLRs) are the principal means of detection and response to microbial infections, including bacteria, viruses, fungi and protozoa. Initial recognition by the TLRs sets off a complex series of signaling events that sets off the immune response to the infection.

76 Janusz M, Lisowski J. **Proline-rich polypeptide (PRPS) – an immunomodulatory peptide from ovine colostrum.** *Archivum Immunologiae et Therapiae Experimentalis* 41:275-279 (1993). A unique, non-species specific polypeptide which plays an immunomodulatory role in the immune system. It can induce the differentiation of thymocytes into functional T cells as well as increase the permeability of skin blood vessels. What makes it unique is that a second exposure to the polypeptide reverses the changes induced by first exposure.

77 Julius MH, Janusz M, Lisowski J. **A colostrum protein that induces the growth and differentiation of resting B lymphocytes.** *Journal of Immunology* 140:1366-1371 (1988). Colostrinin has also been shown to induce the growth and differentiation of resting B lymphocytes. T and B lymphocytes are the two main types of lymphocytes involved in the immune response.

78 Sirota L, Straussberg R, Notti I, Bessler H. **Effect of human colostrum on interleukin-2 production and natural killer cell activity.** *Archive of Diseases in Childhood: Fetal and Neonatal Edition* 72(3):F99-102 (1995). Colostrum stimulates or inhibits the production of IL-2 depending on its concentration. It also inhibits the activity of natural killer cells, but the production of IL-2 reverses this effect. This is thought to be another way that colostrum modulates the immune system response.

365

*References*

79 Shau H, Kim A, Golub SH. **Modulation of natural killer and lymphokine-activated killer cell cytotoxicity by lactoferrin.** *Journal of Leukocyte Biology* 51(4):343-349 (1992). Lactoferrin strongly augments the cytotoxic functions of natural killer (NK) cells and lymphokine-activated killer (LAK) cells. Newborn infants have low NK and LAK activity so lactoferrin may 'turn on' these cells in the infant.

80 Pihoker C, Gilliam L, Hampe C, Lernmark A. **Auto-antibodies in Diabetes.** *Diabetes* 54:S52-S61 (2005).

81 McDevitt H. **Characteristics of Autoimmunity in Type I Diabetes and Type I.5**

- Overlap With Type 2 Diabetes.** *Diabetes* 54:S4-S10 (2005).
- 82 Boitard C, Efendic S, Ferrannini E, Henquin J, Steiner D, Cerasi E. **A Tale of Two Cousins: Type 1 and Type 2 Diabetes.** *Diabetes* 54:S1-S3 (2005).
- 83 Tuomi T. **What Do They Have in Common? Type 1 and Type 2 Diabetes. Section I: Aspects of Pathophysiology.** *Diabetes* 54:S40-S45 (2005).
- 84 Knip M, Veijola R, Virtanen S, Hyoty H, Vaarala O, Akerblom H. **Environmental Triggers and Determinants of Type 1 Diabetes.** *Diabetes* 54:S125-S136 (2005).
- 85 Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I. **Increased Monocytic Activity and Biomarkers of Inflammation in Patients With Type 1 Diabetes.** *Diabetes* 55:774-779 (2006).
- 86 Dohm GL, Elton CW, Raju MS, Mooney ND, DiMarchi R, Pories WJ, Flickinger EG, Atkinson SM Jr, Caro JF. **IGF-I– Stimulated Glucose Transport in Human Skeletal Muscle and IGF-I Resistance in Obesity and NIDDM.** *Diabetes* 39(9):1028-1032 (1990).
- 87 **A New Way to Fight Diabetes.** *Newsweek* November 15, 1993
- 88 Pennisi. **Immune Therapy Stems Diabetes Progress.** *Science News* 145:37, January 15, 1995.
- 89 Dutta RC. **Peptide immunomodulators versus infection; an analysis.** *Immunology Letters.* 83(3):153-61 (2002). Immune stimulators have been found to be useful in helping to fight off infections, while immunosuppressors have been found useful in autoimmune conditions and transplants.
- 90 Hughes RA. **Immunological treatment of multiple sclerosis.** *Journal of Neurology* 230(2):73-80 (1983). Transfer factor (PRP) slowed the progression of the disease whereas interferon and levamisole did not.
- 91 Nitsch, A, Nitsch, FP. **Clinical Use of Bovine Colostrum.** *Journal of Orthomolecular Medicine* 13(2) (1998). Low molecular weight components of colostrum (PRPs) were used in a clinical study for the treatment of rheumatoid arthritis with promising results.
- 92 Kruzel M, Bacsi A, Choudhury B, Sur S, Boldogh I. **Lactoferrin decreases pollen antigen-induced allergic airway inflammation in a murine model of asthma.** *Immunology* 119(2):159-66 (2006). Pollen grains contain reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidases and in contact with mucosal surfaces generate
- Peptide Immunotherapy: Colostrum—  
A Physician's Reference Guide**
- 366 superoxide anion (O<sub>2</sub><sup>-</sup>). In the presence of iron, O<sub>2</sub><sup>-</sup> may be converted to more reactive oxygen radicals, such as to H<sub>2</sub>O<sub>2</sub> and/or \*OH, which may augment antigen-induced airway inflammation. LF lowered the increase in cellular reactive oxygen species (ROS) levels in bronchial epithelial cells. The results suggest the utility of LF in human allergic inflammatory disorders.
- 93 Tsai WJ, Liu HW, Yen JH, Chen JR, Lin SF, Chen TP. **Lactoferrin in rheumatoid arthritis and systemic lupus erythematosus.** *Gaoxiang Y Xue Ke Xue Za Zhi* 7(1):22-26 (1991).
- 94 Hraba T, Wieczorek Z, Janusz M, Lisowski J, Zimecki M. **Effect of proline-rich polypeptide on experimental autoimmune response to erythrocytes.** *Archivum immunologiae et therapiae experimentalis (Warszawa)* 34(4):437-443 (1986).
- 95 Zimecki M, Hraba T, Janusz M, Lisowski J, Wieczorek Z. **Effect of a proline-rich polypeptide (PRP) on the development of hemolytic anemia and survival of New Zealand black (NZB) mice.** *Archivum immunologiae et therapiae experimentalis (Warszawa)* 39(5-6):461-461 (1991).
- 96 Murdoch C, Finn A. **Chemokine receptors and their role in inflammation and infectious diseases.** *Blood* 95(10):3032-3042 (2000).
- 97 Christopherson KW, Hromas RA. **Endothelial chemokines in autoimmune disease.** *Current Pharmaceutical Design* 10(2):145-154 (2004).
- 98 Kidd, PM. **Autism, an extreme challenge to integrative medicine. Part I: the knowledge base.** *Alternative Medicine Review* August 2002.
- 99 Manev R, Manev H. **Aminoglycoside antibiotics and autism: a speculative hypothesis.** *BMC Psychiatry* 1:5-7 (2001).
- 100 **Autism, Autoimmunity and Immunotherapy:** a Commentary by Vijendra K. Singh, Ph.D. Department of Biology & Biotechnology Center, Utah State University, Logan Scientific Board Member, Autism Autoimmunity Project.
- 101 Kidd PM. **Autism, an extreme challenge to integrative medicine. Part II: medical management.** *Alternative Medicine Review* December 2002.
- 102 Wyplosz, B *et al.* **Correlation Between Chlamydia pneumoniae Detection From Coronary Angioplasty Balloons and Atherosclerosis Severity,** *J Am Coll Cardiol, 2006; 47:1229-1231, doi:10.1016/j.jacc.2005.12.037* (Published online 21 February 2006).
- 103 Lange LG, Schreiner GF. **Immune Mechanisms of Cardiac Disease.** *New England Journal of Medicine.* 330:1129-1135 (1994).

104 Gilliland SE, Nelson CR, Maxwell C. **Assimilation of Cholesterol by Lactobacillus Acidophilus.** *Applied and Environmental Microbiology* 49:377-381 (1985).

105 Frystyk J, Ledet T, Moller N, Flyvbjerg A, Orskov H. **Cardiovascular disease and insulin-like growth factor I.** *Circulation* 106(8):893-895 (2002).

106 Bayes-Genis A, Conover CA, Schwartz RS. **The insulin-like growth factor axis: A review of atherosclerosis and restenosis.** *Circulation Research* 86(2):125-130 (2000). 367

#### References

IGF-I and -2 function as mediators of cardiovascular disease. The dynamic balance of IGFs, their binding proteins (IGFBP) and the proteases (IGFBP proteases) which remove the binding proteins from the IGFs, activating them, constitutes the IGF axis which determines the extent of IGF-dependent cellular effects. Dysregulation of the IGF axis can lead to coronary atherosclerosis through effects on smooth muscle growth, migration, and extracellular matrix synthesis in the atherosclerotic plaque. IGF-I promotes macrophage chemotaxis, excess LDL cholesterol uptake and release of proinflammatory cytokines.

107 Robert L, Godeau G, Gavignet-Jeannin C, Groult N, Six C, Robert AM. **The Effect of Procyanidolic Oligomers on Vascular Permeability. A Study Using Quantitative Morphology.** *Pathologie Biologie* 38:608-616 (1990).

108 Groziak SM, Miller GD. **Natural bioactive substances in milk and colostrum: effects on the arterial blood pressure system.** *British Journal of Nutrition* 84(Suppl 1):S119-S125 (2000).

109 FitzGerald RJ, Murray BA, Walsh DJ. **Hypotensive peptides from milk proteins.** *Journal of Nutrition* 134(4):980S-988S (2004).

110 Jorde R, Bonna KH. **Calcium from dairy products, vitamin D intake, and blood pressure: the Tromso Study.** *American Journal of Clinical Nutrition* 71(6):1530-1535 (2000).

111 Cesarone MR, Belcaro G, Di Renzo A, Dugall M, Cacchio M, Ruffini I, Pellegrini L, Del Boccio G, Fano F, Ledda A, Bottari A, Ricci A, Stuard S, Vinciguerra G. **Prevention of Influenza Episodes With Colostrum Compared With Vaccination in Healthy and High-Risk Cardiovascular Subjects: The Epidemiologic Study in San Valentino.** *Clinical and Applied Thrombosis/Hemostasis* 13(2):130-136 (2007).

112 Gross N, Carey J, Hamilton J. **Quiet Strides in the War on Cancer.** *Business Week*. p. 150, February 6, 1995.

113 Lidbeck A, Allinger UG, Orrhage KM, Ottova L, Brismar B, Gustafsson JA, Raftar J, Nord CE. **Impact of Lactobacillus Acidophilus Supplements on the Fecal Microflora and Soluble Fecal Bile Acids in Colon Cancer Patients.** *Microbial Ecology in Health and Disease* 4:81-8 (1991).

114 Lidbeck A, Nord CE, Gustafsson JA, Raftar J. **Lactobacilli, Anticarcinogenic Activities and Human Intestinal Microflora.** *European Journal of Cancer Prevention* 1:341-353 (1992).

115 Yamaguchi M, Imai T, Maeda T, Sakata M, Miyake A, Linzer DI. **Cyclic adenosine 3',5'-monophosphate stimulation of placental proliferin and proliferin-related protein secretion.** *Endocrinology* 136(5):2040-2046 (1995).

116 Linzer DI, Nathans D. **A new member of the prolactin-growth hormone gene family expressed in mouse placenta.** *EMBO Journal* 4(6):1419-1423 (1985).

117 Bengtson NW, Linzer DI. **Inhibition of tumor growth by the antiangiogenic placental hormone, proliferin-related protein.** *Molecular Endocrinology* 14(12):1934-43 (2000).

Peptide Immunotherapy: Colostrum—

#### A Physician's Reference Guide

368 118 118 Regulier E, Paul S, Marigliano M, Kintz J, Poitevin Y, Ledoux C, Roecklin D, Cauet G, Calenda V, Homann HE. **Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach.** *Cancer and Gene Therapy* 8(1):45-54 (2001).

119 Yamaguchi M, Ogren L, Barnard R, Imai T, Sawada T, Miyake A, Talamantes F. **Selective inhibition of mouse placental lactogen II secretion by tumour necrosis factor alpha.** *Journal of Endocrinology* 143(1):95-105 (1994).

120 Blach-Olszewska Z, Janusz M. **Stimulatory effect of ovine colostrinin (a prolinerich polypeptide) on interferons and tumor necrosis factor production by murine resident peritoneal cells.** *Archivum immunologiae et therapiiae experimentalis (Warszawa)* 45(1):43-47 (1997).

121 Inglot AD, Janusz M, Lisowski J. **Colostrinin, a proline-rich polypeptide from ovine colostrum, is a modest cytokine inducer in human leukocytes.** *Archivum immunologiae et therapiiae experimentalis (Warszawa)* 44(4):215-224 (1996).

122 Sekine K, Watanabe E, Nakamura J, Takasuka N, Kim DJ, Asamoto M, Krutovskikh V, Baba-Toriyama H, Ota T, Moore MA, Masuda M, Sugimoto H, Nishino H, Kakizoe T, Tsuda H. **Inhibition of azoxymethane-initiated colon tumor by bovine lactoferrin administration in F344 rats.** *Japanese Journal of Cancer Research* 88(6):523-526 (1997).

Rats were treated with azoxymethane, a chemical which induces colon cancer in rats. They were then given bovine lactoferrin orally for 36 weeks. 57.5% of the rats in the control group which received no lactoferrin developed carcinomas, while only 25% of the rats which received 0.2% lactoferrin solutions developed carcinomas. Rats which received a stronger dose of lactoferrin, 2%, had only a 15% rate of tumor development.

123 Tanaka T, Kawabata K, Kohno H, Honjo S, Murakami M, Ota T, Tsuda H.

**Chemopreventive effect of bovine lactoferrin on 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male F344 rats.** *Japanese Journal of Cancer Research* 91(1):25-33 (2000). A more detailed study of the effect of lactoferrin administration on chemically induced carcinomas of the tongue in rats. It was found again that a 2% lactoferrin solution produced better protection against the development of carcinoma than the weaker 0.2% solution, though both provided more protection than the control group. With a 2% solution, only 20% of the rats developed cancer, and they showed 64% less multiple tumors than the control group. It was further determined that the method of action of the lactoferrin was through modification of cell proliferation and detoxifying enzymes, such as glutathione S-transferase and quinone reductase.

124 Kuhara T, Iigo M, Itoh T, Ushida Y, Sekine K, Terada N, Okamura H, Tsuda H. **Orally administered lactoferrin exerts an anti-metastatic effect and enhances production of IL-18 in the intestinal epithelium.** *Nutrition and Cancer* 38(2):192-199 (2000). Oral administration of bovine lactoferrin or its hydrolyzed form caused an increase in CD4+ and CD8+ lymphocytes and asialoGM1+ (a specific type of natural killer cell) in the spleen and blood, and their cytotoxic activities against several types of cancer cell lines

#### References

were increased. CD4+ and CD8+ lymphocytes were also increased in intestinal mucosa accompanied by a marked increase in IL-18 production. Using this model, the effects on metastasis of colon carcinoma to the lung was studied and significant inhibition of metastasis was found. The results suggest that the anti-metastatic effect of lactoferrin may be due to enhanced cellular immunity.

125 Tsuda H, Sekine K, Fujita K, Iigo M. **Cancer prevention by bovine lactoferrin and underlying mechanisms – a review of experimental and clinical studies.** *Biochemistry and Cell Biology* 80(1):131-136 (2002). Review article of studies which indicate that bovine lactoferrin is an effective anticancer agent in rat studies, capable of significantly inhibiting colon, esophagus, lung, bladder and tongue carcinogenesis. Following the administration of lactoferrin to animals which had been exposed to a variety of carcinogenic chemicals, phase I enzymes (which seek out carcinogenic materials and "switch them on") were inhibited in colon cancer test subjects while phase II enzyme (which act to detoxify the carcinogens switched on by the phase I enzymes) activity was increased in the tongue cancer study. There was a marked increase in Natural Killer Cell and cytotoxic T-lymphocyte activity in both the mucosal layer of the small intestine and peripheral blood cells, increasing the production of IL-18 and caspase-1 and the subsequent production of interferon-gamma cells. It was also found that lactoferrin has significant anti-Hepatitis C virus activity, and Hepatitis C is a leading cause of liver cancer in Japan.

126 Damiens E, Mazurier J, El Yazidi I, Masson M, Duthille I, Spik G, Boilly-Marier Y. **Effects of human lactoferrin on NK cell cytotoxicity against hematopoietic and epithelial tumor cells.** *Biochimica et Biophysica Acta* 1402(3):277-287 (1998). Human lactoferrin applied at levels found in inflammation was found to boost the cytotoxic activity of natural killer (NK) cells against hematopoietic and breast epithelial tumor cell lines. It also significantly increases the susceptibility to lysis of breast and colon epithelial tumor cell lines but not the hematopoietic tumor cells. Lactoferrin is shown to inhibit epithelial cell proliferation by blocking cell cycle progression.

127 Iigo M, Kuhara T, Ushida Y, Sekine K, Moore MA, Tsuda H. **Orally administered bovine lactoferrin induces caspase-1 and interleukin-18 in the mouse intestinal mucosa: a possible explanation for inhibition of carcinogenesis and metastasis.** *Cytokine* 25(1):36-44 (2004). Oral lactoferrin administration increased the production of IL-18 by intestinal epithelial cells followed by increases in caspase-1 and INF-g, which potentiate the activity of cytotoxic lymphocytes and natural killer cells in attacking cancer cells.

128 Damiens E, El Yazidi I, Mazurier J, Duthille I, Spik G, Boilly-Marier Y. **Lactoferrin inhibits G1 cyclin-dependent kinases during growth arrest of human breast carcinoma cells.** *Journal of Cell Biochemistry* 74(3):486-498 (1999). It is known that lactoferrin inhibits cell proliferation and suppresses tumor growth. The mechanism of how it does this is unknown, however. In this study, lactoferrin applied to a breast carcinoma cell line arrests

Peptide Immunotherapy: Colostrum—

*A Physician's Reference Guide*

370 the growth of these cells at the G1 [growth and preparation of the chromosomes for



replication] to S [DNA synthesis] transition of the cell cycle. The arrest is associated with a dramatic increase in the levels of Cdk2 [cyclin-dependent kinase 2] and cyclin E and an inhibition of Cdk2 kinase activity. Cdk4 activity is also decreased and Cdk inhibitor p21(CIP1) expression is increased. Lactoferrin also maintains the cell cycle regulator retinoblastoma protein pRb in a hypophosphorylated form. Therefore lactoferrin induces growth arrest by modulating the expression and activity of key G1 regulatory proteins.

129 Kroning R, Jones JA, Hom DK, Chuang CC, Sanga R, Los G, Howell SB, Christen RD.

**Enhancement of drug sensitivity of human malignancies by epidermal growth factor.** *British Journal of Cancer* 72(3):615-619 (1995). Study shows that a number of human cancers become more sensitive to chemotherapeutic agents in the presence of epidermal growth factor. Cancers showing increased sensitivity include ovarian carcinoma, cancers of the head, neck, cervix, colon, prostate and pancreas, and non-small-cell lung cancer. Drugs to which the cancers became more sensitized include most common chemotherapeutic agents, such as cisplatin, carboplatin, tetraplatin, taxol, melphalan and 5-fluorouracil.

130 Borissenko M. **Colostrum, growth factors and cancer.** Institute for Colostrum Research, 2004.

131 Nowa and McMichael. **How HIV defeats the immune system.** *Scientific American* Aug:58-65 (1995).

132 Harmsen MC, Swart PJ, Bethune M, Pauwels R, De Clercq E, TheTH, Meijer DK. **Antiviral Effects of Plasma and Milk Proteins: Lactoferrin Shows Potent Activity against Both Human Immunodeficiency Virus and Human Cytomegalovirus Replication In Vitro.** *Journal of Infectious Diseases.* 172:380-8 (1995).

133 Anderson I. **Powdered Milk Cure for Fatal Diarrhea.** *New Scientist*, January 6 1994.

134 Rump JA, Aarndt R, Arnold A, Bendick C, Dichtelmuller H, Franke M, Helm EB, Jager H, Kampmann B, Kolb P. **Treatment of Diarrhoea in Human Immunodeficiency Virus-Infected Patients with Immunoglobulins from Bovine Colostrum.** *Clinical Investigator* 70(7):588-594 (1992).

135 Nord J, Ma P, DiJohn D, Tripodi S, Tacket CO. **Treatment with Bovine Hyperimmune Colostrum of Cryptosporidial Diarrhea in AIDS Patients.** *AIDS.* 4(6):581-584 (1990).

136 Mero A, Kahkonen J, Nykanen T, Parviainen T, Jokinen I, Takala T, Nikula T, Rasi S, Leppaluoto J. **IGF-I, IgA, and IgG responses to bovine colostrum supplementation during training.** *Journal of Applied Physiology* 93(2):7323-739 (2002).

137 Nieman DC, Berk LS, Simpson-Westerberg M, Arabatzis K, Youngberg S, Tan SA, Lee JW, Eby WC. **Effects of long-endurance running on immune system parameters and lymphocyte function in experienced marathoners.** *International Journal of Sports Medicine* 10(5):317-323 (1989).

138 Berk LS, Nieman DC, Youngberg WS, Arabatzis K, Simpson-Westerberg M, Lee JW, 371

#### References

Tan SA, Eby WC. **The effect of long endurance running on natural killer cells in marathoners.** *Medicine and Science in Sports and Exercise* 22:207-212 (1990).

139 Sparling SB, Nieman DC, O'Connor PJ. **Selected scientific aspects of marathon racing. An update on fluid replacement, immune function, psychological factors and the gender difference.** *Sports Medicine* 15(2):116-132 (1993).

140 Burke ER. **Colostrum as an Athletic Enhancer and Help for AIDS.** *Nutrition Science News*, May, 1996.

141 Buckley JD, Brinkworth GD, Southcott E, Butler RN. **Bovine colostrum and whey protein supplementation during running training increase intestinal permeability.** *Asia Pacific Journal of Clinical Nutrition* 13(Suppl):S81 (2004).

142 Buckley JD, Abbott MJ, Brinkworth GD, Whyte PB. **Bovine colostrum supplementation during endurance running training improves recovery, but not performance.** *Journal of Science and Medicine in Sport* 5(2):65-79 (2002). Supplementation with colostrum did not increase serum IGF-I levels or initial performance, but it did significantly improve performance in a second round of performance.

143 Coombes JS, Conacher M, Austen SK, Marshall PA. **Dose effects of oral bovine colostrum on physical work capacity in cyclists.** *Medicine and Science in Sports and Exercise* 34(7):1184-1188 (2002). Colostrum supplementation produced a slight but significant increase in performance in competitive cyclists.

144 Hofman Z, Smeets R, Verlaan G, Lugt R, Verstappen PA. **The effect of bovine colostrum supplementation on exercise performance in elite field hockey players.** *International Journal of Sports Nutrition and Exercise Metabolism* 12(4):461-469 (2002). Colostrum supplementation improved sprint performance of field hockey players compared to whey supplementation.

145 Antonio J, Sanders MS, Van Gammeren D. **The effects of bovine colostrum supplementation on body composition and exercise performance in active men**

**and women.** *Nutrition* 17(3):243-247 (2001). Colostrum supplementation produced a significant increase in lean body mass compared to whey supplementation

146 Mero A, Miikkulainen H, Riski J, Pakkanen R, Aalto J, Takala T. **Effects of bovine colostrum supplementation on serum IGF-I, IgG, hormone, and saliva IgA during training.** *Journal of Applied Physiology* 83(4):1144-1151 (1997). Colostrum supplementation increases levels of IGF-I in athletes during strength and speed training.

147 Mero A, Kahkonen J, Nykanen T, Parviainen T, Jokinen I, Takala T, Nikula T, Rasi S, Leppaluoto J. **IGF-I, IgA, and IgG responses to bovine colostrum supplementation during training.** *Journal of Applied Physiology* 93(2):732-739 (2002). Although colostrum supplementation increases IGF-I levels in the blood, this increase is not due to absorption of the IGF-I from colostrum.

148 Cross CE, Halliwell B, Borish ET, Pryor WA, Ames BN, Saul RL, McCord JM, Harman D. **Oxygen radicals and human disease.** *Annals of Internal Medicine* 107(4):526-545

Peptide Immunotherapy: *Colostrum—*  
*A Physician's Reference Guide*

372 (1987). Oxygen free radicals, the by-products of normal metabolism, have been implicated in disease processes ranging from carcinogenesis to aging, emphasizing the importance of antioxidants in combating these conditions.

149 Ames BN, Shigenaga MK, Hagen TM. **Oxidants, antioxidants, and the degenerative diseases of aging.** *Proceedings of the National Academy of Sciences USA* 90(17):7915-7922 (1993). Oxidant by-products of metabolism cause significant damage to DNA, proteins and lipids. This damage results in aging and the degenerative diseases associated with aging, such as cancer, cardiovascular disease, immune system decline, brain dysfunction and cataracts. Antioxidant defenses against these diseases decline with age, necessitating the supplementation of antioxidants in the diet.

150 Kurz DJ, Decary S, Hong Y, Trivier E, Akhmedov A, Erusalimsky JD. **Chronic oxidative stress compromises telomere integrity and accelerates the onset of senescence in human endothelial cells.** *Journal of Cell Science* 117:2417-2426 (2004). Oxidative stress due to the buildup of oxidization by-products has been linked to the onset of cell senescence in blood vessel lining cells by disrupting telomere integrity. Telomeres are the "tails" of the chromosomes, the length of which determine the number of cell divisions a cell can undergo before reaching its limit. Glutathione, a powerful natural antioxidant, is crucial in maintaining telomere integrity.

151 Borissenko M. **Glutathione: A powerful anti-oxidant found in colostrum.** NZMP August 2002. Both glutathione and its chemical predecessors are present in large quantities in colostrum. As glutathione is not absorbed directly, glutathione production in the body can only be accomplished by supplementation with its antecedents, cystine, glycine and glutamic acid, all of which are abundant in colostrum.

152 Buescher ES, McIlheran SM. **Antioxidant properties of human colostrum.** *Pediatric Research* 24(1):14-19 (1988). Colostrum reduces ferricytochrome C in polymorphonuclear leucocytes (PMNs) and also disrupts other metabolic and enzymatic activities of PMNs which are crucial in PMN respiratory burst mediation of acute inflammation, showing that colostrum is a powerful antioxidant.

153 Buescher ES, McIlheran SM. **Colostrum antioxidants: separation and characterization of two activities in human colostrum.** *Journal of Pediatric Gastroenterology and Nutrition* 14(1):47-56 (1992). Colostrum interferes with the production of PMN respiratory burst products in two ways, ascorbate and uric acid.

154 Boldogh I, Liebenthal D, Hughes TK, Juelich TL, Georgiades JA, Kruzel ML, Stanton GJ. **Modulation of 4HNE-mediated signaling by proline-rich peptides from ovine colostrum.** *Journal of Molecular Neuroscience* 20(2):125-134 (2003). Colostrinin down regulates lipid peroxidation, inhibits glutathione depletion and reduces intracellular levels of reactive oxygen species (ROS). This is one more way that colostrum demonstrates antioxidant activity.

155 Wakabayashi H, Matsumoto H, Hashimoto K, Teraguchi S, Takase M, Hayasawa H.

### 373 References

**Inhibition of iron/ascorbate-induced lipid peroxidation by an N-terminal peptide of bovine lactoferrin and its acylated derivatives.** *Bioscience, Biotechnology, Biochemistry* 63(5):955-957 (1999). Lactoferrin also plays an important antioxidant role in colostrum by preventing lipid peroxidation.

156 Ulcova-Galova Z, Fialova P, Krauz V. **[Immunologic factors in human colostrum and milk.]** *Casopis Lekarů Ceskych* 133(9):275-276 (1994). Colostrum was found to contain IgG, IgM, IgD, IgA, sIgA, C3, C4, orosomucoid, prealbumin, alpha 1-antitrypsin, alpha 1-fetoprotein, alpha 2-macroglobulin, haemopexin, haptoglobulin, beta 2-microglobulin, alpha 2-AP glycoprotein, and IgE.

157 Gutteridge JM, Smith A. **Antioxidant protection by haemopexin of haemstimulated**

**lipid peroxidation.** *Biochemical Journal* 256:861-865 (1988). Haem is a low molecular weight form of iron that is capable of taking part in oxygen radical reactions that can lead to the degradation of proteins, lipids, carbohydrates and DNA. Haemopexin can inhibit such oxidative reactions by as much as 90%.

158 Korhonen H, Syvaaja EL, Ahola-Luttilla H, Sivela S, Kopola S, Husu J, Kosunen TU.

**Bactericidal effect of bovine normal and immune serum, colostrum and milk against *Helicobacter pylori*.** *Journal of Applied Bacteriology* 78(6):655-662 (1995).

*Helicobacter pylori* is a major cause of gastritis and ulcers in humans. Serum and colostrum from non-immunized Friesian cows were found to be highly bactericidal against *H. pylori*. Post-colostral milk did not show any bactericidal effect against *H. pylori*.

159 Bitzan MM, Gold BD, Philpott DJ, Huesca M, Sherman PM, Karch H, Lissner R, Lingwood CA, Karmali MA. **Inhibition of *Helicobacter pylori* and *Helicobacter mustelae***

**binding to lipid receptors by bovine colostrum.** *Journal of Infectious Diseases* 177(4):955-961 (1998). *H. pylori* and *H. mustelae* (a gastric pathogen of ferrets) are both bound by lipid receptors (phosphatidylethanolamine, gangliotetraosylceramide and gangliotriaosyl-ceramide) in the gut, allowing them to carry out their pathogenic activities. Bovine colostrum, however, was shown to prevent binding of the pathogens to these lipid receptors even though there was no detectable anti-*H. pylori* antibody activity in the colostrum.

160 Wada T, Aiba Y, Shimizu K, Takagi A, Miwa T, Koga Y. **The therapeutic effect of bovine lactoferrin in the host infected with *Helicobacter pylori*.** *Scandinavian Journal of Gastroenterology* 34(3):238-243 (1999). Mice infected with *H. pylori* were given a daily dose of bovine lactoferrin for 2-4 weeks. Their intestines were then examined for bacterial content. Numbers of *H. pylori* were reduced to 10% of pre-lactoferrin levels and greatly decreased the numbers of *H. pylori* bound to the intestinal wall. Serum antibody titer to *H. pylori* were reduced to practically zero, indicating that the immune response of the host was no longer recognizing *H. pylori* infection. Therefore it was deduced that lactoferrin has a direct antibacterial effect on *H. pylori* infection and prevents binding of the pathogen to the intestinal lining.

Peptide Immunotherapy: *Colostrum*—

*A Physician's Reference Guide*

374 | 161 Casswall TH, Nilsson HO, Bjorck L, Sjostedt S, Xu L, Nord CK, Boren T, Wadstrom T, Hammarstrom L. **Bovine anti-*Helicobacter pylori* antibodies for oral immunotherapy.** *Scandinavian Journal of Gastroenterology* 37(12):1380-1385 (2002). Bovine colostrum with high titers against *H. pylori* was given to *H. pylori* infected mice. Comparison of treated mice with control mice showed a 50-66% cure rate for *H. pylori* infection in treated mice. Binding studies also showed that the colostrum prevented binding of the *H. pylori*.

162 Masson PL, Heremans JF, Dive JH. **An iron-binding protein common to many external secretions.** *Clinica Chimica Acta* 14:735 (1966). Lactoferrin inhibits the growth of siderophilic (iron-loving) bacteria and *Candida albicans*.

163 Ogra PL, Losonsky GA, Fishaut M. **Colostrum derived immunity and maternal neonatal interaction.** *Annals of the New York Academy of Sciences* 409:82-92 (1983). Peyer's patches are found throughout the intestinal tract, and groups of similar immunoactive cells are found in the bronchial mucosa. Both the intestinal and bronchial immunoactive cell groups respond to allergens, antigens and pathogens by neutralizing or destroying them. In newborns, these special cell groups are not immediately operative but protection is provided by a variety of immune factors from the mother's colostrum. Antibodies found in colostrum protect against *Escherichia coli*, *Salmonella*, *Shigella*, *Vibrio cholera*, *Bacteriodes fragilis*, *Streptococcus pneumoniae*, *Bordetella pertussis*, *Clostridium diphtheria*, *Clostridium tetani*, *Streptococcus mutans* and *Candida albicans*.

164 Lilius EM, Marnila P. **The role of colostral antibodies in prevention of microbial infections.** *Current Opinion in Infectious Diseases* 14(3):295-300 (2001). Colostrum offers passive protection against a variety of microbial pathogens in the form of specific immunoglobulin A, G and M antibodies. It is especially effective in the prevention of various gastroenteric infections.

165 Moller W, Lissner R, Nitsche D. **Use of bovine colostral milk as a preparation for the protection of the liver.** US Patent #5,710,132 (1998). Whole bovine colostrum or an immunoglobulin preparation from colostrum are used to protect the liver from bacterial, viral or protozoan diseases, such as *E. coli*, rotavirus or cryptosporidia infection, as well as detoxify the liver by removing toxic protein metabolites such as ammonia. It can also be used to treat the effects of various liver diseases, such as liver inflammation, viral hepatitis, fibrosis of the liver, cirrhosis of the liver, fatty liver, and so forth. These effects include disturbances of the liver's detoxification, excretory, conjugational and synthesizing functions, portal hypertension due to liver disease, and even coma due to liver failure. Supplementation can also be used to relieve stress on the liver due to liver insufficiency as a result of liver parenchyma damage or viral hepatitis, allowing the liver to heal and recover

function.

166 Tavakkol, Elder JT, Griffiths CE, Cooper KD, Talwar H, Fisher GJ, Keane KM, Foltin SK, Voorhees JJ. **Expression of growth hormone receptor, insulin-like growth factor I (IGF-I) and IGF-I receptor mRNA and proteins in human skin.** *Journal of* 375

#### References

*Investigative Dermatology* 99(3):343-349 (1992). Receptors for growth hormone and IGF-I were isolated from human skin, indicating that skin cells may have the ability to react directly to growth hormone stimulation.

167 Hyde C, Hollier B, Anderson A, Harkin D, Upton Z. **Insulin-like Growth Factors (IGF) and IGF-Binding Proteins Bound to Vitronectin Enhance Keratinocyte Protein Synthesis and Migration.** *Journal of Investigative Dermatology* 122(5):1198-1206 (2004). IGF-II binds directly to vitronectin, a component of the extracellular skin matrix, to enhance protein synthesis and migration by skin cells in wound healing and skin regeneration.

168 Bhora Y, et al. **Effect of growth factors on cell proliferation and epithelialization in human skin.** *Journal of Surgical Research* 59(2):236-244 (1995). Fibroblast growth factor (FGF), IGF-I and epithelial growth factor (EGF) are important factors in healing skin wounds. EGF in particular is capable of initiating epithelial growth.

169 El Ghalbzouri A, Hensbergen P, Gibbs S, Kempenaar J, van der Schors R, Ponec M. **Fibroblasts facilitate re-epithelialization in wounded human skin equivalents.** *Laboratory Investigation* 84(1):102-112 (2004). Re-epithelialization of wounds begins with the migration of keratinocytes (skin cells) from the edges of the wound. This migration is dependent on the interaction of the keratinocytes with dermal fibroblasts and extracellular matrix. This migration is accelerated by EGF and keratinocyte growth factor.

170 Moller S, Jensen M, Svensson P, Skakkebaek NE. **Insulin-like growth factor I (IGF-I) in burn patients.** *Burns* 17(4):279-281 (1991). Impaired wound healing in large burns is related to suppressed levels of IGF-I in the burn area.

171 Kasemkijwattana C, Menetrey J, Bosch P, Somogyi G, Moreland MS, Fu FH, Buranapanitkit B, Watkins SS, Huard J. **Use of growth factors to improve muscle healing after strain injury.** *Clinical Orthopedics* 370:272-285 (2000). Muscle injuries, such as strains, are common in athletes. The use of growth factors, such as IGF-I, in treating such injuries is explored.

172 Sato K, Li Y, Foster W, Fukushima K, Badlani N, Adachi N, Usas A, Fu FH, Huard J. **Improvement of muscle healing through enhancement of muscle regeneration and prevention of fibrosis.** *Muscle & Nerve* 28(3):355-372 (2003). IGF-I can improve muscle regeneration in injured muscle.

173 Liang L, Ding YQ. **[Effect of cytokines on repair of tendon injury]** *Zhongguo Xiufu Chongjian Waikexue* (Chinese) 14(5):283-285 (2000). Cytokines, such as the growth factors, can accelerate tendon repair.

174 Molloy T, Wang Y, Murrell G. **The roles of growth factors in tendon and ligament healing.** *Sports Medicine* 33(5):381-394 (2003). The roles of five different growth factors, IGF-I, TGF- $\beta$ , vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF), in healing tendon and ligament injuries is explored. Each plays a different but vital role in the process.

Peptide Immunotherapy: Colostrum—

*A Physician's Reference Guide*

#### 376 Chapter 5 Notes

175 Roodman GD. **Mechanisms of Bone Metastasis. Review Article.** *New England Journal of Medicine* 350:1655 (2004).

176 Sporn MB, Roberts AB, Shull JH, Smith JM, Ward JM, Sodek J. **Polypeptide transforming growth factors isolated from bovine sources and used for wound healing in vivo.** *Science* 219(4590):1329-1331 (1983). TGF from cows was used to accelerate the healing of experimental wounds in rats by increasing the accumulation of protein, collagen and DNA in the affected area.

177 Holloway NM, Tyler JW, Lakritz J, Carlson SL, Holle J. **Serum immunoglobulin G concentrations in calves fed fresh and frozen colostrum.** *Journal of the American Veterinary Medicine Association* 219(3):357-359 (2001). No significant difference was found between the IgG concentrations of fresh bovine colostrum and frozen and thawed bovine colostrum.

178 Powick, WC. **Inactivation of Vitamin A by rancid fat.** *Journal of Agricultural Research* 31(11):1017-1026 (1925).

179 Godden SM, Smith S, Feirtag JM, Green LR, Wells SJ, Fetrow JP. **Effect of on-farm commercial batch pasteurization of colostrum on colostrum and serum immunoglobulin concentrations in dairy calves.** *Journal of Dairy Science* 86(4):1503-

1523 (2003). Pasteurization of high quality colostrum reduces IgG concentrations by 23.6-58.5%.

180 Meylan M, Rings DM, Shulaw WP, Kowalski JJ, Bech-Nielsen S, Hoffsis GF. **Survival of *Mycobacterium paratuberculosis* and preservation of immunoglobulin G in bovine colostrum under experimental conditions simulating pasteurization.** *American Journal of Veterinary Research* 57(11):1580-1585 (1996). Pasteurization produced a mean loss of 12.3% of the IgG in colostrum.

181 Li-Chan E, Kummer A, Losso JN, Kitts DD, Nakai S. **Stability of bovine immunoglobulins to thermal treatment and processing.** *Food Research International* 28(1):9-16 (1995). Pasteurized milk, reconstituted skim milk powder and whey from cheddar cheese all showed high levels of IgG while canned evaporated milk and UHT sterilized milk had little or no IgG.

182 Yolken RH, Kummer A, Losso JN, Kitts DD, Nakai S. **Antibody to human rotavirus in cow's milk.** *New England Journal of Medicine* 312(10):605-610 (1985). Raw and pasteurized milk contain antibodies against rotavirus, an important cause of gastroenteritis and diarrhea in infants. However, infant formulas and other sterile milk preparations had little or no anti-rotaviral activity.

183 Dominguez E, Perez MD, Calvo M. **Effect of heat treatment on the antigen-binding activity of anti-peroxidase immunoglobulins in bovine colostrum.** *Journal of Dairy Science* 80(12):3182-3187 (1997). A negative correlation was made between temperature

#### References

and time in the denaturation of IgG, i.e. the higher the temperature, the shorter the time needed for denaturation to occur.

184 Collier RJ, Miller MA, Hildebrandt JR, Torkelson AR, White TC, Madsen KS, Vicini JL, Eppard PJ, Lanza GM. **Factors affecting insulin-like growth factor-I concentration in bovine milk.** *Journal of Dairy Science* 74(9):2905-2911 (1991). IGF-1 levels are highest in colostrum and lower in mature milk. Concentration was not altered by pasteurization (79°C for 45 seconds) but was undetectable at higher temperatures (121°C for 5 minutes) used for infant formula preparation and in commercial infant formula.

185 Paulsson MA, Svensson U, Kishore AR, Naidu AS. **Thermal behavior of bovine lactoferrin in water and its relation to bacterial interaction and antibacterial activity.** *Journal of Dairy Science* 76(12):3711-3720 (1993). Lactoferrin which was either unheated or pasteurized showed similar activity, while lactoferrin exposed to UHT treatment decreased its ability to bind to bacterial species and destroyed its ability to inhibit bacterial growth.

#### Chapter 6 Notes

186 Mietens C, Keinhorst H, Hilpert H, Gerber H, Amster H, Pahud JJ. **Treatment of infantile *E. coli* gastroenteritis with specific bovine anti-*E. coli* milk immunoglobulins.** *European Journal of Pediatrics* 132:239-52 (1979).

187 Tacket CO, Losonsky G, Link H, Hoang Y, Guesry P, Hipert H, Levine MM. (1988).

**Protection by milk immunoglobulin concentrate against oral challenge with enterogenic *Escherichia coli*.** *New England Journal of Medicine* 318:1240-1241 (1988).

188 Tzipori CO, Binion SB, Bostwick E, Losonsky G, Roy MJ, Edelman R. **Remission of diarrhoea due to cryptosporidiosis in an immunodeficient child treated with hyperimmune bovine colostrum.** *British Medical Journal* 293:1276-1277 (1986).

189 Ebina T, Sato A, Umezu K, Ishida N, Ohyama S, Oizumi A, Kitaoka S, Suzuki H, Kunno T. **Prevention of rotavirus infection by oral administration of cow colostrum containing antihuman rotavirus antibody.** *Medical Microbiology and Immunology* 174:177-85 (1985).

190 Brussow H, Hipert H, Walther J, Sidoti J, Meitens C, Bachman P. **Bovine milk immunoglobulins for passive immunity to infantile rotavirus gastroenteritis.** *Journal of Clinical Microbiology* 25:982-986 (1987).

191 Hilpert H, Brussow H, Meitens C, Sidoti J, Lerner L, Werchau H. **Use of bovine milk concentrate containing antibody to rotavirus to treat rotavirus gastroenteritis in infants.** *Journal of Infectious Diseases* 156:158-66 (1987).

192 Tacket CO, Binion SB, Bostwick E, Losonsky G, Roy MJ, Edelman R. (1992). **Efficacy of bovine milk immunoglobulin concentrate in preventing illness after *Shigella* Peptide Immunotherapy: Colostrum—**

*A Physician's Reference Guide*

**378 flexneri challenge.** *American Journal of Tropical Medicine and Hygiene* 47:276-283 (1992).

193 Tyrell D. **Breast feeding and virus infection: the immunity of infant feeding.** New York, Plenum Press, 1980, pp. 55-61.

194 Khazenson, 1980, op. cit.

195 Hilpert H, Gerber H, Amster H, Pahud JJ, Ballabriga A, Arcalis L, Farriaux JP, de Peyer E,

- Nussle D. **Bovine milk immunoglobulins (Ig) and their possible utilisation in industrially prepared infant's milk formulae.** In: Food and Immunology, Swedish Nutritional Foundation Symposium XIII, L. Hambraeus, L. A. Hanson, and H. McFarlane, eds., pp 182-196. Almqvist and Wiksell, Stockholm, 1977.
- 196 Rona Z. **Bovine Colostrum emerges as immunity modulator.** *American Journal of Natural Medicine* 5(2):19-23 (1998).
- 197 Kim K, Keller MA, Heiner DC. **Immunoglobulin G subclasses in human colostrum, milk and saliva.** *Acta Paediatrica* 81(2):113-118 (1992). Human colostrum contains 47% IgG1, 44% IgG2, IgG3 <4%, and IgG4 6%.
- 198 Aalberse RC, Van der Gaag R, Van Leeuwen J. **Serological aspects of IgG4 antibodies I. Prolonged immunisation results in an IgG4-restricted response.** *Journal of Immunology* 130(2):722-726 (1983). Individuals immunized over a period of several years with phospholipase from honey bee venom, grass pollen allergen or house dust mite allergen show a shift in IgG4:IgG1 antibody ration that finally results in an IgG4 dominated antibody response.
- 199 Seto A, Okabe T, Ito Y. **Immunoglobulin M associated with secretory component and immunoglobulin A deficiency in bovine colostrum.** *American Journal of Veterinary Research* 38(11):1895-1896 (1977). IgM was found in bovine colostrum associated with the secretory component of sIgA.
- 200 Boes M, Prodeus AP, Schmidt T, Carroll MC, Chen J. **A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection.** *Journal of Experimental Medicine* 188(12):2381-2386 (1998). Mice were tested for their response to an experimentally induced systemic bacterial infection. 20% of wild mice died within 32 hours, while 70% of IgM deficient mice died within the same time period. When IgM deficient mice were given IgM, their resistance was restored to that of wild mice.
- 201 Diamond MS, Sitati EM, Friend LD, Higgs S, Shrestha B, Engle M. **A critical role for induced IgM in the protection against West Nile virus infection.** *Journal of Experimental Medicine* 198(12):1853-1862 (2003). Mice deficient in the production of secreted IgM, even though they were still capable of producing surface IgM and other immunoglobulins, were much more susceptible to lethal infection with West Nile virus than wild mice.
- 202 Thatcher EF, Gershwin LJ. **Colostrum transfer of bovine immunoglobulin E and dynamics of serum IgE in calves.** *Veterinary Immunology and Immunopathology* 20(4):325-334 (1989). Blood serum levels of IgE in calves was high for the first week postpartum, 379

#### References

- after which levels declined until 12 weeks of age, when they began to increase again. This suggests that passive transfer of IgE from the mother via colostrum is important in providing the calf immune protection during the first weeks of life.
- 203 Sarfati M, Vanderbeeken Y, Rubio-Trujillo M, Duncan D, Delespesse G. **Presence of IgE suppressor factors in human colostrum.** *European Journal of Immunology* 16(8):1005-1008 (1986). Human colostrum contains IgE-binding factors which inactivate IgE, suggesting an anti-allergy possible role for colostrum.
- 204 Keller MA, Heiner DC, Myers AS, Reisinger DM. **IgD in human colostrum.** *Pediatric Research* 19(1):122-126 (1985). Concentrations of IgD in human colostrum were measured in a range from 2.2-410 µg/dl (mean concentration 35 µg/dl).
- 205 Korhonen H, Marnila P, Gill HS. **Milk immunoglobulins and complement factors.** *British Journal of Nutrition* 84(Suppl 1):S75-S80 (2000). In addition to immunoglobulins, bovine colostrum also contains the complement system, which plays a crucial role in the passive immunization of the calf. Complement activity in bovine colostrum and milk has both hemolytic and bactericidal functions.
- 206 Nakajima S, Baba AS, Tamura N. **Complement system in human colostrum: presence of nine complement components and factors of alternative pathway in human colostrum.** *International Archives of Allergy and Applied Immunology* 54(5):428-433 (1977). All nine components of the complement system (C1-C9) have been found in human colostrum.
- 207 Lonnerdal B, Iyer S. **Lactoferrin: molecular structure and biological function.** *Annual Review of Nutrition* 15:93-110 (1995).
- 208 Harmsen MC, Swart PJ, de Bethune MP, Pauwels R, De Clercq E, The TH, Meijer DK. **Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro.** *Journal of Infectious Diseases* 172(2):380-388 (1995). Native lactoferrin from colostrum and milk completely blocked CMV infection and inhibited the HIV-1 cytopathic effect. Lactoferrin likely exerts its effect at the level of virus adsorption and/or penetration as the effect is no longer seen once the virus is inside target cells.
- 209 Andersson Y, Lindquist S, Lagerqvist C, Hernell O. **Lactoferrin is responsible for**

- the fungistatic effect of human milk.** *Early Human Development* 59(2):95-102 (2001). Lactoferrin inhibits the growth of *Candida albicans* through its ability to sequester iron.
- 210 Levay PF, Viljoen M. **Lactoferrin: a general review.** *Haematologica* 80(3):252-267 (1995).
- 211 Valenti P, Marchetti M, Superti F, Amendolia MG, Puddu P, Gessani S, Borghi P, Belardelli F, Antonini G, Seganti L. **Antiviral activity of lactoferrin.** *Advances in Experimental and Medical Biology* 443:199-203 (1998).
- 212 Superti F, Amendolia MG, Valenti P, Seganti L. **Anti-rotaviral activity of milk proteins: lactoferrin prevents rotavirus infection in the enterocyte-like cell** Peptide Immunotherapy: *Colostrum—A Physician's Reference Guide*
- 380 line HT-29.** *Medical Microbiology and Immunology (Berlin)* 186(2-3):83-91 (1997). Antiviral activity against rotavirus of alpha lactalbumin, beta lactoglobulin, apo-lactoferrin (iron-free) and iron saturated lactoferrin were compared to that of mucin, which has known antirotaviral activity. Beta lactoglobulin and both forms of lactoferrin showed anti-rotaviral activity with the strongest response elicited by apo-lactoferrin, which hinders viral attachment to cells by binding directly to the viruses. It also markedly inhibits viral antigen synthesis in the viral adhesion stage.
- 213 Hashizume S, Kuroda K, Murakami H. **Identification of lactoferrin as an essential growth factor for human lymphocytic cell lines in serum-free medium.** *Biochimica et Biophysica Acta* 763(4):377-382 (1983). Lactoferrin is an essential growth factor for lymphocytes. It has higher growth stimulatory activity than transferrin. Bovine lactoferrin was found to be as effective as human.
- 214 Gahr M, Speer CP, Damerau B, Sawatzki G. **Influence of lactoferrin on the function of human polymorphonuclear leukocytes and monocytes.** *Journal of Leukocyte Biology* 49(5):427-433 (1991). Polymorphonuclear leukocytes (PMN) exposed to lactoferrin from colostrum exhibit increased random motility and are able to produce more superoxide. Monocytes and monocyte-derived macrophages did not exhibit the same effects when exposed to lactoferrin, so this is a specific effect of lactoferrin on PMN.
- 215 Damiens E, Mazurier J, El Yazidi I, Masson M, Duthille I, Spik G, Boilly-Marier Y. **Effects of human lactoferrin on NK cell cytotoxicity against haematopoietic and epithelial tumour cells.** *Biochimica et Biophysica Acta* 1402(3):277-287 (1998). Lactoferrin has a pronounced effect on NK cell cytotoxicity against cells from hematopoietic and epithelial cell tumor lines.
- 216 Kuhara T, Yamauchi K, Tamura Y, Okamura H. **Oral administration of lactoferrin increases NK cell activity in mice via increased production of IL-18 and type I IFN in the small intestine.** *Journal of Interferon and Cytokine Research* 26(7):489-499 (2006). Orally administered bovine lactoferrin increases NK cell populations in blood and spleen and enhances interferon-gamma production. It also increases the production of IL-18 and increases the production of interferon-alpha and interferon-beta in the Peyer's Patches in the intestines and mesenteric lymph nodes.
- 217 Artym, J. **[Antitumor and chemopreventive activity of lactoferrin]** *Postępy Higieny i Medycyny Doświadczalnej* 60:352-369 (2006). Lactoferrin participates in iron homeostasis, immunoregulatory, anti-inflammatory, anti-tumor, and analgesic activity, regulation of bone metabolism, embryonic development, reproductive functions, and others. It demonstrates direct anti-tumor activity, such as lytic, pro-apoptotic (programmed cell death), antiproliferative, anti-angiogenic, anti-oxidant and chelation of iron. It also has chemopreventive properties, regulates the activity of phase I and phase II enzymes participating in the activation and detoxification of carcinogens, and regulates the composition of the intestinal microflora. It stimulates the release of a number of cytokines, including IL-1, IL-6,
- 381**
- References**
- IL-8, IL-18, INF-g and TNF-a. It increases the number and activity of T and B lymphocytes and NK cells and increases the phagocytic activity of monocytes and macrophages.
- 218 Ward PP, Uribe-Luna S, Conneely OM. **Lactoferrin and host defense.** *Biochemistry and Cell Biology* 80(1):95-102 (2002). Lactoferrin is a prominent component of the first line of defense against infection and inflammation. It accomplishes its activity through a variety of methods, most notably iron sequestration and its effect on down-regulating TNF- $\alpha$ , which controls the inflammatory cascade.
- 219 Elrod, KC, Moore WR, Abraham WM, Tanaka RD. **Lactoferrin, a potent tryptase inhibitor, abolishes late-phase airway responses in allergic sheep.** *American Journal of Respiratory Critical Care Medicine* 156(2 Pt 1):375-381 (1997). Lactoferrin released from neutrophil granules inhibits tryptase, which is involved in late-phase bronchoconstriction and airway hyperactivity in asthma.
- 220 Kuhara T, Iigo M, Itoh T, Ushida Y, Sekine K, Terada N, Okamura H, Tsuda H. **Orally administered lactoferrin exerts an antimetastatic effect and enhances**

**production of IL-18 in the intestinal epithelium.** *Nutrition and Cancer* 38(2):192-199 (2000). A study on the protective effects of lactoferrin supplementation against lung metastasis in experimentally induced colon cancer. In addition to the increase in cytotoxic cells seen in other studies, there was also an increase in IL-18 production in the intestinal epithelium, suggesting it plays a role in mediating the inhibition of the cancers.

221 Baveye S, Elass E, Mazurier J, Spik G, Legrand D. **Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process.** *Clinical Chemistry and Laboratory Medicine* 37(3):281-286 (1999).

222 Artym, 2006. op cit.

223 Chipman DM, Sharon N. **Mechanism of lysozyme action.** *Science* 165(892):454-465. Lysozyme degrades the outer wall of gram-positive bacteria by hydrolyzing  $\beta$ -1,4 linkages of outer wall constituents.

224 Ellison RT III, Giehl TJ. **Killing of gram-negative bacteria by lactoferrin and lysozyme.** *Journal of Clinical Investigation* 88(4):1080-1091 (1991). Lactoferrin and lysozyme act in concert to kill gram-negative bacteria. Lactoferrin alters the protective outer membrane of the bacteria, allowing lysozyme to penetrate to the inner membrane, disrupting it and causing the bacteria to lyse (burst).

225 Steele WF, Morrison M. **Anti-streptococcal activity of lactoperoxidase.** *Journal of Bacteriology* 97(2):635-639 (1969).

226 Bjorck L, Rosen C, Marshall V, Reiter B. **Antibacterial activity of the lactoperoxidase system in milk against pseudomonads and other gram-negative bacteria.** *Applied Microbiology* 30(2):199-204 (1975).

227 Pakkanen R, Aalto J. **Review Paper: Growth Factors and Antimicrobial Factors of Bovine Colostrum.** *International Dairy Journal* 1997(7):285-297 (1997). Cows pass immunity from mother to calf via the immune factors in colostrum. It also contains many Peptide Immunotherapy: *Colostrum—A Physician's Reference Guide*

382 growth factors. IGF-1 and IGF-2 are especially important in stimulating cell growth in the gut of the newborn. Both the growth factors and immune factors may become important components of clinical nutrition in the future.

228 Torre C, Jeusette I, Serra M, Brazis P, Puigdemont A. **Bovine colostrum increases proliferation of canine skin fibroblasts.** *Journal of Nutrition* 7(Suppl):2058S-2060S (2006). Bovine colostrum is a rich source of immunoglobulins, insulin-like growth factors, transforming growth factor- $\beta$ , platelet-derived growth factor, epidermal growth factor, basic fibroblast growth factor, vascular endothelial growth factor, tumor necrosis factor and telomerase. Bovine colostrum stimulates the proliferation of skin fibroblasts in dogs, an important model for topical applications in wound repair and periodontal tissue repair.

229 Donovan SM, Odle J. **Growth factors in milk as mediators of infant development.** *Annual Review of Nutrition* 14:147-167 (1994). Many of the growth factors found in colostrum and milk, such as IGF-I, IGF-II, insulin, relaxin, epidermal growth factor, TGF- $\alpha$ , TGF- $\beta$ , nerve growth factor and others, are essential to the normal growth and development of the newborn.

230 Borody TJ, Surace R, Warren E. **Tunnel vision in the bowel.** *Centre for Digestive Diseases, Australia* (2001). The growth factors in colostrum help heal intestinal erosions and ulcerations. It also contains anti-inflammatory factors and is nutrient rich.

231 Canalis E, McCarthy TL, Centrella M. **Growth factors and cytokines in bone cell metabolism.** *Annual Review of Medicine* 42:17-24 (1991). Growth factors regulate the growth and differentiated function of cells. Skeletal cells synthesize fibroblast growth factor, platelet-derived growth factor, insulin-like growth factor, transforming growth factor beta, and additional cytokines. Some of the growth factors produced by bone cells primarily stimulate bone cell replication, whereas others also affect the differentiated function of the osteoblast.

232 Canalis E, McCarthy TL, Centrella M. **The role of growth factors in skeletal remodeling.** *Endocrinology and Metabolism Clinics of North America* 18(4):903-918 (1989). Growth factors play a significant role in bone remodeling, normal bone maintenance, fracture repair and wound healing.

233 Molloy T, Wang Y, Murrell G. **The roles of growth factors in tendon and ligament healing.** *Sports Medicine* 33(5):381-394 (2003). Growth factors are one of the most important components of healing. IGF-I is involved in the early stages following injury in the proliferation and migration of fibroblasts (connective tissue cells) and the increase of collagen production. TGF- $\beta$  is active during inflammation of the injured area and plays a role in cellular migration and proliferation. VEGF is most active following the inflammatory phase when it stimulates angiogenesis, the growth of blood vessels into the damaged area. PDGF comes into play immediately after injury and acts to stimulate the production of the other growth factors as well as tissue remodeling. FGF is a powerful stimulator of



## References

- angiogenesis and cell proliferation and migration. Adding these factors to the wound site, such as through colostrum supplementation, has been shown to speed the healing process.
- 234 Flidel-Rimon O, Roth P. **Effects of milk-borne colony stimulating factor-I on circulating growth factor levels in the newborn infant.** *Journal of Pediatrics* 131(5):748-750 (1997). Levels of CSF-I were 25 times greater in colostrum than in serum at birth.
- 235 Yagi H, Suzuki S, Noji T, Nagashima K, Kuroume T. **Epidermal growth factor in cow's milk and milk formulas.** *Acta Paediatrica Scandinavica* 75(2):233-235 (1986). EGF was found in both bovine and human milk in very nearly the same amounts.
- 236 Xiao X, Xiong A, Chen X, Mao X, Zhou X. **Epidermal growth factor concentrations in human milk, cow's milk and cow's milk-based infant formulas.** *Chinese Medical Journal (English)* 115(3):451-454 (2002). EGF content of cow's milk, human term and preterm colostrum and different milk-based formulas. Highest levels of EGF were found in colostrum from mothers with premature infants, suggesting an adaptation to help the premature infants develop their guts faster. EGF levels in cow's milk were similar to that of term human milk. EGF levels in non-hydrolyzed milk-based formulas were much lower than whole milk and undetectable in hydrolyzed formulas.
- 237 Boonstra J, Rijken P, Humbel B, Cremers F, Verkleij A, van Bergen en Henegouwen P. **The epidermal growth factor.** *Cell Biology International* 19(5):413-430 (1995). Epidermal growth factor (EGF) is a single polypeptide of 53 amino acid residues involved in the regulation of cell proliferation. It exerts its effects in the target cells by binding to the plasma membrane located EGF receptor.
- 238 Bhora FY, Dunkin BJ, Batzri S, Aly HM, Bass BL, Sidawy AN, Harmon JW. **Effect of growth factors on cell proliferation and epithelialization in human skin.** *Journal of Surgical Research* 59(2):235-244 (1995). EGF, FGF and IGF-I are all mitogenic in healing wounds of the skin.
- 239 Dunbar AJ, Priebe IK, Belford DA, Goddard C. **Identification of betacellulin as a major peptide growth factor in milk: purification, characterization and molecular cloning of bovine betacellulin.** *Biochemistry Journal* 344(Pt 3):713-721 (1999). Betacellulin, a member of the Epidermal Growth Factor family, was isolated from bovine milk whey. It is a glycosylated protein. Its presence in milk suggests it may play a role in the growth and development of the neonatal gastrointestinal tract.
- 240 Bastian SE, Dunbar AJ, Priebe IK, Owens PC, Goddard C. **Measurement of betacellulin levels in bovine serum, colostrum and milk.** *Journal of Endocrinology* 168(1):203-212 (2001). Betacellulin, a member of the Epidermal Growth Factor (EGF) family, was isolated from bovine colostrum, milk and serum. Highest levels were found in fetal bovine serum, suggesting an endocrine role in the bovine fetus.
- 241 Hironaka T, Ohishi H, Masaki T. **Identification and partial purification of a basic fibroblast growth factor-like growth factor derived from bovine colostrum.** Peptide Immunotherapy: *Colostrum—A Physician's Reference Guide*
- 384 *Journal of Dairy Science* 80(3):488-495 (1997). A protein that behaves like FGF was isolated from the cream fraction of bovine colostrum.
- 242 Canalis, 1989, op cit.
- 243 Szabo S, Sandor Z. **Basic fibroblast growth factor and PDGF in GI diseases.** *Baillieres Clinical Gastroenterology* 10(1):97-112 (1996). Both bFGF and PDGF play a role in the healing of gastric and duodenal ulcers.
- 244 Calhoun DA, Maheshwari A, Christensen RD. **Recombinant granulocyte colony stimulating factor administered enterally to neonates is not absorbed.** *Pediatrics* 112(2):421-423 (2003). G-CSF is present in amniotic fluid, colostrum and milk. It primarily acts locally on cells in the gut.
- 245 Collier RJ, Miller MA, Hidlebrandt JR, Torkelson AR, White TC, Madsen KS, Vicini JL, Eppard PK, Lanza GF. **Factors affecting insulin-like growth-I concentration in bovine colostrums.** *Journal of Dairy Science* 74(9):2905-2911 (1991). While lower than the concentrations of human milk, bovine colostrum and milk contained IGF-I in quantities that decreased with time after birth of the calf.
- 246 Torre, 2006, op cit.
- 247 Blumenfeld I, Srouji S, Lanir Y, Laufer D, Livne E. **Enhancement of bone defect healing in old rats by TGF-beta and IGF-I.** *Experimental Gerontology* 37(4):553-565 (2002). Bone healing in the elderly is often slow and is dependent on the availability of various hormones and growth factors. Bone defects induced in aged rats healed much more quickly in rats given either TGF- $\beta$  or IGF-I, with a combination of both producing the fastest healing.
- 248 Adams GR, Haddad F. **The relationships among IGF-I, DNA content, and protein accumulation during skeletal muscle hypertrophy.** *Journal of Applied Physiology*

81(6):2509-2516 (1996). The muscle of rats respond to functional overload by increased IGF-I expression. The elevated IGF-I appear to contribute to the hypertrophy response.

249 Bayes-Genis A, Conover CA, Schwartz RS. **The insulin-like growth factor axis: A review of atherosclerosis and restenosis.** *Circulation Research* 86(2):125-130 (2000). IGF-I, IGF-2 and their binding proteins are secreted by cells of the cardiovascular system. The dynamic balance of these factors, known as the IGF axis, influences vascular smooth muscle growth, migration and extracellular matrix synthesis. Dysregulation of the axis can result in the formation of atherosclerotic plaque and restenosis.

250 Rabinovsky ED. **The multifunctional role of IGF-I in peripheral nerve regeneration.** *Neurological Research* 26(2):204-210 (2004). The ability of IGF-I to promote nerve elongation and branching, angiogenesis (growth of blood vessels), the activation of muscle stem cells and so forth affects multiple layers of the regenerative response of peripheral nerves.

251 Xu RJ. **Development of the newborn GI tract and its relation to colostrum/ milk intake: a review.** *Reproduction, Fertility and Development* 8(1):35-48 (1996). In the immediate postnatal period, the GI tract undergoes profound growth, morphological

385

#### References

changes and functional maturation. These changes are related to the onset of colostrum ingestion. Both EGF and IGF-I play a role in postal GI development.

252 O'Dell SD, Day IN. **Insulin-like growth factor II (IGF-II).** *International Journal of Biochemistry and Cell Biology* 30(7):767-771 (1998). IGF-2 plays a key role in mammalian growth, regulating fetal cell division and differentiation and possibly metabolic regulation.

253 Aranda P, Sanchez L, Perez MD, Ena JM, Calvo M. **Insulin in bovine colostrum and milk: evolution throughout lactation and binding to caseins.** *Journal of Dairy Science* 74(12):4320-4325 (1991). Highest levels of insulin were found in first milking colostrum (327 µg/l), which fell by 50% over the first 24 hours.

254 Fernandez-Moreno MD, Serrano-Rios M, Prieto JC. **Identification of insulin receptors in epithelial cells from duodenum, jejunum, ileum, caecum, colon and rectum in the rat.** *Diabetes Metabolism* 13(2):135-139 (1987).

255 Blum JW, Baumrucker CR. **Colostrum and milk insulin-like growth factors and related substances: mammary gland and neonatal (intestinal and systemic) targets.** *Domesticated Animal Endocrinology* 23(1-2):101-110 (2002). Both IGFs and IGFBPs influence mammary gland biology towards the end of lactation. IGFBP-3, the major IGFBP in cows, binds to both IGF and lactoferrin. With lactoferrin, it can enter the nucleus of epithelial cells and affect apoptotic (programmed cell death) signaling through retinoic-xreceptors as part of mammary gland involution.

256 Bayes-Genis, 2000, op. cit.

257 Shing Y, Klagsbrun M. **Purification and characterization of a bovine colostrum-derived growth factor.** *Molecular Endocrinology* 1(5):335-338 (1987). PDGF was identified in bovine colostrum.

258 Canalis E, Varghese S, McCarthy TL, Centrella M. **Role of platelet derived growth factor in bone cell function.** *Growth Regulation* 2(4):151-155 (1992). PDGF is a mitogen of osteoblasts and probably plays a role in bone remodeling. It also plays a role in inflammation and wound healing.

259 Hollinger JO, Hart CE, Hirsch SN, Lynch S, Friedlaender GE. **Recombinant human platelet-derived growth factor: biology and clinical applications.** *Journal of Bone and Joint Surgery* 90(Suppl 1):48-54 (2008). PDGF functions as a potent chemoattractant and mitogen for osteogenic (bone-forming) cells and promotes angiogenesis (formation of blood vessels), making it valuable in the treatment of bone and soft tissue disorders, such as osteoporosis, diabetes and the effects of smoking.

260 Carlberg M, Larsson O. **Stimulatory effect of PDGF on HMG-CoA reductase activity and N-linked glycosylation contributes to increased expression of IGF-I receptors in human fibroblasts.** *Experimental Cell Research* 223(1):142-148 (1996). PDGF mediates the growth activation of fibroblasts.

261 Szabo, 1996, op cit.

262 Kim HR, Upadhyay S, Li G, Palmer KC, Deuel TF. **Platelet-derived growth factor Peptide Immunotherapy: Colostrum—**

*A Physician's Reference Guide*

**386 induces apoptosis in growth-arrested murine fibroblasts.** *Proceedings of the National Academy of Sciences (USA)* 92(21):9500-9504 (1995). PDGF is a potent mitogen (inducer of cell division) in fibroblasts. When fibroblasts are deprived of serum, however, they stop their development. If then stimulated by PDGF, the cells undergo apoptotic cell death. This suggests that PDGF can influence both cell division and cell death, depending on the state of the cell.

263 Molloy, 2003, op. cit.

- 264 Okada M, Ohmura E, Kamiya Y, Murakami H, Onoda N, Iwashita M, Wakai K, Tsushima T, Shizume K. **Transforming growth factor (TGF)-alpha in human milk.** *Life Sciences* 48(12):1151-1156 (1991).
- 265 Wagner CL, Forsythe DW, Pittard WB. **Variation in the biochemical forms of transforming growth factor-alpha present in human milk and secreted by human milk macrophages.** *Biology of the Neonate* 68(5):325-333 (1995). TGF-a, a component of human colostrum and milk, plays a significant role in postnatal gut development.
- 266 Wagner CL, Forsythe DW, Wagner MT. **The effect of recombinant TGF-alpha, human milk, and human milk macrophage media on gut epithelial proliferation is decreased in the presence of a neutralizing TGF-alpha antibody.** *Biology of the Neonate* 74(5):363-371 (1998).
- 267 Wagner CL, Forsythe DW. **Effect of human milk and recombinant EGF, TGFalpha, and IGF-I on small intestinal cell proliferation.** *Advances in Experimental Medicine and Biology* 478:373-374 (2000).
- 268 Fallon J, Reid S, Kinyamu R, Opolo I, Opolo R, Baratta J, Korc M, Endo TL, Duong A, Nguyen G, Karkehabadhi M, Twardzik D, Patel S, Loughlin S. **In vivo induction of massive proliferation, directed migration, and differentiation of neural cells in the adult mammalian brain.** *Proceedings of the National Academy of Sciences (USA)* 97(26):14686-14691 (2000). TGF-a infused directly into damaged rat forebrains resulted in massive proliferation, directed migration and neurodifferentiation (PMD).
- 269 Saito S, Yoshida M, Ichijo M, Ishizaka S, Tsujii T. **Transforming growth factor-beta (TGF-beta) in human milk.** *Clinical and Experimental Immunology* 94(1):220-224 (1993). Both TGF-b1 and TGF-b2 were found in human milk.
- 270 Ginjala V, Pakkanen R. **Determination of transforming growth factor-beta 1 (TGFbeta 1) and insulin-like growth factor (IGF-I) in bovine colostrum samples.** *Journal of Immunoassay* 19(2-3):195-207 (1998).
- 271 Pakkanen, R. **Determination of transforming growth factor-beta 2 (TGF-beta 2) in bovine colostrum samples.** *Journal of Immunoassay* 19(1):23-37 (1998). TGF-b2 is the major form of TGF-b in colostrum.
- 272 Tokuyama Y, Tokuyama H. **Purification and identification of TGF-beta 2-related growth factor from bovine colostrum.** *Journal of Dairy Research* 60(1):99-109 (1993). 387
- References*
- High levels of TGF-b2 activity are found in early bovine colostrum.
- 273 Purup S, Vestergaard M, Pedersen O, Sejrsen K. **Biological activity of bovine milk on proliferation of human intestinal cells.** *Journal of Dairy Research* 74(1):58-65 (2007). Bovine milk and colostrum contain a number of biologically active components that affect the growth and development of human intestinal tissues, including TGF-b1, TGF-b2, IGF-I, IGF-2 and others.
- 274 Coffman RL, Lebman DA, Shrader B. **Transforming growth factor beta specifically enhances IgA production by lipopolysaccharide-stimulated murine B lymphocytes.** *Journal of Experimental Medicine* 170(3):1039-1044 (1989).
- 275 Chen SS, Li Q. **Transforming growth factor-beta 1 (TGF-beta 1) is a bifunctional immune regulator for mucosal IgA responses.** *Cellular Immunology* 128(2):353-361 (1990). TGF-b1 is a potent costimulator with LPS-induced IgA responses while also exerting a profound immunosuppressive effect on IL-5 induced IgA synthesis. TGF-b1 is produced by intestinal epithelial cells that may help ensure the integrity of the mucosal surface.
- 276 Centrella M, McCarthy TL, Canalis E. **Skeletal tissue and transforming growth factor beta.** *FASEB Journal* 2(15):3066-2073 (1988). TGF-b regulates replication and differentiation of mesenchymal precursor cells, chondrocytes, osteoblasts and osteoclasts. Its activity is controlled at many different levels by both local and systemic agents. It is vital to skeletal growth during development, maintenance of bone mass in adults, and healing of fractures.
- 277 Centrella M, McCarthy TL, Canalis E. **Effects of transforming growth factors on bone cells.** *Connective Tissue Research* 20(1-4):267-275 (1989). TGF-b controls abundance and biochemical function of osteoclasts and osteoblasts.
- 278 Torre, 2006, op cit.
- 279 Molloy, 2003, op cit.
- 280 Bessler H, Straussberg R, Hart J, Notti I, Sirota L. **Human colostrum stimulates cytokine production.** *Biology of the Neonate* 69(6):376-382 (1996). Human colostrum stimulates the production of IL-1, IL-3 and IL-6 in blood monocytes.
- 281 Bocci V, von Bremen K, Corradeschi F, Luzzi E, Paulesu L. **What is the role of cytokines in human colostrum?** *Journal of Biological Regulators and Homeostatic Agents* 5(4):121-124 (1991). Colostrum contains IL-1, IL-6, TNF-a and interferon-g which may

exert an important immunostimulatory role particularly on oropharyngeal-associated lymphoid tissue. Oral supplementation with cytokines may be of benefit to aged or immunodeficient people.

282 Goto M, Maruyama M, Kitadate K, Kirisawa R, Obata Y, Koiwa M, Iwai H. **Detection of interleukin-1 beta in sera and colostrum of dairy cattle and in sera of neonates.** *Journal of Veterinary Medical Science* 59(6):437-441 (1997). IL-1b was present in high volumes in bovine milk for 20 days prepartum and 3 days postpartum.

Peptide Immunotherapy: *Colostrum*—

*A Physician's Reference Guide*

388 283 Hagiwara K, Kataoka S, Yamanaka H, Kirisawa R, Iwai H. **Detection of cytokines in bovine colostrum.** *Veterinary Immunology and Immunopathology* 76(3-4):183-190 (2000). IL-1b, IL-6, TNF- $\alpha$ , INF-g and IL-1 receptor antagonist (IL-1ra) were found in higher concentrations in bovine colostrum than in mature milk. These appear to play a role in neonatal immunity.

284 Zizka J, Kverka M, Novotna O, Stankova I, Lodinova-Zadnikova R, Kocourkova I, Sterzl I, Prokesova L. **Perinatal period cytokines related to increased risk of future allergy development.** *Folia Microbiologica (Praha)* 52(5):549-555 (2007). Cytokine levels were tested in the colostrum, cord blood and amniotic fluid of healthy and allergic mothers.

Differences in levels of IL-5, IL-10, TGF- $\beta$ , TNF- $\alpha$ , EGF and eotaxin were found. Allergic mothers and children also tended to have higher levels of IL-4.

285 Zizka, 2007, *ibid*

286 Rudloff HE, Schmalstieg FC Jr, Palkowetz KH, Paszkiewicz EJ, Goldman AS. **Interleukin-6 in human milk.** *Journal of Reproductive Immunology* 23(1):13-20 (1993). IL-6 was isolated from human milk (colostrum) collected within the first day postpartum.

287 Hashira S, Okitsu-Negishi S, Yoshino K. **Interleukin 8 in the human colostrum.** *Biology of the Neonate* 82(1):34-38 (2002). IL-8 was produced by colostrum cells *in vitro*.

288 Garofalo R, Chheda S, Mei F, Palkowetz KH, Rudloff HE, Schmalstieg FC, Rassin DK, Goldman AS. **Interleukin-10 in human milk.** *Pediatric Research* 37(4pt1):444-449 (1995). IL-10 was found in both aqueous and lipid phases of human milk (colostrum)

289 Bryan DL, Hawkes JS, Gibson RA. **Interleukin-12 in human milk.** *Pediatric Research* 45(6):858-859 (1999). Concentrations of IL-12 in human colostrum, transitional milk and mature Interleukin-12 in human milk were studied, with highest concentrations being found in colostrum, declining over time to mature milk.

290 Takahata Y, Takada H, Nomura A, Ohshima K, Nakayama H, Tsuda T, Nakano H, Hara T. **Interleukin-18 in human milk.** *Pediatric Research* 50(2):268-272 (2001). IL-18 levels were found to be highest in colostrum compared to transitional and mature milk. IL-18 levels were correlated to high concentrations of soluble Fas ligand. Levels of IL-18 were significantly higher in mothers with preterm delivery and pregnancy problems, indicating that IL-18 plays a significant role in host defense of high-risk infants.

291 Bocci, 1991, *op. cit.*

292 Bocci, 1991, *op. cit.*

293 Buescher ES, McWilliams-Koeppen P. **Soluble tumor necrosis factor-alpha (TNFalpha) receptors in human colostrum and milk bind to TNF-alpha and neutralize TNF-alpha bioactivity.** *Pediatric Research* 44(1):37-42 (1998). TNF- $\alpha$  receptors in colostrum and milk bind to TNF- $\alpha$  and have the ability to block its activity. As TNF- $\alpha$  is the controlling factor in the inflammatory cascade, the ability of TNF- $\alpha$  receptors to turn it off signifies that this is one of the main anti-inflammatory mechanisms in colostrum and milk.

389

#### References

294 Kumura H, Miura A, Sato E, Tanaka T, Shimazaki K. **Susceptibility of bovine osteopontin to chymosin.** *Journal of Dairy Research* 71(4):500-504 (2004). Osteopontin is found in bovine colostrum.

295 Nagatomo T, Ohga S, Takada H, Nomura A, Hikino S, Imura M, Ohshima K, Hara T. **Microarray analysis of human milk cells: persistent high expression of osteopontin during the lactation period.** *Clinical and Experimental Immunology* 138(1):47-53 (2004). Osteopontin is expressed in human milk at high levels beginning with the first milk or colostrum. It reaches a peak in early (transitional) milk. It may play a role in the immunological development of infants by activating T-lymphocytes.

296 Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ, Cantor H. **Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity.** *Science* 287(5454):860-864 (2000). Cell-mediated (type-1) immunity is necessary for immune protection against most intracellular pathogens and, when excessive, can result in organ-specific autoimmune destruction. Mice deficient in the expression of the Eta-1 (osteopontin) gene have severely impaired type-1 immunity

to both viral and bacterial infections. Osteopontin apparently acts through regulation of macrophage IL-10 and IL-12 expression through its interaction with the CD44 and integrin receptors respectively.

297 Vidal, K, van den Broek P, Lorget F, Donnet-Hughes A. **Osteoprotegerin in human milk: a potential role in the regulation of bone metabolism and immune development.** *Pediatric Research* 55(6):1001-1008 (2004). Osteoprotegerin, a cytokine member of the Tumor Necrosis Factor superfamily, is found in human milk and colostrum as well as bovine colostrum and milk. It inhibits osteoclast activity and helps regulate the immune system. It may help explain the mechanism of antiresorptive effect of milk on bone, helping prevent osteoporosis. Its presence in colostrum may help prevent immune and bone disorders in the newborn.

298 Maheshwari A, Christensen RD, Calhoun DA. **ELR+ CXC chemokines in human milk.** *Cytokine* 24(3):91-102 (2003). CXC chemokines with the glutamic acid-leucinearginine motif (ELR) are found in human milk and are crucial mediators in neutrophil-dependent inflammation. All except NAP2/CXCL7 are found in higher concentrations in milk than in serum and are secreted by mammary epithelial cells. They may help protect intestinal epithelial cells.

299 Bottcher MF, Jenmalm MC, Bjorksten B. **Cytokine, chemokine and secretory IgA levels in human milk in relation to atopic disease and IgA production in infants.** *Pediatric Allergy and Immunology* 14(1):35-41 (2003). Levels of IL-4, -5, -6, -8, -10, -13, -16, IFN- $\gamma$ , TGF- $\beta$ 1, TGF- $\beta$ 2, RANTES, eotaxin and SIgA were measured in colostrum and mature milk in relation to the development of positive skin prick tests for allergies and allergic symptoms in infants up to 2 years.

300 Srivastava MD, Srivastava A, Brouhard B, Saneto R, Groh-Wargo S, Kubit J. **Cytokines in Peptide Immunotherapy: Colostrum—**  
*A Physician's Reference Guide*

390 **human milk.** *Research Communications in Molecular Pathology and Pharmacology* 93(3):263-287 (1996). Chemokines present in milk and colostrum included GRO- $\alpha$ , MCP-1, RANTES and IL-8.

301 Takahata Y, Takada H, Nomura A, Nakayama H, Ohshima K, Hara T. **Detection of interferon-gamma-inducible chemokines in human milk.** *Acta Paediatrica* 92(6):659-665 (2003). Levels of IP-10 and MIG were significantly higher in colostrum and transitional milk than in mature milk. IP-10 and MIG were produced both by mammary epithelial and milk cells. IP-10 and MIG may contribute to the migration and activation of intestinal T-lymphocytes in the early neonatal period.

302 Srivastava, 1996, op. cit.

303 Takahata, 2003, op. cit.

304 Bottcher, 2003, op. cit.

305 Staroscik, 1983, op. cit.

306 Janusz, 1993, op. cit.

307 Elahi S, Buchanan RM, Attah-Poku S, Townsend HG, Babiuk LA, Gerdtts V. **The host defense peptide beta-defensin 1 confers protection against *Bordetella pertussis* in newborn piglets.** *Infection and Immunity* 74(4):2338-2352 (2006).

308 Armogida SA, Yannaras NM, Melton AL, Srivastava MD. **Identification and quantification of innate immune system mediators in human breast milk.** *Allergy and Asthma Proceedings* 25(5):297-304 (2004). Mediators of the innate immune system were found in human colostrum and milk, including defensins, cathelicidins, and toll-like receptors.

309 Filipp D, Alizadeh-Khiavi K, Richardson C, Palma A, Paredes N, Takeuchi O, Akira S, Julius M. **Soluble CD14 enriched in colostrum and milk induces B cell growth and differentiation.** *Proceedings of the National Academy of Sciences (USA)* 98(2):603-608 (2001).

310 Pasare C, Medzhitov R. **Toll-like receptors: linking innate and adaptive immunity.** *Microbes and Infection* 6(15):1382-1387 (2004). Toll-like receptors are the principal means of detection and response to microbial infections, including bacteria, viruses, fungi and protozoa. Initial recognition by the Toll-like receptors sets off a complex series of signaling events that sets off the immune response to the infection.

311 LeBouder E, Rey-Nores JE, Rushmere NK, Grigorov M, Lawn SD, Affolter M, Griffin GE, Ferrara P, Schiffrin EJ, Morgan BP, Labeta MO. **Soluble forms of Toll-like receptor (TLR)-2 capable of modulating TLR2 signaling are present in human plasma and breast milk.** *Journal of Immunology* 171(12):6680-6689 (2003). Failure of the innate immune response to bacterial infection can lead to septic shock and death. Toll-like receptors play a crucial role in the innate immune response and is found in human colostrum and milk.

312 Murakami M, Dorschner RA, Stern LJ, Lin KH, Gallo RL. **Expression and secretion of**

## References

- cathelicidin antimicrobial peptides in murine mammary glands and human milk.** *Pediatric Research* 57(1):10-15 (2004). Antimicrobial peptides belonging to the cathelicidin family have recently been identified as being important components of the mammalian immune response. These peptides were found in both mouse and human milk and colostrum. They have antimicrobial activity against both gram-negative and gram-positive bacteria.
- 313 Newburg, DS. **Human milk glycoconjugates that inhibit pathogens.** *Current Medical Chemistry* 6(2):117-127 (1999). The protection offered by human milk may not be limited to just secretory IgA. Milk and colostrum contain numerous complex carbohydrates, including glycoproteins, glycolipids, glycosaminoglycans, mucins and oligosaccharides. Those with homology to cell surface glycoconjugate pathogen may inhibit pathogen binding by competing for binding sites. One of the fucosyloligo-saccharides inhibits *E. coli* toxin. Another inhibits infection by *Campylobacter jejuni*. Milk oligo-saccharides inhibit the binding of *Streptococcus pneumoniae* and enteropathogenic *E. coli*. Lactadherin inhibits rotavirus. A mannosylated glycopeptide inhibits binding by enterohemorrhagic *E. coli*. A glycosaminoglycan prevents binding of gp120 (a form of HIV) to CD4, the first step in HIV infection. Milk mucin inhibits binding of S-fimbriated *E. coli*. Ganglioside GM1 reduces diarrhea due to cholera toxin and *E. coli* labile toxin. Glycosphingolipid Gb3 binds to shiga toxin.
- 314 Kawasaki Y, Isoda H, Tanimoto M, Dosako S, Idota T, Ahiko K. **Inhibition by lactoferrin and kappa-casein glycomacropeptide of binding of Cholera toxin to its receptor.** *Bioscience, Biotechnology and Biochemistry* 56(2):195-198 (1992). Both lactoferrin and GMP from cow's milk inhibited the binding of Cholera toxin to a cultured cell line and ganglioside GM1.
- 315 Kawasaki Y, Isoda H, Shinmoto H, Tanimoto M, Dosako S, Idota T, Nakajima I. **Inhibition by kappa-casein glycomacropeptide and lactoferrin of influenza virus hemagglutination.** *Bioscience, Biotechnology and Biochemistry* 57(7):1214-1215 (1993).
- 316 Brody EP. **Biological activities of bovine glycomacropeptide.** *British Journal of Nutrition* 84(Suppl 1):S39-S46 (2000). Glycomacropeptide (GMP) has been found to be able to bind cholera and *E. coli* endotoxins, inhibit bacterial and viral adhesion, suppress gastric secretions, promote the growth of bifidobacteria and modulation of the immune system.
- 317 Makowski L, Brittingham KC, Reynolds JM, Suttles J, Hotamisligil GS. **The fatty acid binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity: Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and I-kappa beta kinase activities.** *Journal of Biological Chemistry* 280(13):12888-12895 (2005). The fatty acid-binding protein aP2 regulates two molecular pathways in macrophages to coordinate cholesterol uptake and inflammatory activity.
- 318 Sawyer L, Kontopidis G. **The core lipocalin, bovine beta-lactoglobulin.** *Biochimica et Biophysica Acta* 1482(1-2):136-148 (2000).
- Peptide Immunotherapy: *Colostrum—A Physician's Reference Guide*
- 392 319 Superti F, Ammendolia MG, Valenti P, Seganti L. **Anti-rotaviral activity of milk proteins: lactoferrin prevents rotavirus infection in the enterocyte-like cell line HT-29.** *Medical Microbiology and Immunology (Berlin)* 186(2-3):83-91 (1997). Antiviral activity against rotavirus of alpha lactalbumin, beta lactoglobulin, apo-lactoferrin (iron-free) and iron saturated lactoferrin were compared to that of mucin, which has known antirotaviral activity. Beta lactoglobulin and both forms of lactoferrin showed anti-rotaviral activity with the strongest response elicited by apo-lactoferrin, which hinders viral attachment to cells by binding directly to the viruses. It also markedly inhibits viral antigen synthesis in the viral adhesion stage.
- 320 Ulcova-Gallova Z, Fialova P, Krauz V. **[Immunologic factors in human colostrum and milk].** *Casopis Lekarů Ceskych* 133(9):275-276 (1994). Colostrum was found to contain IgG, IgM, IgD, IgA, sIgA, C3, C4, orosomuroid, prealbumin, alpha 1-antitrypsin, alpha 1-fetoprotein, alpha 2-macroglobulin, haemopexin, haptoglobulin, beta 2-microglobulin, alpha 2-AP glycoprotein, and IgE.
- 321 Sorensson J, Ohlson M, Bjornson A, Haraldsson B. **Orosomuroid has a cAMP dependent effect on human endothelial cells and inhibits the action of histamine.** *American Journal of Physiology – Heart and Circulatory Physiology* 278(5):H1725-1731 (2000). Orosomuroids negate the effect of histamine on human capillary endothelial cells and uses cAMP as a secondary messenger.
- 322 Kang SW, Lim SW, Choi SH, Shin KH, Chun BG, Park IS, Min BH. **Antisense oligonucleotide of clusterin mRNA induces apoptotic cell death and prevents adhesion of rat ASC-17D Sertoli cells.** *Molecules and Cells* 10(2):193-198 (2000). When the production of clusterin is blocked by antisense oligonucleotides of clusterin mRNA, cultured Sertoli cells are unable to attach to the Petri dish and therefore die. This

indicates that clusterin plays an important role in cell-cell and cell-substratum interactions.

323 Carver JA, Rekas A, Thorn DC, Wilson MR. **Small heat-shock proteins and clusterin: intra- and extracellular molecular chaperones with a common mechanism of action and function?** *IBUMB Health* 55(12):661-668 (2003). So-called small heat shock (stress) proteins (sHsps) and clusterin both function as molecular chaperones, although they are not chemically related and sHsps are found intracellularly while clusterin is mostly found extracellularly. They act to prevent the aggregation and precipitation of target proteins under stress conditions, such as elevated temperature and redox reactions. Both are found in increased concentrations in disease states that involve protein misfolding and the deposition of highly structured protein aggregates (amyloid fibrils), such as Alzheimer's, Creutzfeld-Jakob and Parkinson's diseases.

324 Ulcova-Galova, 1994, op cit.

325 Gutteridge JM, Smith A. **Antioxidant protection by haemopexin of haemstimulated lipid peroxidation.** *Biochemical Journal* 256:861-865 (1988). Haem is a low molecular weight form of iron that is capable of taking part in oxygen radical reactions that

393

#### References

can lead to the degradation of proteins, lipids, carbohydrates and DNA. Haemopexin can inhibit such oxidative reactions by as much as 90%.

326 Tolosano E, Altruda F. **Hemopexin: structure, function, and regulation.** *DNA and Cell Biology* 21(4):297-306 (2002). Hemopexin's main role appears to be to act as an antioxidant after blood heme overload. It does not appear to participate in iron metabolism to any significant degree.

327 Smith A, Eskew JD, Borza CM, Pendrak M, Hunt RC. **Role of heme-hemopexin in human T-lymphocyte proliferation.** *Experimental Cell Research* 232(2):246-254 (1997). Heme-hemopexin supports and stimulates proliferation of human acute T-lymphoblastic (MOLT-3) cells, precursor cells to mature T-lymphocytes. MOLT-3 cells express approximately 58,000 hemopexin receptors per cell, about 20% of which are on the cell surface. Heme-hemopexin appears to act not only as an iron source, but the binding of the molecule to the receptor triggers a signaling pathway involved in the regulation of cell growth, stimulating the cells to proliferate.

328 Suzuki K, Namiki H. **[Serum hemopexin: suppressive effect on neutrophil functions and prospect of clinical application to autoimmune conditions]** *Nippon Rinsho* 62(3):577-586 (2004). Serum hemopexin suppresses neutrophil adhesion and phagocytosis by a mechanism unrelated to its haem-binding ability.

329 Suzuki K, Kobayashi N, Doi T, Hijikata T, Machida I, Namiki H. **Inhibition of Mg<sup>++</sup>-dependent adhesion of polymorphonuclear leukocytes by serum hemopexin: differences in divalent-cation dependency of cell adhesion in the presence and absence of serum.** *Cell Structure and Function* 28(4):243-253 (2003). Hemopexin has a strong inhibitory effect on the binding of polymorphonuclear leukocytes to fibrinogen or serum-coated surfaces. In the presence of Ca<sup>++</sup>, however, adhesion was not affected.

330 Arredouani MS, Kasran A, Vanoirbeek JA, Berger FG, Baumann H, Ceuppens JL. **Haptoglobin dampens endotoxin-induced inflammatory effects both *in vitro* and *in vivo*.** *Immunology* 114(2):263-271 (2005). Haptoglobin regulates monocyte activation following LPS stimulation. The increase in haptoglobin in the acute phase reaction may represent a feedback effect which dampens the severity of cytokine release and protects against endotoxin-induced damage.

331 Schmidt J, Kuhlenschmidt MS. Microbial adhesion of *Cryptosporidium parvum*: Identification of a colostrum-derived inhibitory lipid. *Molecular Biochemistry and Parasitology* 162(1):32-39 (2008).

332 Schlimme E, Martin D, Meisel H. **Nucleosides and nucleotides: natural bioactive substances in milk and colostrum.** *British Journal of Nutrition* 84(Suppl 1):S59-S68 (2000).

333 Carver JD, Cox WI, Barness LA. **Dietary nucleotide effects upon murine natural killer cell activity and macrophage activation.** *Journal of Parenteral and Enteral Nutrition* 14(1):18-22 (1990). Weanling mice fed a diet that included nucleotides exhibited

Peptide Immunotherapy: *Colostrum*—

*A Physician's Reference Guide*

394 increased NK cell activity and lower macrophage activation than control animals fed a diet with no extra nucleotides.

334 Carver JD. **Dietary nucleotides: effects on the immune and gastrointestinal systems.** *Acta Paediatrica Supplement* 88(430):83-88 (1999). Infants fed diets with nucleotide supplementation have a lower incidence of diarrhea, higher antibody levels following *Haemophilus influenzae* vaccination, and higher NK cell activity.

335 Juul SE, Christensen RD. **Absorption of enteral recombinant human erythropoietin by neonates.** *Annals of Pharmacotherapy* 37(6):782-786 (2003). EPO is a component

of colostrum, but its function is unknown. To test whether or not EPO in colostrum is absorbed in sufficient quantities to stimulate erythropoiesis, recombinant human erythropoietin was given orally to infants. Circulating amounts of EPO, however, did not increase.

336 Gyawu P, Pope GS. **Oestrogens in milk.** *Journal of Steroid Biochemistry* 19(1C):877-882. Both estrogen and progesterone are found in colostrum and milk.

337 Baram T, Koch Y, Hazum E, Fridkin M. Gonadotropin-releasing hormone in milk. *Science* 198(4314):300-302 (1977). GnRH has been found in the colostrum and milk of man, cow, and rat. TRH is also present, though in much lower quantities.

338 Zhang T, Iguchi K, Mochizuki T, Hoshino M, Yanaihara C, Yanaihara N. **Gonadotropin-releasing hormone-associated peptide immunoreactivity in bovine colostrum.**

*Proceedings of the Society for Experimental Biology and Medicine* 194(3):270-273 (1990).

The presence of a peptide associated with GnRH in colostrum suggests that the GnRH precursor is synthesized and processed in the mammary gland.

339 Oda S, Satoh H, Sugawara T, Matsunaga N, Kuhara T, Katoh K, Shoji Y, Nihei A, Ohta M, Sasaki Y. **Insulin-like growth factor-I, GH, insulin and glucagon concentrations in bovine colostrum and in plasma of dairy cows and neonatal calves around parturition.** *Comparative Biochemistry and Physiology A* 94(4):805-808.

340 Aranda, 1991, op cit.

341 Pinotti L, Rosi F. **Leptin in bovine colostrum and milk.** *Hormone and Metabolic Research* 38(2):89-93 (2006). Leptin concentration is 56% lower in colostrum than in mature milk.

342 Amarant T, Fridkin M, Koch Y. **Luteinizing hormone-releasing hormone and thyrotropin-releasing hormone in human and bovine milk.** *European Journal of Biochemistry* 127(3):647-650 (1982). Both human and bovine milk and colostrum had high levels of LHRH and TRH.

343 Eriksson L, Valtonen M, Laitinen JT, Paananen M, Kaikkonen M. **Diurnal rhythm of melatonin in bovine milk: pharmacokinetics of exogenous melatonin in lactating cows and goats.** *Acta Veterinaria Scandinavica* 39(3):301-310 (1998). Levels of melatonin in the colostrum and milk of cows and goats follow the diurnal rhythm of melatonin in the blood with a short delay.

395

#### References

344 Koldovsky O, Thornburg W. **Hormones in milk.** *Journal of Pediatric Gastroenterology and Nutrition* 6(2):172-196 (1987). Hormones in colostrum and milk include EGF, Erythropoietin, GnRH, growth hormone, prolactin, thyroid hormones and others.

345 Gyawu, 1983, op cit.

346 Koldovsky, 1987, op cit.

347 Lippert TH, God B, Voelter W. **Immunoreactive relaxin-like substance in milk.** *IRCS Journal of Medical Science* 9:925 (1981). First report of relaxin in bovine and human milk/colostrum. Levels in bovine milk/colostrum were 2916 ng/l, while in human milk levels were between 195 and 438 ng/l between days 3 and 6 postpartum and blood serum levels of relaxin decreased from 83-32 ng/l between days 3 and 6, disappearing entirely after day 7, indicating that the mammary gland is the primary source of the relaxin. Relaxin is most likely involved in nipple development in the mother rather than having any significant effect on the newborn.

348 Rao RK, Lam K, Philipps AF, Williams C, Lake M, Koldovsky O. **Presence of multiple forms of peptidase inhibitors in rat milk.** *Journal of Pediatric Gastroenterology and Nutrition* 17(4):414-420 (1993). Peptides such as somatostatin, epidermal growth factor, TGF- $\alpha$  and insulin-like growth factors are found in the colostrum of many species.

349 Baram, 1977, op cit.

350 Guth PS. **Kinins produced from bovine colostrum by kallikrein and saliva.** *British Journal of Pharmacology* 14:549-552 (1959).

351 Tausin J, Miclo L, Gaillard JL. **Angiotensin-I-converting enzyme inhibitory peptides from tryptic hydrolysate of bovine alphaS2-casein.** *FEBS Letters* 531(2):369-374 (2002).

352 Pihlanto-Leppala A, Koskinen P, Piilola K, Tupasela T, Korhonen H. **Angiotensin I-converting enzyme inhibitory properties of whey protein digests: concentration and characterization of active peptides.** *Journal of Dairy Research* 67(1):53-64 (2000).

353 Ijas H, Collin M, Finckenberg P, Pihlanto-Leppala A, Korhonen H, Korpela R, Vapaatalo H, Nurminen M-L. **Antihypertensive opioid-like milk peptide  $\alpha$ -lactorphin: lack of effect on behavioral tests in mice.** *International Dairy Journal* 14(3):201-205 (2004).  $\alpha$ -lactorphin, a peptide derived from milk whey, lowers blood pressure in hypertensive rats without the sedative effects of other opioid-like peptides.

354 Dawes J, Clezardin P, Pratt DA. **Thrombospondin in milk, other breast secretions,**



**and breast tissue.** *Seminars in Thrombosis and Hemostasis* 13(3):378-384 (1987).

Thrombospondin, a protein important in cell-cell and cell-matrix communication and wound repair, and a potent inhibitor of angiogenesis and tumor growth, is found in high concentrations in colostrum and mature milk. Highest concentrations are found in colostrum.

355 Saumet A, de Jesus N, Legrand C, Dubernard V. **Association of thrombospondin-I Peptide Immunotherapy: Colostrum—**  
*A Physician's Reference Guide*

**396 with the actin cytoskeleton of human thrombin-activated platelets through an alphaIIb beta3- or CD36-independent mechanism.** *Biochemistry Journal* 363(Pt 3):473-482 (2002). Thrombospondin-I participates in platelet aggregation by binding to the surface of the platelets.

356 Isenberg JS, Romeo MJ, Yu C, Yu CK, Nghiem K, Monsale J, Rick ME, Wink DA, Frazier WA, Roberts DD. **Thrombospondin-I stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling.** *Blood* 111(2):613-623 (2008). Thrombospondin-I promotes platelet aggregation by overcoming the antithrombotic activity of nitric oxide.

357 Bal dit Sollier C, Drouet L, Pignaud G, Chevallier C, Caen J, Fiat AM, Izquierdo C, Jolles P. **Effect of kappa-casein split peptides on platelet aggregation and on thrombus formation in the guinea-pig.** *Thrombosis Research* 81(4):427-437 (1996). GMP inhibits platelet aggregation and fibrinogen binding, preventing the formation of arterial thrombosis, a leading cause of stroke and heart attack.

358 Chabance B, Jolles P, Izquierdo C, Mazoyer E, Francoual C, Drouet L, Fiat AM. **Characterization of an antithrombotic peptide from kappa-casein in newborn plasma after milk ingestion.** *British Journal of Nutrition* 73(4):583-590 (1995). Both human and bovine kappa-caseinoglycopeptides were found in the blood serum of infants after ingestion of either bovine or human milk and colostrum, suggesting these bioactive peptides are produced by the digestion of milk.

359 Chabance B, Qian ZY, Migliore-Samour D, Jolles P, Fiat AM. **Binding of the bovine caseinoglycopeptide to the platelet membrane glycoprotein GPIb alpha.** *Biochemistry and Molecular Biology International* 42(1):77-84 (1997). Bovine kappa-caseinoglycopeptide inhibits platelet aggregation by binding to a specific membrane protein on the platelets which is involved in platelet aggregation.

360 Christensen T, Wieggers T, Hermansen J, Sottrup-Jensen L. **Plasma-derived protease inhibitors in bovine milk.** *International Dairy Journal* 5:439-449 (1995). Seven plasmaderived inhibitors, alpha2-macroglobulin, alpha2-antiplasmin, antithrombin III, C1-inhibitor, inter-alpha-trypsin inhibitor, bovine plasma elastase inhibitor (EI) and bovine plasma trypsin inhibitor (TI), have been identified in bovine colostrum and milk.

361 Stassen JM, Arnout J, Deckmyn H. **The hemostatic system.** *Current Medicinal Chemistry* 11(17):2245-2260 (2004). The hemostatic system comprises platelet aggregation, coagulation and fibrinolysis. Fibrinolysis is controlled by plasminogen activators inhibitor (PAI-1), alpha2-antiplasmin, alpha2-microglobulin and thrombin-activated fibrinolysis inhibitor (TAFI).

362 Christensen, 1995, op cit.

363 Stassen, 2004, op cit.

364 Christensen, 1995, op cit.

365 Olds RJ, Lane DA, Mille B, Chowdhury V, Thein SL. **Antithrombin: the principal**  
397

#### References

**inhibitor of thrombin.** *Seminars in Thrombosis and Hemostasis* 20(4):353-372 (1994).

366 Habata Y, Fujii R, Hosoya M, Fukusumi S, Kawamata Y, Hinuma S, Kitada C, Nishizawa N, Murosaki S, Kurokawa T, Onda H, Tatemoto K, Fujino M. **Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum.** *Biochemica et Biophysica Acta* 1452(1):25-35 (1999). Apelin, a peptide secreted in large amounts in bovine colostrum and milk, is a ligand for the seven-transmembrane domain receptor 7TMR APJ (angiotensin receptor-like 1). As apelin was found to partially suppress cytokine production by mouse spleen cells in response to T cell receptor/CD3 cross-linking, it may play a role in immunomodulation.

367 Szokodi I, Tavi P, Foldes G, Voutilainen-Myllyla S, Ilves M, Tokola H, Pikkarainen S, Pihola J, Rysa J, Toth M, Ruskoaho H. **Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility.** *Circulation Research* 91(5):434-440 (2002). Both apelin and the orphan receptor APJ are produced in large quantities in the heart. Apelin is one of the most potent stimulators of cardiac contraction known.

368 Kleinz MJ, Davenport AP. **Emerging roles of apelin in biology and medicine.** *Pharmacology and Therapeutics* 107(2):198-211 (2005). Apelin is involved in the regulation of cardiac function and fluid homeostasis and as a substrate for ACE II. It also has the ability

to block HIV infection by blocking the HIV coreceptor APJ.

369 Quigley, JD III, Martin KR, Dowlen HH. **Concentrations of trypsin inhibitor and immunoglobulins in colostrum of Jersey cows.** *Journal of Dairy Science* 78(7):1573-1577 (1995). Mean concentration of trypsin inhibitor in bovine colostrum was 56 mg of trypsin inhibited/ml colostrum. Its function is thought to involve protection of colostrum components from digestion in the gastrointestinal tract.

370 Telemo E, Westrom BR, Ekstrom G, Karlsson BW. **Intestinal macromolecular transmission in the young rat: influence of protease inhibitors during development.** *Biology of the Neonate* 52(3):141-148 (1987). The absorption of large macromolecules in neonatal rats was enhanced when combined with either soy or porcine colostrum protease inhibitor.

371 von Fellenberg R, Horber H. **[Multiple protease inhibitors in colostrum and in bovine udder tissue and their possible functional significance].** *Schweizer Archiv für Tierheilkunde* 122(3):159-168 (1980).

372 Lindberg T. **Protease inhibitors in human milk.** *Pediatric Research* 13(9):969-972 (1979). Protease inhibitors, including trypsin, chymotrypsin and elastase, were found in colostrum, with highest levels on the first day postpartum.

373 Uruena C, Telleria JJ, Blanco-Quiros A, Arranz E, Gomez-Carrasco JA. **Alpha-I antichymotrypsin levels are actively increased in normal colostrum.** *Journal of Pediatric Gastroenterology and Nutrition* 26(4):376-379 (1998). A survey of antiproteases in human colostrum was undertaken. Antithrombin II, inter-a trypsin inhibitor and a-2 macroglobulin were undetectable, and antitrypsin levels were at only 6% of serum levels.

Peptide Immunotherapy: *Colostrum*—

*A Physician's Reference Guide*

398 a-I antichymotrypsin levels were higher than expected, however (0.39  $\mu$ g/l) 0.34 g/l, 41% of serum levels. The protein also differed from serum antichymotrypsin in electrophoretic mobility and Western blot analysis. This indicates that it is probably produced by mammary epithelial cells.

374 Lindberg, 1979, op cit.

375 Pineiro A, Brock JH, Esparza I. **Isolation and properties of bovine colostrum trypsin inhibitor.** *Annales de Reserches Veterinaires* 9(2):281-286 (1978). An inhibitor of bovine trypsin was isolated. It was active against both bovine and rat trypsin and weakly active against bovine chymotrypsin.

376 Lindberg, 1979, op cit.

377 Veselsky L, Cechova D, Jonakova V. **Secretion and immunochemical properties of the trypsin inhibitor from bovine colostrum.** *Hoppe Seylers Zeitschrift für Physiologische Chemie* 359(8):873-878 (1978). A trypsin inhibitor was isolated from bovine colostrum. It is only secreted by the mammary gland during the time colostrum is secreted and is not present in mature milk.

378 Cheung PY, Sawicki G, Gross S, Van Aerde J, Radomski M. **Differential expression of matrix metalloproteinases and the tissue inhibitor in human milk.**

*Proceedings of the Western Pharmacology Society* 44:97-98 (2001). Both MMP-2 (matrix metalloproteinase-2) and TIMP-4 (tissue inhibitor of metalloproteinase-4) are expressed in human milk from days 1-30. MMP-2 was at its highest levels on Day 1, while TIMP-4 peaked at Day 7.

379 Pons SM, et al. **Triacylglycerol composition in colostrum, transitional and mature human milk.** *European Journal of Clinical Nutrition* 54(12):878-882 (2000). Triglyceride profiles for colostrum, transitional and mature human milk were distinctive. However, the predominant triglycerides in colostrum (49%) were also predominant in transitional (34%) and mature (42%) milk.

380 Ronneberg R, Skara B. **Essential fatty acids in human colostrum.** *Acta Paediatrica* 81(10):779-783 (1992). Major fatty acids present included palmitic acid (24.3%) and oleic acid (39.7%). The main polyunsaturated fatty acid was linoleic acid (11.5%). Others included linolenic acid (0.7%) and docosahexaenoic acid (0.6%). The ratio of polyunsaturated to saturated fatty acids was 0.42.

381 Shope RE, Gowen JW. **Cholesterol and cholesterol ester content of bovine colostrum.** *Journal of Experimental Medicine* 48(1):21-24 (1928). Colostrum is rich in cholesterol, which then decreases in content as the mammary gland switches to transitional and mature milk.

382 Haug A, Hostmark AT, Harstad OM. **Bovine milk in human nutrition – a review.** *Lipids in Health and Disease* 6:25 (2007).

383 Lazarou J, Pomerantz BH, Corey PN. **Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.** *Journal of the*

399

*References*

*American Medical Association (JAMA)* 279(15):1200-1205 (1998).

- 384 Ainarson TR. **Drug-related hospital admissions.** *Annals of Pharmacotherapy*; 127(7):832-840 (2003).
- 385 Chen TS, Chang FY. **Clinical characteristics of Helicobacter pylori-negative duodenal ulcer disease.** *Hepatogastroenterology* 55(86-87):1615-1618 (2008).
- 386 van Leerdam ME. **Epidemiology of acute upper gastrointestinal bleeding.** *Best Practice & Research. Clinical Gastroenterology* 22(2):209-224 (2008).
- 387 Bowen B, Yuan Y, James C, Rashid F, Hunt RH. **Time course and pattern of blood loss with ibuprofen treatment in healthy subjects.** *Clinical Gastroenterology and Hepatology* 3(11):1075-1082 (2005).
- 388 Bowen B, Yuan Y, James C, Rashid F, Hunt RH. **Time course and pattern of blood loss with ibuprofen treatment in healthy subjects.** *Clinical Gastroenterology and Hepatology* 3(11):1075-1082 (2005).
- 389 Hollenz M, Stolte M, Leodolter A, Labenz J. **NSAID-associated dyspepsia and ulcers: a prospective cohort study in primary care.** *Digestive Diseases* 24(1-2):189-194 (2006).

### Chapter 8 Notes

- 390 Janusz M, Staroscik K, Zimecki M, Wieczorek Z, Lisowski J. **A proline-rich polypeptide (PRPS) with immunoregulatory properties isolated from ovine colostrum. Murine thymocytes have on their surface a receptor specific for PRPS.** *Archivum immunologiae et therapeuticae experimentalis (Warszawa)* 34(4):427-436 (1986). PRPS has immunoregulatory properties. It induces the maturation of thymocytes into mature helper or suppressor T cells. There is a specific receptor for PRPS on the surface of thymocytes.
- 391 Wieczorek Z, Zimecki M, Spiegel K, Lisowski J, Janusz M. **Differentiation of T cells into helper cells from immature precursors: identification of a target cell for a proline-rich polypeptide (PRPS).** *Archivum immunologiae et therapeuticae experimentalis (Warszawa)* 37(3-4):313-322 (1989). The precursors of helper T cells belong to a minor thymocyte subset bearing the Thy-1 +/-, H-2+, L3T4-, Iy2-, CD3- phenotype. PRPS induced the production of antigens consistent with mature helper T cells.
- 392 Zimecki M, Staroscik K, Janusz M, Lisowski J, Wieczorek Z. **The inhibitory activity of a proline-rich polypeptide (PRPS) on the immune response to polyvinylpyrrolidone (PVP).** *Archivum immunologiae et therapeuticae experimentalis (Warszawa)* 31(6):895-903 (1983). PRPS administered to a test animal before immunization with PVP inhibits the immune response to this antigen. PRPS did this by increasing the activity of suppressor T cells and by increasing the generation of new suppressor T cells.
- 393 Kubis A, Marcinkowska E, Janusz M, Lisowski J. **Studies on the mechanism of action Peptide Immunotherapy: Colostrum—A Physician's Reference Guide**
- 400 **of a proline-rich polypeptide complex (PRPS): effect on the stage of cell differentiation.** *Peptides* 26(11):2188-2192 (2005). PRPS affects the differentiation and maturation of cells of the monocyte/macrophage lineage and may regulate in this way the inflammatory processes in which these cells participate.
- 394 Julius MH, Janusz M, Lisowski J. **A colostrum protein that induces the growth and differentiation of resting B lymphocytes.** *Journal of Immunology* 140(5):1366-371 (1988). PRPS induced resting B cells and supported their progression through the cell cycle to form mature B cells. It had the same action on splenocytes.
- 395 Bishop GA, Haxhinasto SA, Stunz LL, Hostager BS. **Antigen-specific B-lymphocyte activation.** *Critical Reviews in Immunology* 23(3):159-197 (2003). B cells have the exclusive ability to produce and secrete immunoglobulins of various types. They also function in antigen presentation and the production of a number of cytokines and chemokines.
- 396 Zablocka A, Janusz M, Rybka K, Wirkus-Romanowska I, Kupryszewski G, Lisowski J. **Cytokine-inducing activity of a proline-rich polypeptide complex (PRPS) from ovine colostrum and its active nonapeptide fragment analogs.** *European Cytokine Network* 12(3):462-467 (2001). PRPS induces the production of INF-g, TNF-a, IL-6 and IL-10 in human whole blood cultures.
- 397 Kruzel ML, Janusz M, Lisowski J, Fischleigh RV, Georgiades JA. **Towards an understanding of biological role of colostrin peptides.** *Journal of Molecular Neuroscience* 17(3):379-389 (2001). PRPS (colostrinin) is a potent inducer of leukocyte proliferation and of certain cytokines.
- 398 Janusz M, Lisowski J. **Proline-rich polypeptide (PRPS)—an immunomodulatory peptide from ovine colostrum.** *Archivum immunologiae et therapeuticae experimentalis (Warszawa)* 41(5-6):275-279 (1993). PRPS increases the permeability of blood vessels in the skin and causes the differentiation of thymocytes into mature T cells.
- 399 See DM, Gurnee K, LeClair M. **An In Vitro Screening Study of 196 Natural Products for Toxicity and Efficacy.** *Journal of the American Nutraceutical Association* 2(1):25-39 (1999). A comparative study of 196 natural products showed that many demonstrated toxicity and cytochrome p450 activity (indicative of liver toxicity) while

having little or no beneficial action. Some natural products, including *Echinacea*, and glyconutrient-containing products, showed the highest degree of NK cell stimulation. Bovine colostrum showed significant enhancement of NK cell cytotoxicity.

400 See DM. **Transfer Factor™ testing – transfer factor study with 20 cancer patients.** <http://www.immune-system-iq.com/research.htm>. 20 cancer patients (levels 3 and 4) with average life expectancy of 3.7 months received 9 capsules of Transfer Factor Plus™ along with other general nutrients. After 8 months, 16 of the 20 were still alive and were either in remission, improving or stabilized. Baseline for NK cell activity was 6.4. After 4 weeks, it increased to 25.7 and after 6 months to 27.6, an increase of 400%.

401 See D, Mason S, Roshan R. **Increased tumor necrosis factor alpha (TNF- ) and**  
401

#### References

**natural killer cell (NK) function using an integrative approach in late stage cancers.** *Immunological Investigations* 31(2):137-153 (2002). A combination of natural products was shown to increase the cytotoxicity of NK cell TNF- $\alpha$  while decreasing DNA damage in patients with late-stage cancer. 20 patients with stage IV end-stage cancer were evaluated using Transfer Factor Plus (3 tabs 3 times/day), IMU-Plus (40 gm/day), IV (50-100 gm/day) and oral (12 gm/day) ascorbic acid, Agaricus Blazeii Murill teas 10 gm/day), Immune Modulator Mix, nitrogenated soy extract, and Andrographis Paniculata (500 mg twice daily). The 16 survivors of the study showed significantly higher NK function and TNF- $\alpha$  levels over baseline. Side effects were limited to occasional diarrhea and nausea, while quality of life improved for all survivors over the six month period of the study. <http://www.informaworld.com/10.1081/IMM-120004804>

#### Chapter 10 Notes

402 Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, Wang XF, Massague J. **TGF beta signals through a heteromeric protein kinase receptor complex.** *Cell* 71(6):1003-1014 (1992).

#### Chapter 12 Notes

403 Lawrence HS, Borkowsky W. **Transfer factor: current status and future prospects.** *Biotherapy* 9:1-5 (1996).

404 Kim S, Lira SM, Dalal MA, Verity MA, Voskuhl RR. **Estriol ameliorates autoimmune demyelinating disease.** *Neurology* 52(6):1230-1237 (1999).

405 Formby B. **Immunologic response in pregnancy. Its role in endocrine disorders of pregnancy and influence on the course of maternal autoimmune conditions.** *Endocrinology and Metabolic Clinics of North America* 24(1):187-205 (1995).

406 Bjorksten B. **Environment and infant immunity.** *Proceedings of the Nutrition Society* 58(3):729-732 (1999).

407 Nicolini A, Ferrari P, Spinelli R, Carpi A, Sagripanti A, Amborgi F. **Cell-mediated immunity in breast cancer patients.** *Biomedicine and Pharmacotherapy* 50(8):337-343 (1996).

408 Bansal AS, Bruce J, Devine PL, Scells B, Zimmermann PV. **Serum cytokines and tumor markers in patients with non-small cell carcinoma of the lung.** *Disease Markers* 13(3):195-199 (1997).

409 Aziz M, Akhtar S, Malik A. **Evaluation of cell-mediated immunity and circulating immune complexes as prognostic indicators in cancer patients.** *Cancer Detection Peptide Immunotherapy: Colostrum—*

*A Physician's Reference Guide*

402 *and Prevention* 22(2):87-99 (1998).

410 Czarnechi D, Zaleberg J, Kulinschaya E, Kaz T. **Impaired cell-mediated immunity of apparently normal patients who had multiple skin cancers.** *Cancer* 76(2):228-231 (1995).

411 Mallmann P, Krebs D. **[The effect of immunotherapy with thymopentin on the parameters of cellular immunity and the clinical course of gynecologic tumor patients.]** *Onkologie* 12(Suppl 3):15-21 (1989).

412 Mallmann P, Krebs D. **Investigations on cell-mediated immunity in patients with breast and ovarian carcinomas receiving a combination of chemotherapy and immunotherapy with thymopentin.** *Methods and Findings in Experimental Clinical Pharmacology* 12(5):333-340 (1990).

413 Kitahara T, Takeaka T, Yoshino M. **Infection and immunosuppression in cancer patients.** *Gan To Kagaku Ryoho* 16(4 Pt 2-1):1108-1114 (1989).

414 O'Byrne KJ, Dagleish AG, Browning MJ, Steward WP, Harris AL. **The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease.** *European Journal of Cancer* 36(2000):151-169, September 21 (1999).

415 Lawrence HS. **Transfer factor in cellular immunity.** The Harvey Lecture Series 68.

New York: Academic Press, 1987.

416 Pizza G, De Vinci C, Cuzzocrea D, Menniti D, Aiello E, Maver P, Corrado G, Romagnoli P, Dragoni E, LoConte G, Riolo U, Palareti A, Zucchelli P, Fornarola V, Viza D. **A preliminary report on the use of transfer factor for treating stage D3 hormoneunresponsive metastatic prostate cancer.** *Biotherapy* 9(3-1):123-132 (1996).

417 Pilotti V, Mastroianni M, Pizza G, De Vinci C, Busutti L, Palareti A, Gozzetti G, Cavallari A. **Transfer factor as an adjuvant to non-small cell lung cancer (NSCLC) therapy.** *Biotherapy* 9:117-121 (1996).

418 Jirova D, Sperlingova I, Halaskova M, Bendova H, Dabrowska L. **Immunotoxic effects of carbon tetrachloride: the effect on morphology and function of the immune system in mice.** *Central European Journal of Public Health* 4(1):16-20 (1996).

419 Heo Y, Lee WT, Lawrence DA. **In vivo the environmental pollutants lead and mercury induce oligoclonal T cell responses skewed toward type-2 reactivities.** *Cellular Immunology* 179(2):185-195 (1997).

420 Khan A. **Transfer Factor in viral diseases.** *The Lancet* 1(8059):328-329 (1978).

421 Milich DR, Chen MK, Hughes JL, Jones JE. **The secreted hepatitis precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence.** *Journal of Immunology* 160:2013-2021 (1998).

422 Tsai SL, Liaw TF, Chen MH, Huang LY, Kuo GC. **Detection of type-2 like T helper cells in hepatitis C detection: implications for hepatitis C virus chronicity.** *Hepatology* 25:449-458 (1997).

403

#### References

423 Ferrer-Argote VE, Romero-Cabello R, Hernandez-Medoza L, Arista-Viveros A, Rojo-Medina J, Balseca-Olivera F, Fierro M, Gonzalez-Constans R. **Successful treatment of severe complicated measles with non-specific transfer factor.** *In Vivo* 8:555-558 (1994).

424 McCormick DP, Lim-Melia E, Sneed K, Baldwin CD, Chonmatitce T. **Detection of respiratory viruses in middle ear fluids of children with otitis media infections.** *Pediatric Infectious Disease Journal* 19(3):256-258 (2000).

425 Ramilio O. **Role of respiratory viruses in acute otitis media: implications for management of AOM.** *Pediatric Infectious Disease* 18(12):1125-1129 (1999).

426 Khan A, Sellars W, Grater W, Graham M, Pfanzer J, Antonetti A, Bailey J, Hill NO. **The usefulness of transfer factor in asthma associated with frequent infections.** *Annals of Allergy* 40(4):229-232 (1978).

427 Ibid.

428 Khan A. **The syndrome of asthma, recurrent viral infections and T-cell immunodeficiency: investigations and management.** *Annals of Allergy* 43(2):69-72 (1979).

429 Clerici M, Merola M, Ferrario E, Trabattoni D, Villa ML, Stefanon B, Venzon DJ, Shearer GM, De Palo G, Clerici E. **Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection.** *Journal of the National Cancer Institute* 89(3):245-250 (1997).

430 Grohn P. **Transfer factor in chronic and recurrent respiratory tract infections in children.** *Acta Paediatrica Scandinavica* 66:211-217 (1977).

431 De Vinci C, Pizza G, Cuzzocrea D, Menniti D, Aiello E, Maver P, Corrado G, Romagnoli P, Dragoni E, LoConte G, Riolo U, Masi M, Severini G, Fornarola V, Viza D. **Use of transfer factor for the treatment of recurrent non-bacterial female cystitis (NBRC): a preliminary report.** *Biotherapy* 9(1-3):133-138, 1996.

432 Masi M, De Vinci C, Baricordi OR. **Transfer factor in chronic mucocutaneous candidiasis.** *Biotherapy* 9(1-3):97-103 (1996).

433 Matyniak JE, Reiner SL. **T helper phenotype and genetic susceptibility in experimental Lyme disease.** *Journal of Experimental Medicine* 181(3):1251-1254 (1995).

434 Lawrence HS, Borkowsky W. **Transfer Factor: current status and future prospects.** *Biotherapy* 9:1-5 (1996).

435 Hana I, Vrabel J, Pekarek J, Cech K. **The influence of age on transfer factor treatment of cellular immunodeficiency, chronic fatigue syndrome and/or chronic viral infections.** *Biotherapy* 9(1-3):91-95 (1996).

436 Ablashi DV, Levine PH, De Vinci C, Whitman JE Jr, Pizza G, Viza D. **Use of anti HHV-6 transfer factor for the treatment of two patients with chronic fatigue syndrome (CFS): two case reports.** *Biotherapy* 9(1-3):81-86 (1996).

437 Pizza G, Viza D, De Vinci C, Palareti A, Cuzzocrea D, Fornarola V, Baricordi R. **Orally administered HSV-specific transfer factor(TF) prevents genital or labial herpes relapses.** *Biotherapy* 9(1-3):67-72 (1996).

Peptide Immunotherapy: *Colostrum*—

*A Physician's Reference Guide*

404 438 Meduri R, Campos E, Scorolli L, De Vinci C, Pizza G, Viza D. **Efficacy of transfer in treating patients with recurrent ocular herpes infections.** *Biotherapy* 9(1-3):61-66

(1996).

439 Basten A, Pollard JD, Stewart GJ, Frith JA, McLeod JG, Walsh JC, Garrick R, van der Brink CM. **Transfer Factor in treatment of multiple sclerosis.** *Lancet* 2(8201):931-934 (1980).

440 Long KZ, Santos JI. **Vitamins and the regulation of the immune response.** *Pediatric Infectious Disease Journal* 18:283-290 (1999).

441 Ibid.

442 Wu B. **Effect of acupuncture on the regulation of cell-mediated immunity in the patients with malignant tumors.** *Chen Tzu Yen Chiu* 20(3):67-71 (1995).

443 Lawrence HS. **Immune Regulation in Transfer Factors.** New York: Academic Press, p. 613, 1979.

444 Khan A, Sellars WA, Gabela P, Thometz D. **Transfer factor, thymosin and E rosettes.** *New England Journal of Medicine* 292:868 (1975).

445 See D, Gurnce K, Leclair M. **An in vitro screening study of 196 natural products for toxicity and efficacy.** *Journal of the American Medical Association* 2(1) (1999).

446 Khan A. **Transfer factor in viral diseases.** *Lancet* 1(8059):328-329 (1978).

447 Bjerring P, Thestrup-Pedersen K, Zachariae H. **Treatment of Kaposi's varicelliform eruption with adenine arabinoside (Vira-A) and transfer factor.** *Acta Dermato-Venereologica* 62(1):85-87 (1982). Kaposi's varicelliform eruptions are a skin condition caused by herpes virus. Use of an antiviral drug, Vira-A, and transfer factor (PRPs) had a beneficial effect on halting the spread and alleviating the severity of the infection.

448 Pizza G, Meduri R, De Vinci C, Scorolli L, Viza D. **Transfer factor prevent relapses in herpes keratitis patients: a pilot study.** *Biotherapy* 8(1):63-68 (1994). 33 patients suffering from herpes eye infections were treated with HSV-specific PRPs (PRPs). The rate of relapses was reduced from 20.1 before treatment to 0.51 after (6 of 33 patients suffered a relapse).

449 Pizza G, Viza D, De Vinci C, Palareti A, Cuzzocrea D, Fornarola V, Baricordi R. **Orally administered HSV-specific transfer (TF) prevents genital or labial herpes relapses.** *Biotherapy* 9(1-3):67-72 (1996). 22 patients suffering from genital herpes and 22 from labial herpes were treated with bovine HSV-specific transfer factor (PRPs). Untreated patients suffered a relapse rate of 61.2 while those receiving treatment had a relapse rate of 21.4.

450 Meduri R, Campos E, Scorolli L, De Vinci C, Pizza G, Viza D. **Efficacy of transfer factor in treating patients with recurrent ocular herpes infections.** *Biotherapy* 9(1-3):61-66 (1996). Cellular immunity plays an important role in recurrent herpes eye infections. Patients treated with HSV-specific transfer factor (PRPs) showed a significant increase in cell-mediated immune response as measured by the lymphocyte stimulation test and

#### References

leukocyte migration test. Relapse rates went from 13.2 to 4.17. There were no reported side effects.

451 De Vinci C, Pizza G, Cuzzocrea D, Menniti D, Aiello E, Maver P, Corrado G, Romagnoli P, Dragoni E, LoConte G, Riolo U, Masi M, Severini G, Fornarola V, Viza D. **Use of transfer factor for the treatment of recurrent non-bacterial female cystitis (NBRC): a preliminary report.** *Biotherapy* 9(1-3):133-138 (1996). Non-bacterial recurrent cystitis (NBRC) is associated with impaired cell-mediated immunity to both *Candida* and herpes virus. Use of HSV-specific and *Candida*-specific transfer factor (PRPs) showed that specific PRPs could control NBRC and alleviate the symptoms.

452 Estrada-Parra, S, Chavez-Sanchez R, Ondarza-Aguilera R, Correa-Meza B, Serrano-Miranda E, Monges-Nicolau A, Calva-Pellicer C. **Immunotherapy with transfer factor of recurrent herpes simplex type I.** *Archives of Medical Research* 26(Spec. No.):S87-S92 (1995). Transfer factor (PRPs) proved to be the most effective agent when used as immunotherapy against recurrent herpes simplex type I virus.

453 Estrada-Parra S, Nagaya A, Serrano E, Rodriguez O, Santamaria V, Ondarza R, Chavez R, Correa B, Monges A, Cabezas R, Calva C, Estrada-Garcia I. **Comparative study of transfer factor and acyclovir in the treatment of herpes zoster.** *International Journal of Immunopharmacology* 20(10):521-535 (1998). Herpes zoster, or shingles, is a skin disease caused by varicella herpes virus (VHV) and can lie latent for long periods of time. A comparison study was performed between transfer factor (PRPs) and acyclovir, an antiviral drug which has shown the most promise against VHV in 28 patients. Patients who received PRPs had a much more favorable clinical course. Those receiving PRPs showed an increase in interferon-gamma levels and CD4+ lymphocytes. This was not seen in patients receiving acyclovir. This result is very significant and confirms the immunomodulatory properties of PRPs.

454 Raise E, Guerra L, Viza D, Pizza G, De Vinci C, Schiattone ML, Rocaccio L, Cicognani M, Gritti F. **Preliminary results in HIV-I-infected patients treated with transfer**

**factor (TF) and zidovudine (ZDV).** *Biotherapy* 9(1-3):49-54 (1996). Patients with persistent generalized lymphadenopathy or ARC (AIDS-related complex) were treated with HIV-1-specific transfer factor (PRPs) in combination with Zidovudine, an antiviral medication. Patients who received both PRPs and Zidovudine had higher levels of white blood cells, CD8 lymphocytes and IL-2 compared to those on Zidovudine alone. The combination seemed to be safe and well tolerated.

455 Ferrer-Argote VE, Romero-Cabello R, Hernandez-Mendoza L, Arista-Viveros A, Rojo-Medina J, Balseca-Olivera F, Fierro M, Gonzalez-Constandse R. **Successful treatment of severe complicated measles with non-specific transfer factor.** *In Vivo* 8(4):555-557 (1994). Severe complicated measles has a high mortality rate and no specific treatment. 10 patients, one with encephalitis, were treated with PRPs. 9 of 10 survived and were cured. The patient with encephalitis showed no neurologic effects two weeks after receiving the last dose.

Peptide Immunotherapy: *Colostrum*—

*A Physician's Reference Guide*

406 456 De Vinci C, Levine PH, Pizza G, Fudenberg HH, Orens P, Pearson G, Viza D. **Lessons from a pilot study of transfer factor in chronic fatigue syndrome.** *Biotherapy* 9(1-3):87-90 (1996). Of 20 chronic fatigue patients given transfer factor (PRPs), 12 showed improvement.

457 Iseki M, Aoyama T, Koizumi Y, Ojima T, Murase Y, Osano M. **[Effects of transfer factor on chronic hepatitis B in childhood]** *Kansenshogaku Zasshi* 63(12):1329-1332 (1989). Nine children with chronic hepatitis B received transfer factor (PRPs) for 3-17 months. Of these, 4 became hepatitis-B negative. After 22-48 months, 6 of the 9 were negative. No side effects were observed.

458 Vasily DB, Miller OF, Fudenberg HH, Goust JM, Wilson GB. **Epidermodysplasia verruciformis: response to therapy with dialyzable leukocyte extract [PRPs] derived from household contacts.** *Journal of Clinical and Laboratory Immunology* 14(1):49-57 (1984). EV is characterized by severely depressed suppressor T cell levels. Treatment with PRPs showed a gradual yet definite resolution of symptoms.

459 Wilson GB, Metcalf JF, Fudenberg HH. **Treatment of *Mycobacterium fortuitum* pulmonary infection with transfer factor (TF): new methodology for evaluating TF potency and predicting clinical response.** *Clinical Immunology and Immunopathology* 23(2):478-491 (1982).

460 Fabre RA, Perez TM, Aguilar LD, Rangel MJ, Estrada-Garcia I, Hernandez-Pando R, Estrada-Parra S. **Transfer factors as immunotherapy and supplement of chemotherapy in experimental pulmonary tuberculosis.** *Clinical and Experimental Immunology* 136(2):215-223 (2004). Treatment with either mouse or human transfer factors (PRPs) restores Th1 cytokines and TNF- $\alpha$  levels to levels usually seen only at the initial infection, allowing the body to fight off the tuberculosis bacteria.

461 Louie E, Borkowsky W, Klesius PH, Haynes TB, Gordon S, Bonk S, Lawrence HS. **Treatment of cryptosporidiosis with oral bovine transfer factor.** *Clinical Immunology and Immunopathology* 44(3):329-334 (1987).

462 McMeeking A, Borkowsky W, Klesius PH, Bonk S, Holzman RS, Lawrence HS. **A controlled trial of bovine dialyzable leukocyte extract for cryptosporidiosis in patients with AIDS.** *Journal of Infectious Diseases* 161(1):108-112 (1990). A trial using bovine dialyzable leukocyte extract (PRPs) in AIDS patients suffering from cryptosporidial diarrhea was promising with 6 of 7 patients showing improvement or complete elimination of symptoms and oocytes.

463 Tanphaichitra D. **Cellular immunity in typhoid fever, Legionnaires' disease, amebiasis: role of transfer factor and Levamisole in typhoid fever.** *Developments in Biological Standardization* 53:35-40 (1983). Both typhoid fever and Legionnaires' disease impair cellular immunity. Typhoid fever patients treated with transfer factor (PRPs) improved faster in general condition, fever and cellular immunity.

464 Tanphaichitra D. **Tropical disease in the immunocompromised host: melioidosis**  
407

*References*

**and pythiosis.** *Reviews of Infectious Diseases* 11(Suppl 7):S1629-S1643 (1989). Transfer factor (PRPs) was used to restore cellular immunity in AIDS patients suffering from recurrent melioidosis.

465 Feigin RD, Shackelford PG, Eisen S, Spittler LE, Pickering LK, Anderson DC. **Treatment of mucocutaneous candidiasis with transfer factor.** *Pediatrics* 53(1):63-70 (1974).

466 Masi M, De Vinci C, Baricordi OR. **Transfer factor in chronic mucocutaneous candidiasis.** *Biotherapy* 9(1-3):97-103 (1996).

467 Spittler LE, Dau PC. **Immunotherapy in infectious disease, autoimmunity and cancer.** *Acta Neurologica Scandinavica Supplement* 63:227-237 (1977).

468 Zachariae H, Ellegaard J, Grunnet E, Thestrup-Pedersen K. **Transfer factor in mycosis**

- fungoides: three years experience.** *Dermatologica* 160(1):1-6 (1980). Patients treated with transfer factor (PRPs) showed partial or complete remission of symptoms in 7 cases out of 13 studied. T lymphocyte levels returned to normal levels in these patients, and serum IgE levels decreased.
- 469 Pizza G, De Vinci C, Viza D. **Immunotherapeutic approaches for renal cancer.** *Folia Biologica (Praha)* 48(5):167-181 (2002).
- 470 Pizza G, De Vinci C, Cuzzocrea D, Menniti D, Aiello E, Maver P, Corrado G, Romagnoli P, Dragoni E, LoConte G, Riolo U, Palareti A, Zucchelli P, Fornarola V, Viza D. **A preliminary report on the use of transfer factor for treating stage D3 hormoneunresponsive metastatic prostate cancer.** *Biotherapy* 9(1-3):123-132 (1996).
- 471 Pilotti V, Mastrorilli M, Pizza G, De Vinci C, Busutti L, Palareti A, Gozzetti G, Cavallari A. **Transfer factor as an adjuvant to non-small cell lung cancer (NSCLC) therapy.** *Biotherapy* 9(1-3):117-121 (1996).
- 472 Fujisawa T, Yamaguchi Y. **Postoperative immunostimulation after complete resection improves survival of patients with stage I non-small cell lung carcinoma.** *Cancer* 78(9):1892-1898 (1996).
- 473 Phillips J, Boiucheix C, Pizza G, Sartorio C, Viza D. **Effect of in vitro produced transfer factor on Hodgkin patients.** *British Journal of Haematology* 38(3):430-431 (1978).
- 474 Gonzalez RL, Wong P, Spitler LE. **Adjuvant immunotherapy with transfer factor in patients with melanoma metastatic to lung.** *Cancer* 45(1):57-63 (1980).
- 475 Levin AS, Byers VS, Fudenberg HH, Wybran J, Hackett AJ, Johnston JO, Spitler LE. **Osteogenic sarcoma. Immunologic parameters before and during immunotherapy with tumor-specific transfer factor.** *Journal of Clinical Investigation* 55(3):487-499 (1975).
- 476 Boldogh I, Aguilera-Aguirre L, Bacsí A, Choudhury BK, Saavedra-Molina A, Kruzel M. **Colostrinin [PRP] Decreases Hypersensitivity and Allergic Responses to Common Allergens.** *International Archives of Allergy and Immunology* 146(4):298-306 (2008).
- 477 Keech A. **Peptide Immunotherapy: The Use of Bovine Colostrum Proline-Rich Peptide Immunotherapy: Colostrum—**  
A Physician's Reference Guide
- 408 **Polypeptides in Cytokine Modulation for the Alternative Relief of Allergic Symptoms.** *Journal of Allergy and Clinical Immunology* 119(1): S260-S260 (2008).
- 478 Navarro Cruz D, Serrano Miranda E, Orea M, Estrada Parra S, Teran Ortiz L, Gomez Vera J, Flores Sandoval G. **[Transference factor in moderate and severe atopic dermatitis]** *Revista Alergia Mexico* 43(5):116-123 (1996).
- 479 Khan A, Sellars WA, Pflanzner J, Hill JM, Thometz D, Haenke J. **Asthma and T cell immuno-deficiency: improvement with transfer factor and immunopeptide.** *Annals of Allergy* 37(4):264-274 (1976).
- 480 Khan A, Sellars W, Grater W, Graham MF, Pflanzner J, Antonetti A, Bailey J, Hill NO. **The usefulness of transfer factor in asthma associated with frequent infections.** *Annals of Allergy* 40(4):229-232 (1978). 15 patients with asthma and suffering from repeated respiratory infections received transfer factor (PRPs). A marked decrease in respiratory infections and striking improvement in asthma resulted.
- 481 Zimecki M. **A proline-rich polypeptide from ovine colostrum: colostrinin with immuno-modulatory activity.** *Advances in Experimental Medicine and Biology* 606:241-250 (2008). PRPs, originally isolated from ovine (sheep) colostrum, promote T lymphocyte maturation into mature T helper cells and also recruit suppressor T cells in the suppression of autoimmune conditions. They also regulate cytokine production in the blood. In addition, they delay the progress of Alzheimer's and similar dementias.
- 482 Lawrence HS. **Transfer factor and autoimmune disease.** *Annals of the New York Academy of Sciences* 124(1):56-60 (1965).
- 483 Dutta RC. **Peptide immunomodulators versus infection; an analysis.** *Immunology Letters*. 83(3):153-61 (2002). Immune stimulators have been found to be useful in helping to fight off infections, while immunosuppressors have been found useful in autoimmune conditions and transplants.
- 484 Zimecki M, Hraba T, Janusz M, Lisowski J, Wiczorek Z. **Effect of a proline-rich polypeptide (PRPs) on the development of hemolytic anemia and survival of New Zealand black (NZB) mice.** *Archivum Immunologiae et Therapiae Experimentalis (Warszawa)* 39(5-6):461-467 (1991).
- 485 Hraba T, Wiczorek Z, Janusz M, Lisowski J, Zimecki M. **Effect of proline-rich polypeptide on experimental autoimmune response to erythrocytes.** *Archivum Immunologiae et Therapiae Experimentalis (Warszawa)* 34(4):437-443 (1986).
- 486 Hughes RA. **Immunological treatment of multiple sclerosis.** *Journal of Neurology* 230(2):73-80 (1983). PRPs slowed the progression of the disease whereas interferon and levamisole did not.



487 Nitsch A, Nitsch FP. **Clinical Use of Bovine Colostrum.** *Journal of Orthomolecular Medicine* 13(2) (1998). Low molecular weight components of colostrum (PRPs) were used in a clinical study for the treatment of rheumatoid arthritis with promising results.

488 Fudenberg HH, Strelkauskas AJ, Goust JM, Osborne D, Fort D, Vasily D. **“Discoid” lupus** 409

#### References

- erythematosus: dramatic clinical and immunological response to dialyzable leukocyte extract [PRPs].** *Transactions of the Association of American Physicians* 94:279-291 (1981).
- 489 Wolf RE, Fudenberg HH, Welch TM, Spittler LE, Ziff M. **Treatment of Behcet's syndrome with transfer factor.** *Journal of the American Medical Association* 238(8):869-871 (1977). Of five patients treated with PRPs, three showed great improvement, on moderate improvement, and one was unresponsive.
- 490 Franzoni E, Masi M, Conte R, Giovannini A, Malferrari C, Scanabissi E, Specchia F, Ricci G. **Behcet syndrome: report of two early-onset cases treated with transfer factor.** *Italian Journal of Neurological Science* 5(1):93-96 (1984).
- 491 Lloyd AR, Hickie I, Brockman A, Hickie C, Wilson A, Dwyer J, Wakefield D. **Immunologic and psychologic therapy for patients with chronic fatigue syndrome: a double-blind, placebo-controlled trial.** *American Journal of Medicine* 94(2):197-203 (1993). Treatment of chronic fatigue syndrome using both psychological cognitive therapy and dialyzable leukocyte extract (PRPs) resulted in improvement of the condition generally, but there was no specific response found.
- 492 Vezendi S, Schroder I. **Transfer factor therapy of thoracic sarcoidosis.** *Allergologia et Immunopathologia* 17(1):35-37 (1989). Treatment of patients with thoracic sarcoidosis has generally proven beneficial, probably due to the ability of transfer factor (PRPs) to stimulate the immune system.
- 493 Fudenberg HH, Whitten HD, Arnaud P, Khansari N, Tsang KY, Hames CG. **Immune diagnosis of a subset of Alzheimer's disease with preliminary implications for immunotherapy.** *Biomedicine and Pharmacotherapy* 38(6):290-297 (1984).
- 494 Leszek J, Inglot AD, Janusz M, Lisowski J, Krukowska K, Georgiades JA. **Colostrinin: a proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer's disease. A double-blind, placebo-controlled study.** *Archivum Immunologiae et Therapiae Experimentalis (Warszawa)* 47(6):377-385 (1999).
- 495 Leszek J, Inglot AD, Janusz M, Byczkiewicz F, Kiejna A, Georgiades J, Lisowski J. **Colostrinin proline-rich polypeptide complex from ovine colostrum--a long-term study of its efficacy in Alzheimer's disease.** *Medical Science Monitor* 8(10):193-196 (2002).
- 496 Bilikiewicz A, Gaus W. **Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease.** *Journal of Alzheimer's Disease* 6(1):17-26 (2004).
- 497 Mokran V, Simko M, Nyulassy S. **[Epileptic seizures and immune disorders]** *Bratislavské Lekárske Listy* 98(4):229-233 (1997). Out of 125 epileptic patients, only 3.2% showed no disturbances of immunity, indicating that immunomodulatory therapy might be effective in controlling the disorder.
- 498 Simko M, Mokran V, Nyulassy S. **[Immunomodulatory therapy of epilepsy with Peptide Immunotherapy: Colostrum—**  
*A Physician's Reference Guide*
- 410 **transfer factor]** *Bratislavské Lekárske Listy* 98(4):234-237 (1997). Eight epileptic patients treated for 3 months with transfer factor (PRPs) had significant reduction of epileptic episodes.
- 499 Levin AS, Spittler LE, Fudenberg HH. **Transfer factor I: methods of therapy.** *Birth Defects Original Articles Series* 11(1):445-448 (1975). Approximately 50% of patients with a variety of immunodeficiency disorders are induced to a clinically acceptable level of cell-mediated immunity when given transfer factor (PRPs).
- 500 Chan MC, Cheung CY, Chui WH, Tsao SW, Nicholls JM, Chan YO, Chan RW, Long HT, Poon LL, Guan Y, Peiris JS. **Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells.** *Respiratory Research* 6:135 (2005).
- 501 Pizza G, Amadori M, Ablashi D, De Vinci C, Viza D. **Cell mediated immunity to meet the avian influenza A (H5N1) challenge.** *Medical Hypotheses* 67(3):601-608 (2006).

#### Chapter 13 Notes

- 502 UNAIDS/WHO AIDS Epidemic Update 2007.
- 503 United Nations Department of Economic and Social Affairs/Population Division report: **The Impact of AIDS** (2004). <http://www.un.org/esa/population/publications/AIDSimpact/AIDSWebAnnounce.htm>

504 Keech A, Nwabuko U, Chikezie C, Wogu GUE. **Peptide Immunotherapy: A New Direction in HIV/AIDS Treatment.** *In press*

### Appendix Notes

- 505 **An Examination of Immune Response Modulation in Humans by Ai/EI or Utilizing A Double Blind Study.** Immune Consultants, Tucson, Arizona, January 2001.
- 506 Caligiuri MA. **Human natural killer cells.** *Blood* 112(3):461-469 (2008).
- 507 Kirkpatrick CH. **Structural nature and functions of transfer factors.** *Annals of the New York Academy of Sciences* 685:362-368 (1993).
- 508 Whitcomb ME, Rocklin RE. **Transfer factor therapy in a patient with progressive primary tuberculosis.** *Annals of Internal Medicine* 79(2):161-166 (1973).
- 509 Brambell FWR. In: **The Transmission of Passive Immunity From Mother to Young.** Vol. 18. Elsevier Publishing Co., New York, 1969.
- 510 Penhale WJ, Logan EF, Selman IE, Fisher EW, McEwan AD. **Observations on the adsorption of colostral immunoglobulins by neonatal calf and their significance in colibacillosis.** *Ann. Rech. Vet.* 4: 223-229 (1973).

411

### References

- 511 Smith T, Little RB. **The significance of colostrum to the newborn calf.** *Journal of Experimental Medicine* 36: 181-186 (1922).
- 512 McEwan AD, Fisher EW, Selman IE. **Observations on the immunoglobulin level of neonatal calves and their relationship to disease.** *Journal of Comparative Pathology* 80: 259-263 (1970).
- 513 McGuire TC, Pfeiffer NE, Weikel JM, Bartsch RG. **Failure of colostral immunoglobulin transfer in calves dying from infectious disease.** *Journal of the American Veterinary Medicine Association* 169: 713-716 (1976).
- 514 Pahud JJ, Hilbert H, Schwartz K, Amster H, Smiley M. **Bovine milk antibodies in the treatment of enteric infections and their ability to eliminate virulence factors from pathogenic *E. coli*.** In: *The Ruminant Immune System*, edited by J. E. Butler, pp 591-600. Plenum, New York, 1981.
- 515 Hilpert H, Gerber H, Amster H, Pahud JJ, Ballabriga A, Arcalis L, Farriaux JP, de Peyer E, Nussle, D. **Bovine milk immunoglobulins (Ig) and their possible utilisation in industrially prepared infant's milk formulae.** In: *Food and Immunology, Swedish Nutritional Foundation Symposium XIII*, Hambraeus L, Hanson LA, McFarlane H, eds, pp 182-196. Almquist and Wiksell, Stockholm. 1977.
- 516 Chaplin DD. **Overview of the human immune response.** *Journal of Allergy and Clinical Immunology* 117(Suppl. 2):S430-S435 (2006).
- 517 Mosmann TR, Cherwinski, H, Bond, MW, Giedlin MA, Coffman RL. **Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.** *Journal of Immunology* 136:2348-2357 (1986).
- 518 Mosmann TR, Coffman RL. **TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.** *Annual Reviews of Immunology* 7:145-173 (1989).
- 519 Mosmann TR, Sad S. **The expanding universe of T-cell subsets: Th1, Th2 and more.** *Immunology Today* 17:138-146 (1996).
- 520 Abbas AK, Murphy KM, Sher A. **Functional diversity of helper T lymphocytes.** *Nature* 383:787-793 (1996).
- 521 McGuirk, P, Mills, KH. **Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases.** *Trends in Immunology* 23:450-455 (2002).

Peptide Immunotherapy: *Colostrum*—

*A Physician's Reference Guide*

### 412 Appendix C Notes

#### Bovine Lactoferrin

- 522 Kanyshkova TG, Buneva VN, Nevinsky GA. **Lactoferrin and its biological functions.** *Biochemistry (Moscow)* 66(1):1-7 (2001).
- 523 Sanchez L, Calvo M, Brock JH. **Biological role of lactoferrin.** *Archives of Disease in Childhood* 67(5):657-661 (1992).
- 524 Kensler TW, Tsuda H, Wogan GN. **United States-Japan workshop on new rodent models for the analysis and prevention of carcinogenesis.** *Cancer Epidemiology, Biomarkers and Prevention* 8(11):1033-1037 (1999).
- 525 Ushida Y, Sekine K, Kuhara T, Takasuka N, Iigo M, Tsuda H. **Inhibitory effects of bovine lactoferrin on intestinal polyposis in the Apc(Min) mouse.** *Cancer Letters* 134(2):141-145 (1998).
- 526 Ushida Y, Sekine K, Kuhara T, Takasuka N, Iigo M, Maeda M, Tsuda H. **Possible chemopreventive effects of bovine lactoferrin on esophagus and lung**

- carcinogenesis in the rat. *Japanese Journal of Cancer Research* 90(3):262-267 (1999).
- 527 Tanaka K, Ikeda M, Nozaki A, Kato N, Tsuda H, Saito S, Sekihara H. **Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study.** *Japanese Journal of Cancer Research* 90(4):367-371 (1999).
- 528 Wang D, Pabst KM, Aida Y, Pabst MJ. **Lipopolysaccharide-inactivating activity of neutrophils is due to lactoferrin.** *Journal of Leukocyte Biology* 57:865-874 (1995)
- 529 Arnold RR, Cole MF, McGhee JR. **A bactericidal effect for human lactoferrin.** *Science* 197(4300):263-265 (1977).
- 530 Arnold RR, Brewer M, Gauthier JJ. **Bactericidal activity of human lactoferrin: sensitivity of a variety of microorganisms.** *Infection and Immunity* 28(3):893-898 (1980).
- 531 Debbabi H, Dubarry M, Rautureau M, Tome D. **Bovine lactoferrin induces both mucosal and systemic immune response in mice.** *Journal of Dairy Research* 65:283-29 (1998).
- 532 Samaranyake YH, Samaranyake LP, Wu PC, So M. **The antifungal effect of lactoferrin and lysozyme on *Candida krusei* and *Candida albicans*.** *APMIS* 105:875-883 (1997).
- 533 Mattsby-Baltzer I, Roseanu A, Motas C, Elverfors J, Engberg I, Hanson LA. **Lactoferrin or a fragment thereof inhibits the endotoxin-induced interleukin-6 response in human monocytic cells.** *Pediatric Research* 40(2):257-262 (1996).
- 534 Teraguchi S, Shin K, Ozawa K, Nakamura S, Fukuwatari Y, Tsuyuki S, Namihira H, Shimamura S. **Bacteriostatic effect of orally administered bovine lactoferrin on proliferation of *Clostridium* species in the gut of mice fed bovine milk.** *Applied Environmental Microbiology* 61(2):501-506 (1995).
- References*
- 535 Zagulski T, Lipinski P, Zagulska A, Broniek S, Jarzabek Z. **Lactoferrin can protect mice against a lethal dose of *E. coli* in experimental infection *in vivo*.** *British Journal of Experimental Pathology* 70:697-704 (1989).
- 536 Lee, WJ, Farmer JL, Hilty M, Kim YB. **The protective effects of lactoferrin feeding against endotoxin lethal shock in germfree piglets.** *Infection and Immunity* 66(4):1421-1426 (1998).
- 537 Naidu A, Arnold RR. **Lactoferrin interaction with salmonella potentiates antibiotic susceptibility *in vitro*.** *Diagnostic Microbiology and Infectious Disease* 20(2):69-75 (1994).
- 538 Wakabayashi H, Abe S, Okutomi T, Tansho S, Kawase K, Yamaguchi H. **Cooperative anti-*Candida* effects of lactoferrin or its peptides in combinations with azole antifungal agents.** *Microbiological Immunology* 40(11):821-825 (1996).
- 539 Harmsen MC, Swart PJ, de Bethune MP, Pauwels R, De Clercq E, The TH, Meijer DK. **Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication *in vitro*.** *Journal of Infectious Diseases* 172:380-388 (1995).
- 540 Marchetti M, Pisani S, Antonini G, Valenti P, Seganti L, Orsi N. **Metal complexes of bovine lactoferrin inhibit *in vitro* replication of herpes simplex virus type 1 and 2.** *Biometals* 11(2):89-94 (1998).
- 541 Kawasaki Y, Isoda H, Shinmoto H, Tanimoto M, Dosako S, Idota T, Nakajima I. **Inhibition of kappa-casein glycomacropptide and lactoferrin of influenza virus hemagglutination.** *Bioscience, Biotechnology and Biochemistry* 57(7):1214-1215 (1993).
- 542 Superti F, Ammendolia MG, Valenti P, Seganti L. **Antiviral activity of milk proteins: lactoferrin prevents rotavirus infection in the enterocyte-like cell line HT-29.** *Medical Microbiology and Immunology* 186(2-3):83-91 (1997).
- 543 Shimizu K, Matsuzawa H, Okada K, Tazume S, Dosako S, Kawasaki Y, Hashimoto K, Koga Y. **Lactoferrin-mediated protection of the host from murine cytomegalovirus infection by a T-cell dependent augmentation of natural killer cell activity.** *Archives of Virology* 141(10):1875-1889 (1996).
- 544 Yi M, Kaneko S, Yu DY, Murakami S. **Hepatitis C virus envelope proteins bind lactoferrin.** *Journal of Virology* 71(8):5997-6002 (1997).
- 545 Cohen MS, Mao J, Rasmussen GT, Serody JS, Britigan BE. **Interaction of lactoferrin and lipopolysaccharide (LPS): effects on the antioxidant property of lactoferrin and the ability of LPS to prime human neutrophils for enhanced superoxide formation.** *Journal of Infectious Diseases* 166(6):1375-1378 (1992).
- 546 Zimecki M, Mazurier J, Machnicki M, Wiczorek Z, Montreuil J, Spik G. **Immunostimulatory activity of lactoferrin and maturation of CD4-, CD8-murine thymocytes.** *Immunology Letters* 30(1):119-123 (1991).
- Peptide Immunotherapy: Colostrum—  
A Physician's Reference Guide
- 414 **Growth Factors**
- 547 Shing YW, Klagsbrun M. **Human and Bovine Milk Contain Different sets of Growth**

- Factors.** *Endocrinology* 115(1):273-282 (1984).
- 548 Iacopetta BJ, Grieu F, Horisberger M, Sunahara G I. **Epidermal Growth Factor in Human and Bovine Milk.** *Acta Paediatrica* 81(4):287-291 (1992).
- 549 Shamay, A, Cohen N, Niwa M, Gertler A. **Effects of Insulin-Like Growth Factor I on Deoxyribonucleic Acid Synthesis and Galactopoiesis in Bovine Undifferentiated and Lactating Mammary Tissue.** *Endocrinology* 123(2):804-809 (1988).
- 550 Baumrucker CR, Blum JW. **Secretion of Insulin-Like Growth Factors in Milk and their Effect on the Neonate.** *Livestock Production Science* 35: 49-72 (1993).
- 551 Xu RJ, Mellor DJ, Birtles MJ, Breier BH, Gluckman PD. **Effects of Oral IGF-I or IGF-II on Digestive Organ Growth in Newborn Piglets.** *Biology of the Neonate* 66(5):280-287 (1994).
- 552 Baumrucker CR, Hadsell DL, Blum JW. **Effects of Dietary Insulin-Like Growth Factor I on Growth and Insulin-Like Growth Factor Receptors in Neonatal Calf Intestine.** *Journal of Animal Science* 72(2):428-433 (1994).
- 553 Baumrucker CR, Blum JW. **Effects of Dietary Recombinant Human Insulin-Like Growth Factor-I on Concentration of Hormones and Growth Factors in the Blood of Newborn Calves.** *Journal of Endocrinology* 140(1):15-21 (1994).
- 554 Humbel RE. **Insulin-Like Growth Factors, Somatomedins, and Multiplication Stimulating Activity: Chemistry.** *Hormonal Proteins and Peptides*, Edited by Choh, HL, Volume XII, pp 57-72, 1984.
- 555 Mero A, Mikkilainen H, Riski J, Pakkanen R, Aalto J, Takala T. **Effects of Bovine Colostrum Supplementation on Serum IGF-I, IgG, Hormone and Saliva IgA During Training.** *Journal of Applied Physiology* 83(4):1144-1151 (1997).
- 556 Buckley JD, Abbott M, Martin S, Brinkworth G, Whyte P. **Effect of an Oral Bovine Colostrum Supplement on Running Performance.** Abstract from: 1988 Australian Conference of Science and Medicine in Sport, Adelaide, South Australia, October, 1988.
- 557 Buckley JD, Brinkworth GD, Bourdon PC, Gulbin J, Stilwell EJ, David A, Myers N. **Oral Supplementation with Bovine Colostrum Improves Rowing Performance in Elite Female Rowers.** Abstract presented at the 5th I.O.C. World Congress on Sports Sciences, Sydney, Australia. October, 1999.
- 558 Buckley JD, Abbott M, Brinkworth GD, Whyte P. **Oral Supplementation with Bovine Colostrum Increases Vertical Jump Performance.** Abstract presented at the 4th Annual Congress of the European College of Sports Science. Rome, Italy, July, 1999.
- 559 Barton-Davis ER, Shoturma DI, Musaro A, Rosenthal N, Sweeney HL. **Viral Mediated Expression of Insulin-Like Growth Factor I Blocks the Aging-Related Loss**

415

#### References

- of Skeletal Muscle Function.** *Proceedings of the National Academy of Sciences USA* 95(26):15603-15607 (1998).
- 560 Hammerman MR. **Insulin-Like Growth Factors and Aging.** *Endocrinology and Metabolism Clinics of North America* 16(4):995-1011 (1987).
- 561 Cohen P, Ocran I, Fielder PJ, Neely EK, Gargosky SE, Deal CI, Ceda GP, Youngman O, Pham H, Lamons G. **Insulin-like Growth Factors (IGFs): Implications for Aging.** *Psychoneuroendocrinology* 17(4):335-342 (1992).
- 562 Swerdloff RS, Wang C, Hines M, Gorski R. **Effect of Androgens on the Brain and Other Organs During Development and Aging.** *Psychoneuroendocrinology* 17(4):375-383 (1992).
- 563 George-Nascimento C, Lowenson J., Borissenko M, Calderon A, Medina-Selby A, Kuo J, Clarke S, Randolph A. **Replacement of a Labile Aspartyl Residue Increases the Stability of Human Epidermal Growth Factor.** *Biochemistry* 29(41):9584-9591 (1990).
- 564 Hall K, Bang P, Brismar K. **[Insulin-like Growth Factors. Future Treatment in Catabolism?]** *Lakartidningen* 92(26-27):2666-2671 (1995).
- IGF-I and Cancer—Not!**
- 565 Spagnoli A, Rosenfeld RG. **The mechanisms by which growth hormone brings about growth. The relative contributions of growth hormone and insulin-like growth factors.** *Endocrinology and Metabolic Clinics of North America* (3):615-631 (1996)
- 566 Liu JL, LeRoith D. **Insulin-like growth factor I is essential for post-natal growth in response to growth hormone.** *Endocrinology* 140(11):5178-84 (1999).
- 567 Butler AA, Yakar S, Gewolb IH, Karas M, Okubo Y, LeRoith D. **Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology.** *Comparative Biochemistry and Physiology B Biochemistry and Molecular Biology* 121(1):19-26 (1998)
- 568 Hwa V, Oh Y, Rosenfeld RG. **The insulin-like growth factor binding protein (IGFBP) superfamily.** *Endocrinology Reviews* 20(6):761-787 (1999).
- 569 Werner H, Hernandez-Sanchez C, Karnieli E, LeRoith D. **The regulation of IGF-I**

**receptor gene expression.** *International Journal of Biochemistry and Cell Biology* 27(10):987-994 (1995).

570 LeRoith D. **Insulin-like growth factor receptors and binding proteins.** *Baillieres Clinical Endocrinology and Metabolism* 10(1):49-73 (1996).

571 Kelly KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, Hwa V, Ng L, Simpson DM, Rosenfeld RG. **Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics.** *International Journal of Biochemistry and Cell Biology* 28(6):619-637 (1996).

572 Hasegawa T, Hasegawa Y, Rosenfeld, RG, Cohen P. **Insulin-like growth factor binding Peptide Immunotherapy: Colostrum—  
A Physician's Reference Guide**

**416 protein-4 accumulation is negatively correlated with growth rate in TM-3 cells.** *Growth Hormone and IGF Research* 8(4):277-282 (1998)

573 Rosenfeld RG, Hwa V, Wilson L, Lopez-Bermejo A, Buckway C, Choi WK, Devi G, Ingermann A, Graham D, Minniti G, Spagnoli A, Oh Y. **The insulin-like growth factor binding protein superfamily: new perspectives.** *Pediatrics* 1999 Oct; 104(4):1018-1021 (1999).

574 Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkenson P, Hennekens CH, Pollak M. **Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.** *Science* 279(5350):563-566 (1998).

575 Wolk A, Mantzorous CS, Andersson SO, Bergstrom R, Signorello LB, Adami HO, Trichopoulos D. **Insulin-like growth factor-I and prostate cancer risk: a population-based, case-control study.** *Journal of the National Cancer Institute* 90(12):911-5 (1998).

576 Chan JM, Giovannucci E, Andersson SO, Yuen J, Adami HO, Wolk A. **Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer.** *Cancer Causes Control* 9(6):559-566 (1998).

577 Hwa V, Tomasini-Sprenger C, Bermejo AL, Rosenfeld RG, Plymate SR. **Characterization of insulin-like growth factor-binding protein-related protein-I in prostate cancer.** *Journal of Clinical Endocrinology and Metabolism* 83(12):4355-62 (1998).

578 Sprenger CC, Damon SE, Hwa V, Rosenfeld RG, Plymate SR. **Insulin-like growth factor binding protein-related protein I (IGFBP-rPI) is a potent tumor suppressor protein for prostate cancer.** *Cancer Research* 59(10):2370-5 (1999)

579 Papa V, Hartmann KK, Rosenthal SM, Maddux BA, Siiteri PK, Goldfine ID. **Progestins induce down-regulation of insulin-like growth factor-I (IGF-I) receptors in human breast cancer cells: potential autocrine role of IGF-II.** *Molecular Endocrinology* 5(5):709-717 (1991).

580 Goldfine ID, Papa V, Vigneri R, Siiteri P, Rosenthal S. **Progestin regulation of insulin and insulin-like growth factor I receptors in cultured human breast cancer cells.** *Breast Cancer Research and Treatment* 22(1):69-79 (1992).

581 Frittitta L, Vigneri R, Papa V, Goldfine ID, Grasso G, Trischitta V. **Structural and functional studies of insulin receptors in human breast cancer.** *Breast Cancer Research and Treatment* 25(1):73-78 (1993).

582 Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Vigneri R, Goldfine ID, Pezzino V. **Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer.** *Cancer Research* 53(16):3736-3740 (1993).

583 Papa V, Milazzo G, Goldfine ID, Waldman FM, Vigneri R. **Sporadic amplification of the insulin receptor gene in human breast cancer.** *Journal of Endocrinology Investigation* 20(9):531-6 (1997).

584 Yang DH, Kim HS, Wilson EM, Rosenfeld RG, Oh Y. **Identification of glycosylated 38-417**

#### *References*

**kDa connective tissue growth factor (IGFBP related protein 2) and proteolytic fragments in human biological fluids, and up-regulation of IGFBP-rP2 expression by TGF-beta in Hs578T human breast cancer cells.** *Journal of Clinical Endocrinology and Metabolism* 83(7):2593-6 (1998).

585 Gliozzo B, Sung CK, Scalia P, Papa V, Frasca F, Sciacca L, Giorgino F, Milazzo G, Goldfine ID, Vigneri R, Pezzino V. **Insulin-stimulated cell growth in insulin receptor substrate-1-deficient ZR-75-1 cells is mediated by a phosphatidylinositol-3-kinase-independent pathway.** *Journal of Cell Biochemistry* 70(2):268-280 (1998).

586 Bohlke K, Cramer DW, Trichopoulos D, Mantzorous CS. **Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast.** *Epidemiology* 1998 Sep; 9(5):570-573 (1998).

587 Yamanaka Y, Fowlkes JL, Wilson EM, Rosenfeld RG, Oh Y. **Characterization of insulinlike growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domains**

of the **IGFBP-3** molecule. *Endocrinology* 140(3):1319-1328 (1999).

588 Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ. **Prospective study of colorectal cancer risk in men and plasma levels of insulinlike growth factor (IGF)-I and IGF binding protein-3.** *Journal of the National Cancer Institute* 91(7):620-5 (1999).

589 How HK, Yeoh A, Quah TC, Oh Y, Rosenfeld RG, Lee KO. **Insulin-like growth factor binding proteins IGFBPs and IGFBP-related protein-I levels in cerebrospinal fluid of children with acute lymphoblastic leukemia.** *Journal of Clinical Endocrinology and Metabolism* 84(4):1283-1287 (1999).

590 Vorwerk P, Wex H, Hohmann B, Oh Y, Rosenfeld RG, Mittler U. **CTGF (IGFBP-rP2) is specifically expressed in malignant lymphoblasts of patients with acute lymphoblastic leukemia (ALL).** *British Journal of Cancer* 83(6):756-760 (2000).

591 Sueoka N, Lee HY, Wiehle S, Cristiano RJ, Fang B, Ji L, Roth JA, Cohen P, Kurie JM. Insulinlike growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells. *Oncogene* 19(38):4432-4436 (2000).

592 Chan (1998), op cit.

593 Bohlke (1998), op cit.

594 Yamanaka (1998), op cit.

595 Ma (1999), op cit.

596 Sprenger (1999), op cit.

597 Yang (1998), op cit.

598 Sueoka (2000), op cit.

599 Mantozoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. **Insulin-like growth factor-I in relation to prostate cancer and benign prostatic hyperplasia.** *British Journal of Cancer* 76(9):1115-1118 (1997).

Peptide Immunotherapy: Colostrum—  
*A Physician's Reference Guide*  
 418 600 Goldfine (1992), op cit.

601 Yang (1998), op cit.

602 Cohen P, Nunn SE, Peehl DM. **Transforming growth factor-beta induces growth inhibition and IGF-binding protein-3 production in prostatic stromal cells: abnormalities in cells cultured from benign prostatic hyperplasia tissues.** *Journal of Endocrinology* 164(2):215-23 (2000).

603 Travers SH, Labarta JI, Gargosky SE, Rosenfeld RG, Jeffers BW. **Insulin-like growth factor binding protein-I levels are strongly associated with insulin sensitivity and obesity in early pubertal children.** *Journal of Clinical Endocrinology and Metabolism* 83(6):1935-1939 (1998).

604 Burvin R, LeRoith D, Harel H, Zloczower M, Marbach M, Karnieli E. **The effect of acute insulin-like growth factor-II administration on glucose metabolism in the rat.** *Growth Hormone and IGF Research* 8(3):205-210 (1998).

605 Spagnoli A, Chiarelli F, Vorwerk P, Boscherini B, Rosenfeld RG. **Evaluation of the components of insulin-like growth factor (IGF) and IGF binding protein (IGFBP) system in adolescents with type I diabetes and persistent microalbuminuria: relationship with increased excretion of IGFBP-3 18 kD N-terminal fragment.** *Clinical Endocrinology (Oxford)* 51(5):587-96 (1999).

606 Travers (1998), op cit.

607 Signorello LB, Wu J, Tzonou A, Trichopoulos D, Mantozoros CS. **Hormones and hair patterning in men: a role for insulin-like growth factor I.** *Journal of the American Academy of Dermatology* 40(2):200-203 (1999).

608 de Lacerda L, Carvalho JA, Stannard B, Werner H, Boguszewski MC, Sandrini R, Malozowski SN, LeRoith D, Underwood, LE. **In vitro and in vivo responses to shortterm recombinant human insulin-like growth factor-I (IGF-I) in a severely growth-retarded girl with ring chromosome 15 and deletion of a single allele for IGF-I receptor gene.** *Clinical Endocrinology (Oxford)* 51(5):541-550 (1999).

609 Butler AA, Blakesley VA, Poulaki V, Tsokos M, Wood TL, LeRoith D. **Stimulation of tumor growth by recombinant insulin-like growth factor-I (IGF-I) is dependent on the dose and level of IGF-I receptor expression.** *Cancer Research* 58(14):3021-3027 (1998).

610 Grimberg A, Cohen P. **Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis.** *Journal of Cell Physiology* 183(1):1-9 (2000).

611 Werner H, Karnieli E, Rauscher FJ, LeRoith D. **Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor-I receptor gene. Proceedings of the National Academy of Sciences USA** 93(16):8318-23 (1996).

612 Mannhardt B, Weinzimmer SA, Wagner M, Fiedler M, Cohen P, Jansen P, Zwerschke W.

## References

**Human papillomavirus type 16 E7 oncoprotein binds and inactivates growthinhibitory insulin-like growth factor binding protein-3.** *Molecular and Cell Biology* 20(17):6483-95 (2000).

**Glutathione: A Powerful Antioxidant Found In Colostrum**

613 Glutathione. **Alternative Health Care.** 2(4) May 1999. <http://www.healthalternative.org/vol2.htm> 24 June 2002.

614 Bounous G. **Whey Protein Concentrate (WPC) and Glutathione Modulation in Cancer Treatment.** *Anticancer* 20(6C):4785-4792 (2000).

615 Kennedy RS, Konokil GP, Bounous G, Baruchel S. **The Use of a Protein Concentrate in the Treatment of Pathogens with Metastatic Carcinoma: A Phase I-II Clinical Study.** *Anticancer Research* 15:2643-2650 (1995).

616 Petrosino SP. **The Benefits of Glutathione (GSH).** The Nutrition Advisor. <http://NutritionAdvisor.com> 20 June 2002.

617 Parodi PV. **Cow's Milk Components With Anti-Cancer Potential.** *Australian Journal of Dairy Technology* 56:65-73 (2001).

618 Zhang YH, Kramer TR, Taylor PR, Li JY, Blot WJ, Brown CC, Guo W, Dawsey SM, Li B. **Possible immunologic involvement of antioxidants in cancer prevention.** *American Journal of Clinical Nutrition* 62(6 Suppl):1477S-1482S (1995).

619 Buescher ES, McIlheran SM. **Antioxidant Properties of Human Colostrum.** *Pediatrics Research* 24(1)14-19 (1988).

620 Lands LC, Grey VL, Smountas AA. **The Effect of Supplementation With a Cysteine Donor on Muscular Performance.** *Journal of Applied Physiology* 87(4):1381-1385 (1999).

621 Reeds PJ, Burrin DG, Stoll B, Jahoor F, Wykes L, Henry J, Frazer M. **Enteral Glutamate is the Preferential Source of Mucosal Glutathione Synthesis in the Piglet.** *American Journal of Physiology* 273(2 Pt.1):E408-E415 (1997).

622 Micke P, Beeh KM, Schlaak JK, Buhl R. **Oral Supplementation With Whey Proteins Increases Plasma Glutathione Levels of HIV-Infected Patients.** *European Journal of Clinical Investigation* 31(20):171-178 (2001).

623 **Health-Enhancing Properties of Dairy Ingredients—Composition of Whey.** *Dairy Council Digest* June 24, 2002.

**Complex Lipids**

624 Lambersten G, Christiansen EN. **Milk Fat: Nutrition And Product Development.** *Scandinavian Journal of Nutrition* 41:88-90 (1997). <http://www.snf.ideon.se/sjn/temanr/pdf/297milk%20fat.pdf>

625 Paltauf F, Hermetter A. **Phospholipids: Natural, Semi-synthetic, Synthetic.** In: *Peptide Immunotherapy: Colostrum—A Physician's Reference Guide*

420 *Phospholipids*, Hanin and Pepeu (eds.). New York, Plenum Press, 1990, pp 1-12.

626 Laegreid A, Otnaess AB, Fuglesang J. **Human and Bovine Milk: Comparison and Enterotoxin-Inhibitory Activity.** *Pediatric Research* 20(5):416-421 (1986).

627 Malmsten M, Bergenstahl B, Nyberg L, Odham G. **Sphingomyelin from Milk: Characterization of Liquid Crystalline, Liposome and Emulsion Properties.** *JAACS* 71(9):1021-1026 (1994).

628 Holmgren J., Svenerholm AM, Ahren C. **Non-Immunoglobulin Fraction of Human Milk Inhibits Bacterial Adhesion (Hemagglutination) and Enterotoxin Binding of *Escherichia coli* and *Vibrio cholerae*.** *Infection and Immunity* 33(1):136-141 (1981).

629 Hannun YA, Linsardic CM. **Sphingolipid breakdown products: anti-proliferative and tumor-suppressor lipids.** *Biochimica et Biophysica Acta* 1154(3-4):223-236 (1993).

630 Dillehay DL, Webb SK, Schmelz EM, Merrill AH Jr. **Dietary sphingomyelin inhibits 1,2-dimethylhydrazine-induced colon cancer in CFI mice.** *Journal of Nutrition* 124(5):615-620 (1994).

631 Modrak DE, Rodriguez MD, Goldenberg DM, Lew W, Blumenthal R. **Sphingomyelin Enhances Chemotherapy Efficacy and Increases Apoptosis in Human Colonic Tumor Xenografts.** *International Journal of Oncology* 20(2):379-384 (2002).

632 Takamizama K, Iwamori M, Mutai M, Nagai Y. 1986. **Gangliosides of Bovine Buttermilk. Isolation and Characterization of a Novel Monosialoganglioside with a Branching Structure.** *Journal of Biological Chemistry* 261(12): 5625-5630 (1986).

633 Sinfioriana E, Agostinis C, Merlo P, Gualtieri S, Mauri M, Mancuso A. **Cognitive Decline in Aging Brain.** *Clinical Trials Journal* 24(1):115-124 (1987).

634 Kidd, PM. **Phosphatidylserine Offers Nutritional Support for Brain Function.** *Vitamin Retailer* January, 1999.

635 Amaducci L. The SMID Group. **Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study.** *Psychopharmacology Bulletin* 24(1):130-134

(1988).

636 Caffarra P, Santamaria V. **The effects of phosphatidylserine in patients with mild cognitive decline: an open trial.** *Clinical Trials Journal* 24(1):109-114 (1987).

637 Cenacchi T, Bertoldin T, Farina C, Fiori MG, Crepaldi G. **Cognitive decline in the elderly: A double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration.** *Aging* 5:123-133 (1993).

638 Funfgeld EW, Nedwick P. **Neurohomologous phosphatidylserine in Parkinson's patients with associated disorders of cerebral metabolism.** *Clinical Trials Journal* 24(1):42-61 (1987).

639 Nunzi MG, Milan F, Guidolin D, Zanotti A, Toffano G. **Therapeutic properties of Phosphatidylserine in the Aging Brain.** In: *Phospholipids*, Hanin and Pepeu (eds.). New York: Plenum Press, 1990.

640 Villardita C, Grioli S, Salmeri G, Nicoletti F, Pennisi G. **Multicenter Clinical Trial of**  
421

#### References

**Brain Phosphatidylserine in Elderly Patients With Intellectual Deterioration.**

*Clinical Trials Journal* 24(1):84-93 (1987).

641 Pakula R, Konikoff FM, Rubin M, Ringel Y, Peled Y, Tietz A, Gilat T. **The Effects of Dietary Phospholipids Enriched with Phosphatidylethanolamine on Bile and Red Cell Membrane Lipids in Humans.** *Lipids* 31(3):295-303 (1996).

642 Holub BJ. **The nutritional significance, metabolism, and function of myo-inositol and phosphatidylinositol in health and disease.** *Advances in Nutrition Research* 4:107-141 (1982).

#### Lactose Intolerance, Dairy Products, and Colostrum

643 Sahi T. **Genetics and epidemiology of adult-type hypolactasia.** *Scandinavian Journal of Gastroenterology Supplement* 202:7-20 (1994).

644 Scrimshaw NS, Murray EB. **The acceptability of milk and milk products in populations with a high prevalence of lactose intolerance.** *American Journal of Clinical Nutrition* 48(4 Suppl):1079-1159 (1988).

645 Vesa TH, Korpela RA, Sahi T. **Tolerance to small amounts of lactose in lactose maldigesters.** *American Journal of Clinical Nutrition* 64(2):197-201 (1996).

646 Suarez FL, Savaiano D, Arbisi P, Levitt MD. **Tolerance to the daily ingestion of two cups of milk by individuals claiming lactose intolerance.** *American Journal of Clinical Nutrition* 65(5):1502-1506 (1997).

647 Gilliland SE, Kim HS. **Effect of viable starter culture bacteria in yogurt on lactose utilization in humans.** *Journal of Dairy Science* 67:1-6 (1984).

648 Jennes R, Sloan RE. **The composition of milks of various species: a review.** *Dairy Science Abstracts* 32:599-612.

649 Kolars JC, Levitt MD, Aouji M, Savaiano DA. **Yogurt—an autodigesting source of lactose.** *New England Journal of Medicine* 310(1):1-3 (1984).

650 Hertzler SR, Huynh BC, Savaiano DA. **How much lactose is low lactose?** *Journal of the American Dietetic Association* 96(3):243-246 (1996).

#### Colostrum Plus Probiotics, Prebiotics, and Complex Lipids

##### The Ideal Combination

651 Smith T, Little RB. **The significance of colostrum to the newborn calf.** *Journal of Experimental Medicine* 36:181-186 (1922).

652 McGuire TC, Pfeiffer NE, Weikel JM, Bartsch RG. **Failure of colostrum immunoglobulin transfer in calves dying from infectious disease.** *Journal of the American Veterinary Medical Association* 169:713-716 (1976).

653 Brambell FWR. **The Transmission of Passive Immunity From Mother to Young.**

Peptide Immunotherapy: *Colostrum—*

*A Physician's Reference Guide*

422 *Proceedings of the Nutrition Society* 28:35-41 (1969).

654 McEwan AD, Fisher EW, Selman IE. **Observations on the immunoglobulin level of neonatal calves and their relationship to disease.** *Journal of Comparative Pathology* 80:259-263 (1970).

655 Hilpert H, Gerber H, Amster H, Pahud JJ, Ballabriga A, Arcalis L, Farriaux JP, de Peyer E, Nussle, D. **Bovine milk immunoglobulins (Ig): Their possible utilization in industrially prepared infant's milk formulae.** In: Food and Immunology, Swedish Nutritional Foundation Symposium XIII, Hambraeus, Hanson and McFarlane (eds.), pp 182-196. Stockholm: Almquist and Wiksell, 1977.

656 Penhale WJ, Logan EF, Selman IE, Fisher EW, McEwan, AD. **Observations on the adsorption of colostrum immunoglobulins by neonatal calf and their significance in colibacillosis.** *Annales de Recherches Vétérinaires* 4:223-229 (1973).

657 Pahud JJ, Hilbert H, Schwartz K, Amster H, Smiley M. **Bovine milk antibodies in the**



**treatment of enteric infections and their ability to eliminate virulence factors from pathogenic E. coli.** In: *The Ruminant Immune System*, edited by J. E. Butler, pp 591-600. New York: Plenum Press, 1981.

658 Tacket CO, Losonsky G, Link H, Hoang Y, Guesry P, Hilpert H, Levine MM. **Protection by milk immunoglobulin concentrate against oral challenge with enterogenic *Escherichia coli*.** *New England Journal of Medicine* 318(19):1240-1241 (1988).

659 Tacket CO, Binion SB, Bostwick E, Losonsky G, Roy MJ, Edelman R. **Efficacy of bovine milk immunoglobulin concentrate in preventing illness after *Shigella flexneri* challenge.** *American Journal of Tropical Medicine and Hygiene* 47(3):276-283 (1992).

660 Mietens C, Keinhorst H, Hilpert H, Gerber H, Amster H, Pahud JJ. **Treatment of infantile E. coli gastroenteritis with specific bovine anti-E. coli milk immunoglobulins.** *European Journal of Pediatrics* 132: 239-52 (1979).

661 Brussow H, Hilpert H, Walther J, Sidoti J, Meitens C, Bachman P. **Bovine milk immunoglobulins for passive immunity to infantile rotavirus gastroenteritis.** *Journal of Microbiology* 25: 982-986 (1987).

662 Ebina T, Sato A, Umezū K, Ishida N, Ohyama S, Oizumi A, Kitaoka S, Suzuki H, Kunno T. **Prevention of rotavirus infection by oral administration of cow colostrum containing antihuman rotavirus antibody.** *Medical Microbiology and Immunology* 174(4):177-185 (1985).

663 Hilpert H, Brussow H, Meitens C, Sidoti J, Lerner L, Werchau H. **Use of bovine milk concentrate containing antibody to rotavirus to treat rotavirus gastroenteritis in infants.** *Journal of Infectious Diseases* 156(1):158-166 (1987).

664 Tzipori CO, Binion SB, Bostwick E, Losonsky G, Roy MJ, Edelman R. **Remission of diarrhoea due to cryptosporidiosis in an immunodeficient child treated with hyperimmune bovine colostrum.** *British Medical Journal Clinical Research Edition* 293(6557):1276-1277 (1986).

423

#### References

665 McConnell MA, Buchanan G, Borissenko MV, Brooks HJL. **A Comparison of IgG and IgG1 Activity in an Early Milk Concentrate from Non-Immunized Cows and a Milk from Hyperimmunized Animals.** *Food Research International* 34:255-261 (2001).

666 Pascall IC, Surani MA, Barton SC, Vaughan TJ, Brown KD. **Directed expression of simian virus 40 T-antigen in transgenic mice using the epidermal growth factor gene promoter.** *Journal of Molecular Endocrinology* 12(3):313-325 (1994).

667 Baird A. **Fibroblast growth factors: activities and significance of nonneurotrophin neurotrophic growth factors.** *Current Opinions in Neurobiology* 4(1):78-86 (1994).

668 **Hormonal Proteins and Peptides.** *Growth Factors*, Vol. XII, Choh, H.L. (ed) 1984.

669 Tannock GW. **Normal Microflora.** *An introduction to the Microbes Inhabiting the Human Body*, Chapman & Hill, 1995.

670 Payne MJ. **Probiotic Organisms.** *Recent Advances in Microbiology* 3:215-254 (1995).

671 Sanders ME. **Probiotics.** *Food Technology* 53(11):67-77 (1999).

672 Shahani KM, Chandan RC. **Nutritional and healthful aspects of cultured and culture-containing dairy foods.** *Journal of Dairy Science* 62(10):1685-1694 (1979).

673 Friend BA, Shahani KM. **Nutritional and therapeutic aspects of lactobacilli.** *Journal of Applied Nutrition* 36:125-53 (1984).

674 Gomes AM, Malcata FX. **Bifidobacterium spp. and Lactobacillus acidophilus: biological, biochemical, technological and therapeutical properties relevant for use as probiotics.** *Trends in Food Science & Technology* 10:139-157 (1999).

675 Siitonen S, Vapaatalo H, Salminen S, Gordin A, Saxelin M, Wikberg R, Kirkkola AL. **Effect of Lactobacillus GG yoghurt in prevention of antibiotic associated diarrhea.** *Annals of Medicine* 22(1):57-59 (1990).

676 Oksanen PJ, Salminen S, Saxelin M, Hamalainen P, Ihanntola-Vormisto A, Muurasniemi-Isoviita L, Nikkari S, Oksanen T, Porsti I, Salminen E. **Prevention of travellers' diarrhea by Lactobacillus GG.** *Annals of Medicine* 22(1):53-56 (1990).

677 Isolaari E, Juntunen M, Rautanen T, Sillanaukee P, Koivula T. **A human Lactobacillus strain (*Lactobacillus casei* sp. Strain GG) promotes recovery from acute diarrhea in children.** *Pediatrics* 88(1):90-97 (1991).

678 Seki M, Igarashi T, Fukuda Y, Simamura S, Kaswashima T, Ogasa K. **The effect of Bifidobacterium cultured milk on "regularity" among an aged group.** *Nutritional Foodstuff* 31:379-387 (1978).

679 Nanji AA, Khettry U, Sadrzadeh SM. **Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease).** *Proceedings of the Society for Experimental Biology and Medicine* 205:243-247 (1994).

680 Gade J, Thorn P. **Paraghurt for patients with irritable bowel syndrome. A controlled clinical investigation from general practice.** *Scandinavian Journal of*

*Primary Health Care* 7(1):23-26 (1989).

Peptide Immunotherapy: *Colostrum*—

*A Physician's Reference Guide*

424 681 Krus W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. **Double-blind comparison of an oral *Escherichia coli* preparation and mesalazine in maintaining remission of ulcerative colitis.** *Alimentary Pharmacology and Therapeutics* 11(5):853-858 (1997).

682 Majamaa H, Isolauri E. Probiotics: a novel approach in the management of food allergy. *Journal of Allergy and Clinical Immunology* 99:179-185 (1997).

683 Aso Y, Akazan H. **Prophylactic effect of a *Lactobacillus casei* preparation on the recurrence of superficial bladder cancer.** *Urologica Internationalis* 49(3):125-129 (1992).

684 Alm L. **Effect of fermentation on B-vitamin content of milk in Sweden.** *Journal of Dairy Science* 65:353-9 (1982).

685 Tomomatsu H. (1994) **Health Effects of Oligosaccharides.** *Food Technology* 48:61-65 (1994).

686 Tungland BC. **A Natural Prebiotic.** *The World of Food Ingredients*, September 1998.

687 Urashima T, Saito T., Ohmisy K, Shimazaki K. **Structural Determination of Three Neutral Oligosaccharides in Bovine Colostrum, including the Novel Trisaccharide; GalNAc alpha 1-3Gal beta 1-4Glc.** *Biochimica et Biophysica Acta* 1073(1):225-229 (1990).

688 O'Carroll P. **Formulating yogurt.** *The World of Food Ingredients*, April 1997.

689 Deis DR. **New Directions for Cultured Dairy Products.** *Food Product Design Elements*. 25 March 2001. <http://www.foodproductdesign.com/archive/200/0300de.html>

690 van den Broek A. **Functional Foods: The Japanese Approach.** *International Food Ingredients* 1(2):4-9 (1993)

691 Klont R, Mannion P. **Inulin and Oligofructose.** *The World of Food Ingredients*, September 1998.

692 Sensus Product Bulletins, P.O. Box 1308, 4700 BH Roosendaal, The Netherlands (1997).

693 Brandt L. **New Inulin Offers High Performance.** *Prepared Foods*, May 1998.

694 Remesy C, Levrat M, Gamet L, Demigne CD. **Cecal fermentations in rats fed oligosaccharides (inulin) are modulated by dietary calcium level.** *American Journal of Physiology* 264(5 Pt 1):G855-G862 (1993).

695 Paltauf F, Hermetter A. **Phospholipids: Natural, Semi-synthetic, Synthetic.** In: *Phospholipids*, Hanin and Pepeu (eds.). New York, Plenum Press, 1990, pp 1-12.

696 Lambersten G, Christiansen EN. **Milk Fat: Nutrition And Product Development.** *Scandinavian Journal of Nutrition* 41:88-90 (1997). <http://www.snf.ideon.se/sjn/temanr/pdf/297milk%20fat.pdf>

697 Laegreid A, Otnaess AB, Fuglesang J. **Human and Bovine Milk: Comparison and Enterotoxin-Inhibitory Activity.** *Pediatric Research* 20(5):416-421 (1986).

698 Takamizama K, Iwamori M, Mutai M, Nagai Y. 1986. **Gangliosides of Bovine Buttermilk. Isolation and Characterization of a Novel Monosialoganglioside with a Branching Structure.** *Journal of Biological Chemistry* 261(12): 5625-5630 (1986). 425

#### References

699 Malmsten M, Bergenstahl B, Nyberg L, Odham G. **Sphingomyelin from Milk: Characterization of Liquid Crystalline, Liposome and Emulsion Properties.** *JAACS* 71(9):1021-1026 (1994).

700 Holmgren J., Svenerholm AM, Ahren C. **Non-Immunoglobulin Fraction of Human Milk Inhibits Bacterial Adhesion (Hemagglutination) and Enterotoxin Binding of *Escherichia coli* and *Vibrio cholerae*.** *Infection and Immunity* 33(1):136-141 (1981).

701 Hannun YA, Linaudic CM. **Sphingolipid breakdown products: anti-proliferative and tumor-suppressor lipids.** *Biochimica et Biophysica Acta* 1154(2-3):223-236 (1993).

702 Dillehay DL, Webb SK, Schmetz EM, Merrill AH Jr. **Dietary sphingomyelin inhibits 1,2-dimethylhydrazine-induced colon cancer in CFI mice.** *Journal of Nutrition* 124(5):615-620 (1994).

703 Modrak DE, Rodriguez MD, Goldenberg DM, Lew W, Blumenthal R. **Sphingomyelin Enhances Chemotherapy Efficacy and Increases Apoptosis in Human Colonic Tumor Xenografts.** *International Journal of Oncology* 20(2):379-384 (2002).

704 Kidd PM. **Phosphatidylserine Offers Nutritional Support for Brain Function.** *Vitamin Retailer*, January 1999.

705 Nunzi MG, Milan F, Guidolin D, Zanotti A, Toffano G. **Therapeutic properties of Phosphatidylserine in the Aging Brain.** In: *Phospholipids*, Hanin and Pepeu (eds.). New York: Plenum Press, 1990.

706 Sinfioriana E, Agostinis C, Merlo P, Gualtieri S, Mauri M, Mancuso A. **Cognitive Decline in Aging Brain.** *Clinical Trials Journal* 24(1):115-124 (1987).

707 Villardita C, Grioli S, Salmeri G, Nicoletti F, Pennisi G. **Multicenter Clinical Trial of**

### **Brain Phosphatidylserine in Elderly Patients With Intellectual Deterioration.**

*Clinical Trials Journal* 24(1):84-93 (1987).

708 Amaducci L. **Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study.** *Psychopharmacology Bulletin* 24(1):130-134 (1988).

709 Caffarra P, Santamaria V. **The effects of phosphatidylserine in patients with mild cognitive decline: an open trial.** *Clinical Trials Journal* 1987; 24(1): 109-114.

710 Cenacchi T, Bertoldin T, Farina C, Fiori MG, Crepaldi G. **Cognitive decline in the elderly: A double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration.** *Aging* 5(2):123-133 (1993).

711 Funfgeld EW, Nedwidek P. **Neurohomologous phosphatidylserine in Parkinson's patients with associated disorders of cerebral metabolism.** *Clinical Trials Journal* 24(1):42-61 (1987).

712 Pakula R, Konikoff FM, Rubin M, Ringel Y, Peled Y, Tietz A, Gilat T. **The Effects of Dietary Phospholipids Enriched with Phosphatidylethanolamine on Bile and Red Cell Membrane Lipids in Humans.** *Lipids* 31(3):295-303 (1996).

713 Cohen BM, Babb SM, Yurgelun-Todd D. **Brain choline uptake and cognitive function in middle age.** *Biological Psychiatry* 41:905 (1997).

Peptide Immunotherapy: *Colostrum*—

*A Physician's Reference Guide*

426 714 Holub BJ. **The nutritional significance, metabolism, and function of myo-inositol and phosphatidylinositol in health and disease.** *Advances in Nutrition Research* 4:107-141 (1982).

### **Pasteurization**

715 University of Guelph. **Pasteurization module.** <http://www.foodsci.uoguelph.ca/dairyedu/pasteurization.html> 17/05/02

716 **Grade "A" Pasteurized Milk Ordinance.** 1999 Revision. U.S. Department of Health & Human Services. Public Health Services, Food and Drug Administration, Washington DC, United States of America.

717 International Dairy Foods Association. **Regulation and Food Safety, Current Systems for Thermal Processing.** [www.idfa.org/reg/fda/fedhaccp.htm](http://www.idfa.org/reg/fda/fedhaccp.htm) 11/06/02.

718 Korhonen H. **Immune Milk Preparations—Novel Means for Prevention and Treatment of Human Microbial Diseases.** September 2000, Agricultural Research Centre, Food Research, FIN-31600 Jokioinen, Finland.

719 **Dairy Heat Treatment.** Discussion Paper 35. Ministry of Agriculture and Forestry, Wellington, New Zealand.

720 Chen CC, Tu YY, Chang HM. **Thermal Stability of Bovine Milk Immunoglobulin G (IgG) and the Effect of Added Thermal Protectants on the Stability.** *Journal of Food Science* 65(2):188-193 (2000).

721 Li-Chan E, Kummer A, Losso JN, Kitts DD, Nakai S. (1995). **Stability of Bovine Immunoglobulins to Thermal Treatment and Processing.** *Food Research International* 28:9-16 (1995).

722 Mainer G, Dominguez E, Randrup M, Sanchez L, Calvo M. **Effect of Heat Treatment on Anti-Rotavirus Activity of Bovine Colostrum.** *Journal of Dairy Research* 66:131-137 (1999).

723 Dominguez E, Perez MD, Calvo M. **Effect of Heat Treatment on the Antigen-Binding Activity of Anti-Peroxidase Immunoglobulins in Bovine Colostrum.** *Journal of Dairy Science* 80(12):3182-3187 (1997).

724 Wei H, Loimaranta V, Tenovuo J, Rokka S, Syvaaja EL, Korhonen H, Joutsjoki V, Marnila P. **Stability and Activity Specific Antibodies Against Streptococcus mutans and Streptococcus sobrinus in Bovine Milk Fermented with Lactobacillus Strain GG or Treated at Ultra-High Temperature.** *Oral Microbiological Immunology* 17(1):9-15 (2002).

### **Freeze Drying vs Spray Drying**

725 **Food Processing and Preservation.** Microsoft Encarta Online Encyclopedia 2000.

726 **How Food Preservation Works.** Marshal Brian's How Stuff Works <http://www.howstuffworks.com>.

427

### **References**

727 Jennings TA. **Overview of the Lyophilization Process.** INSIGHT 1(9):1-6 (2000). <http://www.phase-technology.com>.

728 McConnell MA, Buchan GAA, Borissenko MV, Brooks HJL. **A Comparison of IgG and IgG1 Activity in an Early Milk Concentrate from Non-Immunized Cows and a Milk from Hyperimmunized Animals.** *Food Research International* 34:255-261 (2001).

729 Mujumdar AS. **Handbook for Industrial Drying.** 1987, New York: Marcel Dekker.

730 Donnelly PE, Petch SF, McLaren RD, Oakley AP. **Development of a Dried Colostrum.** *Proceedings of the New Zealand Society of Animal Production* 48:143-146 (1988).

731 Scopes RK. **Protein Purification: Principles and Practice.** Springer Advanced Texts in

- Chemistry, 1988; C.R. Cantor (ed), 2nd edition, pp. 237- 252.
- 732 Borissenko M, Bryce M. **The Effect of Spray Drying versus Freeze Drying on IGF-I Levels in Colostrum.** Manuscript in progress.
- 733 Hilpert H, Gerber H, Amster H, Pahud JJ, Ballabriga A, Arcalis L, Farriaux JP, de Peyer E, Nussle D. **Bovine milk immunoglobulins (Ig) their possible utilization in industrially prepared infant's milk formulae.** In: Food and Immunology, Swedish Nutritional Foundation Symposium XIII, edited by L Hambraeus, LA Hanson, and H McFarlane, pp 182-196. Almquist and Wiksell, Stockholm, 1977.
- 734 Xu RJ, Mellor DJ, Birtles MJ, Breier BH, Gluckman PD. **Effects of Oral IGF-I or IGF-II on Digestive Organ Growth in Newborn Piglets.** *Biology of the Neonate* 66(5):280-287 (1994).
- 735 Baumrucker CR, Hadsell DL, Blum JW. **Effects of Dietary Insulin-Like Growth Factor I on Growth and Insulin-Like Growth Factor Receptors in Neonatal Calf Intestine.** *Journal of Animal Science* 72(2):428-433 (1994).
- 736 Baumrucker CR, Blum JW. **Secretion of Insulin-Like Growth Factors in Milk and their Effect on the Neonate.** *Livestock Production Science* 35: 49-72 (1993).
- 737 Mero A, Mikklulainen H, Riski J, Pakkanen R, Aalto J, Takala T. **Effects of Bovine Colostrum Supplementation on Serum IGF-I, IgG, Hormone and Saliva IgA During Training.** *Journal of Applied Physiology* 83(4):1144-1151 (1997).
- 738 Mietens C, Keinhorst H, Hilpert H, Gerber H, Amster H, Pahud JJ. **Treatment of infantile E. coli gastroenteritis with specific bovine anti-E. coli milk immunoglobulins.** *European Journal of Pediatrics* 132(4):239-252 (1979).
- 739 Brussow H, Hilpert H, Walther J, Sidoti J, Meitens C, Bachman P. **Bovine milk immunoglobulins for passive immunity to infantile rotavirus gastroenteritis.** *Journal of Clinical Microbiology* 25(6):982-6 (1987).
- 740 Ebina T, Sato A, Umezu K, Ishida N, Ohyama S, Oizumi A, Aikawa K, Katagiri S, Katsushima N, Imai A. **Prevention of rotavirus infection by oral administration of cow colostrum containing antihuman rotavirus antibody.** *Medical Microbiology and Immunology* 174(4):177-85 (1985).
- 741 Tacket CO, Binion SB, Bostwick E, Losonsky G, Roy MJ, Edelman R. (1992). **Efficacy of Peptide Immunotherapy: Colostrum—A Physician's Reference Guide**
- 428 **bovine milk immunoglobulin concentrate in preventing illness after *Shigella flexneri* challenge.** *American Journal of Tropical Medicine and Hygiene* 47(3):276-283 (1992).
- 742 Hilpert H, Brussow H, Meitens C, Sidoti J, Lerner L, Werchau H. **Use of bovine milk concentrate containing antibody to rotavirus to treat rotavirus gastroenteritis in infants.** *Journal of Infectious Diseases* 156(1):158-166 (1987).
- 743 Tzipori S, Robertson D, Chapman C. **Remission of diarrhoea due to cryptosporidiosis in an immunodeficient child treated with hyperimmune bovine colostrum.** *British Medical Journal Clinical Research Edition* 293(6557):1276-1277(1986).
- 744 McConnell MA, Buchan G, Borissenko MV, Brooks HJL. (1998). **A Comparative Study Of Immunoglobulin Levels in Four Colostrum Derived Milks.** Abstract presented at the Joint Annual Meeting of The New Zealand Microbiology Society and The New Zealand Society for Biochemistry and Molecular Biology. Masterton, New Zealand, November, 1998.
- 745 McConnell MA, Buchanan G, Borissenko MV, Brooks HJL. **A Comparison of IgG and IgG1 Activity in an Early Milk Concentrate from Non-Immunized Cows and a Milk from Hyperimmunized Animals.** *Food Research International* 34:255-261 (2001).
- 746 **Health-Enhancing Properties of Dairy Ingredients—Composition of Whey.** *Dairy Council Digest* June 24, 2002. [http://www.nationaldairyCouncil.org/lv104/nutrib/digest/dairydigest\\_722b.htm](http://www.nationaldairyCouncil.org/lv104/nutrib/digest/dairydigest_722b.htm) 24/6/02.
- 747 **Antioxidant Activity of Colostrum.** <http://www.doctors-choice.com/activity.html> 22 June, 2002
- 748 Buescher ES, McIlheran SM. **Antioxidant Properties of Human Colostrum.** *Pediatrics Research* 24(1)14-19 (1988).
- 749 Micke P, Beeh KM, Schlaak JK, Buhl R. **Oral Supplementation With Whey Proteins Increases Plasma Glutathione Levels of HIV-Infected Patients.** *European Journal of Clinical Investigations* 31(20):171-178 (2001).
- 750 **Glutathione.** *Alternative Health Care.* Volume Two, Article Four, May 1999. <http://www.healthalternative.org/vol2.htm> 24 June 2002.
- 751 Borissenko M. **Glutathione—A Powerful Antioxidant Found in Colostrum. Science Review.** *Institute of Colostrum Research* August 2002 [www.colostrumresearch.org](http://www.colostrumresearch.org)
- 752 Petrosino SP. **The Benefits of Glutathione (GSH).** *The Nutrition Advisor.* <http://NutritionAdvisor.com> 20 June 2002.
- 753 **The-Analysis-Glutathione.** <http://www.digitalnaturopath.com/treat/treat/T147297.html> 24 June, 2002.

754 Parodi PW. **Cow's Milk Components With Anti-Cancer Potential.** *Australian Journal of Dairy Technology* 56:65-73 (2001).

755 Bounous G. **Whey Protein Concentrate (WPC) and Glutathione Modulation in Cancer Treatment.** *Anticancer* 20(6C):4785-4792 (2000).

756 Lands LC, Grey VL, Smountas AA. **The Effect of Supplementation With a Cysteine** 429

#### References

**Donor on Muscular Performance.** *Journal of Applied Physiology* 87(4):1381-1385 (1999).

757 Leppaluoto J, Rasi S, Martikkala V, Puukka M. **Bovine Colostrum Supplementation Enhances Physical Performance on Maximal Exercise Tests.** 2000 Pre-Olympic Congress Sports Medicine and Physical Education International Congress on Sport Science. Brisbane, Australia. 7-13 September, 2000.

758 Coombes JS, Conacher M, Austen SK, Marshall PA. **Dose effects of Oral Bovine Colostrum Supplementation on Physical Work Capacity in Cyclists.** 2000 Pre-Olympic Congress Sports Medicine and Physical Education International Congress on Sport Science. Brisbane, Australia. 7-13 September, 2000.

759 Buckley JD, Abbott M, Martin S, Brinkworth G, Whyte P. **Effect of an Oral Bovine Colostrum Supplement on Running Performance.** Abstract from: 1988 Australian Conference of Science and Medicine in Sport, Adelaide, South Australia, October, 1988.

760 Murdie A, Cummins R, McKay J. **Effect of Bovine Colostrum on Immunological Status of Competitive Swimmers.** Global Bioactives Summit, July 25-7, 2001, Hamilton, New Zealand.

761 Griffin F, Hopkins W, Rehrer N, Thomson C, Walmsley A. **The Effects of Dietary Supplementation with Bovine Colostrum on the Training, Immunologic Status, and Performance of Competitive Distance Runners.** Annual Sport Science New Zealand Conference, September 2-30, 2001, Wellington, New Zealand.

762 Coombes JS, Conacher M, Austen SK, Marshall PA. **Dose Effects of Oral Bovine Colostrum on Physical Work Capacity in Cyclists.** *Medicine & Science in Sports & Exercise* 34(7):1184-88 (2002).

763 Burke E. **Colostrum as an Athletic Enhancer and Help for AIDS.** *Nutrition Science News.* May, 1996.

764 Kuipers H, van Breda E, Verlaan G, Smeets R. **Effects of Oral Bovine Colostrum Supplementation on Serum Insulin-Like Growth Factor-I Levels.** *Nutrition* 18(7-8):566-567 (2002).

765 Baumrucker CR, Blum JW. **Effects of Dietary Recombinant Human Insulin-Like Growth Factor-I on Concentration of Hormones and Growth Factors in the Blood of Newborn Calves.** *Journal of Endocrinology* 140(1):15-21 (1994).

766 Humbel RE. **Insulin-Like Growth Factors, Somatomedins, and Multiplication Stimulating Activity: Chemistry.** *Hormonal Proteins and Peptides*, Edited by Choh, HL, Volume XII, pp 57-72, 1984.

767 Antonio J, Sanders MS, Van Gammeren D. **The Effects of Bovine Colostrum Supplementation on Body Composition and Exercise Performance in Active Men and Women.** *Nutrition* (3):243-7 (2001).

768 Barton-Davis ER, Shoturma DI, Musaro A, Rosenthal N, Sweeney HL. **Viral Mediated Expression of Insulin-Like Growth Factor I Blocks the Aging-Related Loss Peptide Immunotherapy: Colostrum—**

*A Physician's Reference Guide*

**430 of Skeletal Muscle Function.** *Proceedings of the National Academy of Sciences USA* 95(26):15603-15607 (1998).

769 Buckley JD, Abbott M, Brinkworth GD, Whyte P. **Oral Supplementation with Bovine Colostrum Increases Vertical Jump Performance.** Abstract presented at the 4th Annual Congress of the European College of Sports Science. Rome, Italy. July, 1999.

770 Buckley JD, Abbott M, Brinkworth GD, Whyte P. **Bovine Colostrum Supplementation During Training Increases Vertical Jump Performance.** 2000 Pre-Olympic Congress Sports Medicine and Physical Education International Congress on Sport Science. Brisbane, Australia. 7-13 September, 2000.

771 Buckley JD, Brinkworth GD, Bourdon PC, Gulbin J, Stilwell EJ, David A, Myers N. **Oral Supplementation with Bovine Colostrum Improves Rowing Performance in Elite Female Rowers.** Abstract presented at the 5th I.O.C. World Congress on Sports Sciences, Sydney, Australia. October, 1999.

772 Sen CK, Atalay M, Hanninen O. **Exercise-Induced Oxidative Stress: Glutathione Supplementation and Deficiency.** *Journal of Applied Physiology* 77(5):2177-87 (1994).

773 Sjodin B, Hellsten-Westling Y, Apple FS. **Biochemical Mechanisms for the Oxygen Free Radical Formation During Exercise.** *Sports Medicine* 10(4):236-254 (1990).

774 Lands LC, Grey VL, Smountas AA. **Effect of Supplementation With A Cysteine**

- Donor On Muscular Performance.** *Journal of Applied Physiology* 87(4):1381-1385 (1999).
- 775 Wilson T, Liggins GC, Joe L. **Purification and characterization of a uterine phospholipase inhibitor that loses activity after labor onset in women.** *American Journal of Obstetrics and Gynecology* 160(3):602-606 (1989).
- 776 Wilson T, Liggins GC, Aimer GP, Skinner SJ. **Partial purification and characterization of two compounds from amniotic fluid which inhibit phospholipase activity in human endometrial cells.** *Biochemistry and Biophysics Research Communications* 131(1):22-29 (1985).
- 777 Wilson T, Christie DL. **Gravidin, an endogenous inhibitor of phospholipase A2 activity, is a secretory component of IgA.** *Biochemistry and Biophysics Research Communications* 176(1):447-452 (1991).
- 778 Playford RJ, Floyd DN, Macdonald CE, Calnan DP, Adenekan RO, Johnson W, Goodlad RA, Marchbank T. **Bovine Colostrum is a Health Food Supplement which Prevents NSAID Induced Gut Damage.** *Gut* 44(5):653-658 (1999).
- 779 Playford RJ, Macdonald CE, Calnan DP, Floyd DN, Poda T, Wicks AC, Bashir O, Marchbank T. **Co-administration of the Health Food Supplement, Bovine Colostrum, Reduces the Acute Non-Steroidal Anti-Inflammatory Drug-Induced Increase in Intestinal Permeability.** *Clinical Science (London)* 100(6):627-633 (2001).
- 780 Playford RJ, Macdonald CE, Johnson WS. **Colostrum and Milk-Derived Peptide Growth Factors for the Treatment of Gastrointestinal Disorders.** *American Journal of Clinical Nutrition* 72(1):5-14 (2000).

43 |

#### References

- 781 Mero A. **Bovine Colostrum.** *Sports Dietary Supplements Update.* 13/6/02, <http://www.esportmed.comsdsu/content/viewnotes.cfm?sis=31>.
- 782 **Drugs in Sport Update.** *Australian Sports Drug Agency (ASDA) Newsletter* Spring 1998 Edition, Volume 2, Issue 3. [http://www.nevdgp.org.au/geninf/health\\_info\\_search.htm](http://www.nevdgp.org.au/geninf/health_info_search.htm) 9/09/02.
- 783 Paton CD, Hopkins WG. **Performance Enhancement at the Fifth IOC World Congress on Sport Sciences.** *Sport Science* 3(3) (1999). <http://www.sportsci.org/jour/9903/cdpwghIOC.html> 9/09/02.
- 784 Hopkins WG, Hawley JA, Burke LM. **Design and Analysis of Research on Sport Performance Enhancement.** *Medicine & Science in Sports & Exercise* 31(3):472-85 (1999).
- 785 **Olympic Movement Anti-Doping Code, Appendix A: Prohibited Classes of Substances and Prohibited Methods.** 1 April 2000. <http://www.nevdgp.org.au/geninf/asda/drugsin1.html> 30/9/02.
- 786 **Substitutes Appendix A of the OMAC 1999—Olympic Movement Anti-Doping Code, Appendix A: Prohibited Classes of Substances and Prohibited Methods—2003.** 1 January 2003. <http://www.usantidoping.org/files/2003IOCprohibited.pdf>, published 27 September 2002 3/10/02.
- 787 **ASDA Drugs in Sport: Information on Substances** <http://www.asda.org.au/au/dis.html> 13 December 2002.

#### Leptin

- 788 Houseknecht KL, Mantzoros CS, Kuliawat R, Hadro E, Flier JS, Kahn BB. **Evidence for leptin binding to proteins in serum of rodents and humans: modulation with obesity.** *Diabetes* 45(11):1638-1643 (1996).
- 789 Golden PL, Maccagnan TJ, Pardridge WM. **Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels.** *Journal of Clinical Investigation* 99(1):14-18 (1997).
- 790 Diamond FB, Eichler DC, Duckett G, Jorgenson EV, Shulman D, Rot AW. **Demonstration of a leptin binding factor in human serum.** *Biochemistry and Biophysics Research Communications* 233:818-822 (1997).
- 791 Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S. **Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight reduced subjects.** *Nature Medicine* 1(11):1155-1161 (1995).
- 792 Lammert A, Kiess W, Bottner A, Glasow A, Kratzsch J. **Soluble leptin receptor represents the main leptin binding activity in human blood.** *Biochemistry and Biophysics Research Communications* 283(4):982-988 (2001).

Peptide Immunotherapy: *Colostrum—*

*A Physician's Reference Guide*

- 432 793 Huang L, Wang Z, Li C. **Modulation of circulating leptin levels by its soluble receptor.** *Journal of Biological Chemistry* 276:6343-6349 (2001).
- 794 Wadden TA, Considine RV, Foster GD, Anderson DA, Sarwer DB, Caro JS. **Short and**

**long-term changes in serum leptin dieting obese women: effects of caloric restriction and weight loss.** *Journal of Clinical Endocrinology and Metabolism* 83(1):214-218 (1998).

795 Rissanen P, Makimattila S, Vehmas T, Taavitsainen M, Rissanen A. **Effect of weight loss and regional fat distribution on plasma leptin concentration in obese women.**

*International Journal of Obstetrics and Related Metabolic Disorders* 23(6):645-649 (1999).

796 Bougoulia M, Tzotzas T, Efthymiou H, Koliakos G, Konstantinidis T, Triantos A, Krassas

GE. **Leptin concentrations during oral glucose tolerance test (GTT) in obese and normal weight women.** *International Journal of Obstetrics and Related Metabolic Disorders* 23(6):625-628 (1999).

797 Mueller WM, Gregoire FM, Stanhope KL, Mobbs CV, Mizuno TM, Warden CH, Stern JS, Havel PJ. **Evidence that glucose metabolism regulates leptin secretion from cultured rat adipocytes.** *Endocrinology* 139(2):551-558 (1998).

798 Gavrilova O, Barr V, Marcus-Samuels B, Reitman M. **Hyperleptinemia of pregnancy associated with the appearance of a circulating form of the leptin receptor.**

*Journal of Biological Chemistry* 272:30546-30551 (1997).

799 Hassink SG, de Lancey E, Sheslow DV, Smith-Kirwin SM, O'Connor DM, Considine RV, Opentanova I, Dostal K, Spear ML, Leef K, Ash M, Spitzer AR, Funanage VL.

**Placental leptin: an important new growth factor in intrauterine and neonatal development.** *Pediatrics* 100(1):E1 (1997).

800 Studzinski S, Puzio I, Tataru M. **Leptin and its role at the time around birth.** *Zootechnica* 225(43):5-14 (2001).

801 Zabielski R, Wolinski J. **Role of colostrum and milk leptin in the development of the gastrointestinal tract.** *Zootechnica* 225(43):15-20 (2001).

802 Cohen P, Miyazaki M, Socci ND, Hagge-Greenberg A, Liedtke W, Soukas AA, Sharma R, Hudgins LC, Ntambi JM, Friedman JM. **Role for stearyl-CoA desaturase-1 in leptin-mediated weight loss.** *Science* 297(5579):240-243 (2002).

803 Heymsfield SB, Greenburg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, Lubina JA, Patane J, Self B, Hunt P, McCamish M. **Recombinant leptin for weight loss in obese and lean adults.** *JAMA* 282(16):1568-1575 (1999).

804 Fruhbeck G, Diez-Caballero A, Salvador J, Alvarez-Cienfuegos J. **Chronobiology of recombinant leptin therapy.** *JAMA* 283(12):1567-1568 (2002).

805 Sinha MK, Caro JF. **Clinical Aspects of Leptin.** *Vitamins and Hormones* 54:1-30 (1998).

806 Tsang SH. **Obesity: from the mouse house to the ambulatory care clinic.** *P&S Medical Review* 5(1) (1998).

433

References

## Appendix D Notes

### Can Colostrum Assist AIDS Patients?

807 Nowa and McMichael. **How HIV defeats the immune system.** *Scientific American* Aug:58-65 (1995).

808 Harmsen MC, Swart PJ, Bethune M, Pauwels R, DeClercq E, The TH, Meijer DK. **Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication *in vitro*.** *Journal of Infectious Diseases* 172(2):380-388 (1995).

809 Stephan W, Dichtelmuller H, Lissner R. **Antibodies from colostrum in oral immunotherapy.** *Journal of Clinical Biochemistry* 28(1):19-23 (1990).

810 Richie DJ, Becker ES. **Update on the Management of Intestinal Cryptosporidiosis in AIDS.** *Annals of Pharmacotherapy* 28(6):767-778 (1994).

811 Rump JA, Aarndt R, Arnold A, Bendick C, Dichtelmuller H, Franke M, Helm EB, Jager H, Kampmann B, Kolb P. **Treatment of diarrhea in human immunodeficiency virus-infected patients with immunoglobulins from bovine colostrum.** *Clinical Investigation* 70(7):588-594 (1992).

812 Ungar BL, Ward DJ, Fayer R, Quinn CA. **Cessation of cryptosporidium-associated diarrhea in AIDS patients after treatment with hyperimmune bovine colostrum.** *Gastroenterology* 98(2):486-489 (1990).

813 Bogstedt AK, Johansen K, Hatta H, Kim M, Casswall T, Svensson L, Hammarstrom L. **Passive immunity against diarrhea.** *Acta Paediatrica* 85(2):125-128 (1996).

814 Plettenberg A, Stoehr A, Stellbrink HJ, Albrecht H, Meigel W. **A preparation from bovine colostrum in the treatment of HIV-positive patients with chronic diarrhea.** *Clinical Investigation* 71(1):42-45 (1993).

815 Bricker DS. **Colostrum: implications for accelerated recovery in damaged muscles and cartilage, prevention of some pathogenic disease.** *The American Chiropractor* Nov. 1991:4-5.